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Chapter 1 
 
Introduction 
 

  
General epidemiology of colorectal cancer 
 
The large bowel 
The large bowel can be divided into the colon, the rectosigmoid, and rectum. The colon 
starts where the small bowel ends. It is 1.5-1.8 metres long when stretched. The 
rectum forms the final 10-15 cm of the large bowel, opening to the outside at the anus. 
The rectosigmoid is the transitional zone between the colon and the rectum 1. 
 
Incidence 
In the Netherlands, colorectal cancer is the third most common cancer (14%) among 
males, after prostate (21%) and lung cancer (16%), and it is the second most frequent 
tumor (13%) among females after breast cancer (33%). In 2003, almost 10.000 
patients were diagnosed with the disease; in this year, 4.500 patients died of the 
disease 1. The incidence in the Netherlands compared to other European countries, is 
relatively high, and ranks in the top-10 2.  Worldwide, colorectal cancer accounted for 
about 1 million of new cancer diagnoses in 2002, representing nearly 10% of all new 
cancers among both men and women 2. It occurs more frequently in the industrialised 
world. The disease rarely occurs before age 40, the risk of colorectal cancer becomes 
highest around age 70 1. The lifetime risk to develop colorectal cancer is 5.6% in the 
industrialised world 1, 3. As a percentage of total mortality, the risk of dying from 
colorectal cancer in the Netherlands is highest around age 60 (about 5%), later in life 
other causes of death proportionally start to occur more often 4.  
 
Stages of the disease  
Colorectal carcinogenesis starts with hyperplasia of the epithelial cells, when the tissue 
becomes dysplastic. This process results in the earliest identifiable lesion, the aberrant 
crypt focus 5. The dysplastic tissue may further develop into so-called polyps, which are 
benign tumors. Several types of polyps exist. The adenomatous polyp, or adenoma, 
which consists of glandular epithelial tissue that lines the inner layer of the wall of the 
large bowel, is regarded as the most important type of polyp in colorectal 
carcinogenesis. Approximately 98% of the colorectal cancers are adenocarcinomas, 
which originate from these adenomas 6.  It has been estimated that colorectal cancer 
takes at least 5 years to develop from dysplasia , although most studies estimate that it 
takes between 10 and 30 years 7, 8. Most of that time is thought to be needed for 
adenoma formation. The Dukes staging system and the TNM staging system are most 
commonly used to classify invasiveness of the disease. They systems consist of four 
stages and are interchangeable; Dukes A to D and stage I to IV. In stage I colorectal 
cancer, the cancer has grown through several layers of the large bowel, except its 
muscular wall. Stage II colorectal cancers have grown through the wall, but have not 
yet involved the lymph nodes. When the cancer has spread to at least one lymph node 
in the nearby area, but not to other body parts, the cancer is classified as being stage 
III. Stage IV is the most advanced stage of the disease; the cancer has reached distant 
organs or tissue, most commonly the liver or the lungs. In the Eindhoven Cancer 
Registry area, the TNM stage distribution was as follows in the period 2000-2002: stage 
  
 
 
I 21%, stage II 33%, stage III 27%, stage IV 19% (excluding patients with unknown 
stage, which is approximately 3%) 1.  
 
Survival 
The 5-year relative survival rate of patients with colorectal cancer was 59% for patients 
diagnosed in the period 2000-2002 in the Eindhoven Cancer Registry area 1. Survival 
rates for rectal cancer used to be worse than for colon cancer until recently, but are 
now at an equal level. Prognosis is better if cancer is detected at an earlier stage. 
Stage specific survival ranges between more than 90% for patients with stage I disease 
at time of diagnosis, to less than 5% for patients with stage IV disease at time of 
diagnosis. Survival in the Netherlands is high compared to other European countries; 
only France and Switzerland show better survival rates (although the data for these 
countries may be based on a selective, better population) 9. 
 
Risk factors 
Several risk factors, both genetic and environmental influence the formation and 
development of colorectal cancer. Individuals can be at increased risk due to their 
genetic constitution. The most common hereditary forms of colorectal cancer are 
hereditary non-polyposis colorectal cancer (HNPCC), also called Lynch syndrome, which 
accounts for approximately 3% of cases, and familial adenomatous polyposis (FAP), 
which accounts for less than 1% of colorectal cancer cases 10. HNPCC is related to 
inherited mutations in one of the mismatch repair genes and FAP is caused by inherited 
mutations in the APC tumor-suppressor gene. Individuals with HNPCC have a lifetime 
colorectal cancer risk up to 80%, and individuals with FAP have a colorectal cancer risk 
of virtually 100% 11. 
Other high-risk groups include individuals with adenomas, and patients with 
inflammatory bowel disease like ulcerative colitis and Crohns disease 12. 
Over the years a number of lifestyle- or environment-related risk factors have been 
identified, although the data are not entirely consistent. These include: physical 
activity, obesity, vitamin D and calcium, red and processed meat, dietary fat, fish, fruit 
and vegetables, fiber, folate, smoking, alcohol consumption, aspirin and other non-
steroidal anti-inflammatory drugs, and postmenopausal hormone use (Table 1) 13-23. 
In most cases, the environment and the genetic background of a person determine the 
risk of colorectal cancer together: the environment affects the activity of the genes and 
the effect of a certain environmental factor depends on the genes, the so-called gene-
environment interaction 24-26. 
 
 
Prevention, diagnosis and staging of colorectal cancer 
 
Primary prevention 
Most of the aforementioned risk factors obviously play an important role in primary 
prevention. For some of them, the effect on preventing colorectal cancer has even 
been established in randomized controlled trials, such as aspirin use 27.  
 
 
  
Table 1: Risk factors for colorectal cancer 
 
Risk factor Strength of 
association (RR) a 
Strength of 
evidence 
Subsite-dependent effect b 
Family history 1.8 +++ +++ (colon) 
Body height  1.3 ++ + (colon) 
Obesity  1.5 +++ 0 
Physical activity  0.6 ++ +++ (colon) 
Vegetables  0.7  1.0 0, + 0 
Fruit  0.8  1.0 0 Unknown 
Fibre  0.7  1.0 0 0 
Red/ processed meat  1.2 + ++ (colon) 
Fish consumption  0.7 ++ Unknown 
Saturated fat  1.4 + Unknown 
Calcium intake  0.6  1.0 0 + (colon) 
Vitamin D intake  0.5 ++ Unknown 
Vitamin B6  0.5 + +++ (colon) 
Folate  0.5 +++ 0, + (colon) 
Magnesium  0.5 + Unknown 
Selenium  0.6 + Unknown 
Smoking  1.5 + 0, + (rectum) 
Alcohol  1.4 ++ 0, + (colon) 
Statins  0.5 0 + (colon) 
Oestrogen replacement 
therapy 
 0.8 ++ Unknown 
Cholecystectomy  1.2 + +++ (proximal colon) 
Prior pelvic irradiation  1.7 + +++ (rectum) 
Aspirin  
(long-term regular use) 
 0.7 +++ Unknown 
Diabetes mellitus  1.3 ++ ++ (colon) 
Inflammatory bowel disease  1.5 +++ Unknown 
 
RR=relative risk 
a
 In absence of a recent meta-analysis, or conflicting results of recent meta-analyses, a range of 
the reported relative risks in recent studies is given 
b The subsite having an association with the risk factor is shown between parentheses. 
 
0 Inconsistent/inconclusive 
+ probable 
++ likely 
+++ definite 
 
However, agents with chemopreventive properties, such as aspirin and postmenopausal 
estrogens, have potential adverse effects so a careful consideration of the risk-benefit 
ratio is required before general recommendations can be made. Promising in this 
respect is supplementation with vitamin D and/or folate, which have a more positive 
safety profile than for example aspirin 28. The recommended daily dose of vitamin D is 
400 IE, while adverse events (i.e., hypercalcaemia) occur at daily doses of 50,000 IE or 
more 29. Calcium supplementation is already recommended by the American College of 
Gastroenterology to prevent initial or recurrent colorectal adenomas.  
 
 
 
  
 
 
Secondary prevention 
Recommendations for colorectal cancer screening, as with other screening, must take 
into account the effectiveness, sensitivity, false-positive rate, safety, and convenience 
of the test 4. In addition, cost and cost-effectiveness of the screening program need to 
be considered in the context of what is best for the individual patient, as well as for 
clinical policy in general. The pathogenesis of colorectal cancer allows opportunities to 
prevent cancer or improve its prognosis finding and removing polyps to prevent the 
onset of cancer and finding and removing early cancers to prevent disease progression. 
Also, the length of the progression from polyp to cancer offers a wide window of 
opportunity so that sensitive tests (e.g., sigmoidoscopy and colonoscopy) do not need 
to be repeated yearly, and less sensitive tests (e.g., fecal occult blood, FOBT) 
performed yearly have a chance of finding lesions missed on earlier screening 4.  
Studies have proven that FOBT, when performed every 1 to 2 years in people ages 50 
to 80, reduces the number of deaths due to colorectal cancer by as much as 30 
percent. Unlike FOBT, sigmoidoscopy can find and remove precancerous or cancerous 
growths in the rectum and lower colon. Studies suggest that regular screening with 
sigmoidoscopy after age 50 can reduce the number of deaths from colorectal cancer. 
Often FOBT and sigmoidoscopy are combined in screening programs. Colonoscopy can 
find and remove precancerous or cancerous growths throughout the colon, including 
the upper part of the colon, where they would be missed by sigmoidoscopy. However, 
it is not known whether this benefit outweighs the risks of colonoscopy, which include 
bleeding and puncturing of the lining of the colon 4. More research is being conducted 
to address these issues and to explore the possibilities of other screening tools such as 
virtual colonoscopy, also in the Netherlands 4. 
 
 
Tertiary prevention 
Increasing levels of physical activity after diagnosis, and vitamin D status (either by 
ingestion or through solar irradiation) at and after time of diagnosis have been 
positively related to prognosis of colon cancer, and may act positively in concert with 
conventional therapies of colon cancer 30, 31. 
 
Diagnosis and staging 
Patients with colorectal cancer may be diagnosed by having one or more of the 
following symptoms: abdominal pain, change in bowel habit, blood in stools, weakness, 
anemia without other gastrointestinal symptoms, and weight loss 32, 33. A large 
proportion of patients with early disease does however have no clinical symptoms (i.e., 
screen detected patients), these usually appear with more advanced disease 34. 
Diagnostic tests, besides a physical exam and a digital rectal exam, include 
sigmoidoscopy, colonoscopy (both comprising the possibility of taking a biopsy), 
double-contrast barium enema, blood tests (haemoglobin, carcinoembryonic antigen 
(CEA), CA 19-9), ultrasound (also endorectal and intraoperative), computed 
tomography (CT, also virtual colonoscopy, spiral CT, portography, CT-guided needle 
biopsy), magnetic resonance imaging (MRI), chest X-ray, positron emission 
tomography (PET), angiography 4, 35, 36. A number of these tests are also used for pre- 
  
and peroperative staging. After resection, the pathologist examines the specimen. The 
spread of the disease, including the existence of tumour tissue in the lymph nodes 
present in the specimen will be examined. Also histology, degree of differentiation, and 
radicality of the resection (especially important in case of rectal cancer) are assessed 
37. 
 
 
Short overview of treatment options 
 
Surgery 
Surgery is the main treatment for colorectal cancer. Usually the cancer and a length of 
normal bowel on either side of the cancer (as well as nearby lymph nodes) are 
removed. The two ends are then sewn back together. For colon cancer, a colostomy is 
not usually needed, although sometimes a temporary colostomy may be constructed. 
Sometimes very early colon cancer can be removed through colonoscopy. Surgery for 
colon cancer can also be performed with a new approach called laparoscopic or 
keyhole surgery. Laparoscopic surgery for colon cancer works probably as well as the 
standard approach 38. For rectal cancer, other types of surgery are requested. A low 
anterior resection is used for tumours located in the middle or upper part of the 
rectum, close to where it connects with the colon. Permanent colostomy is not 
indicated with this procedure. For cancers in the lower part of the rectum, an 
abdominoperineal resection is done. After this surgery, a permanent colostomy is 
necessary. Surgery that includes total mesorectal excision (TME) often provides the 
best possible patient outcomes and survival. For stage IV colorectal cancer patients, 
surgery is often palliative or even omitted because of too widespread disease 39, 40. 
 
Adjuvant chemotherapy 
Stage I patients do not receive any adjuvant therapy (Table 2). A subgroup of stage II 
patients may be considered to receive adjuvant chemotherapy (nowadays in the 
Netherlands this is usually a combination of 5-fluoruracil (5-FU), leucovorin, and 
oxaliplatin). This high-risk stage II group consists of patients with T4 tumours, fewer 
than 10 lymph nodes examined, or a poor tumour differentiation. For stage III colon 
cancer adjuvant chemotherapy is considered standard receive (same regimen as high 
risk stage II patients), among stage III rectal cancer patients this may be considered. 
Selected stage IV colorectal cancer patients may be treated with a combination of the 
aforementioned agents (or irinotecan instead of oxaliplatin, or capecitabine instead of 
5-FU) plus bevacuzimab 39.  
 
Radiotherapy 
Preoperative radiotherapy is considered standard for T2-T4 rectal cancer (Table 2). For 
patients with high and relatively small tumours, it may be omitted. Patients who are 
expected to have a positive circumferential margin or 4 or more positive lymph nodes 
(clinical staging), radiotherapy may be combined with chemotherapy. Radiotherapy also 
may also be used in a postoperative setting, for T4 colon tumours, and in a palliative 
setting 39. 
 
  
 
 
Table 2: Summary of treatment options for colorectal cancer 
 
 Colon Rectum 
Stage I - Resection - Resection 
- TME for tumours in middle or lower rectum  
- T1: transanal endoscopic microsurgery 
(TEM) 
- T2: preoperative radiotherapy (5x5 Gy) 
Stage II - Resection 
- High-risk patients: adjuvant 
chemotherapy (FOLFOX-4) 
- Resection 
- TME for tumours in middle or lower rectum 
- T3: preoperative radiotherapy (5x5 Gy) 
- T4/ fixed tumours: (chemo)radiation (50 Gy), 
followed by resection (TME) after 6 weeks, 
possibly intraoperative radiotherapy 
Stage III - Resection 
- Adjuvant chemotherapy 
(FOLFOX-4) 
- Resection 
- TME for tumours in middle or lower rectum 
- T2-T3: preoperative radiotherapy (5x5 Gy) 
- T4/ fixed tumours: (chemo)radiation (50 Gy), 
followed by resection (TME) after 6 weeks, 
possibly intraoperative radiotherapy 
- suspicion of 4 or more positive lymph nodes: 
chemoradiation can be considered 
Stage IV - Resection can be considered 
- Palliative chemotherapy 
- Resection can be considered 
- Palliative chemotherapy 
 
 
Methods, population and setting 
 
Eindhoven Cancer Registry 
The Eindhoven Cancer Registry (ECR) was started in 1955 as part of a programme for 
nation-wide cancer registration in the area of southeastern North Brabant. Data on all 
new cancer patients were collected directly from pathology reports and patients 
medical records. The registry was started in three hospitals in Eindhoven and gradually 
expanded to include the southeastern part of province of North Brabant, the Northern 
part of the province of Dutch Limburg (since 1970) and the middle and southwestern 
part of North Brabant since 1986 (except the small most western part) (Figure 1). 
Other regional registries had discontinued their 
activities, until a successful nationwide program 
was re-established since 1984. Since 1989 the 
whole Dutch population is covered by nine 
regional cancer registries, which established the 
National Cancer Registry. 
 
 
The area in the population-based Eindhoven 
Cancer Registry is now served by 10 general 
hospitals at 16 locations and two large 
radiotherapy institutes. The area does not contain 
university or specialized cancer hospitals. There 
are six pathology laboratories, all participating in 
the nationwide PALGA network, which also 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The current area of the Eindhoven  
Cancer Registry of the Comprehensive 
Cancer Centre South 
  
notifies the regional cancer registries. The cancer registry receives lists of newly 
diagnosed cases on a regular base from the pathology departments. In addition, the 
medical records departments of the hospitals provide lists of outpatients and 
hospitalised cancer patients. Following this notification, the medical records of newly 
diagnosed patients (and tumours) are collected, and trained registrars from the cancer 
registry abstract the necessary information. Data are checked for duplicate records. 
Patients who live in the catchment area of the Eindhoven cancer Registry, but are 
diagnosed in hospitals elsewhere in the Netherlands, are regularly retrieved from all 
other Dutch cancer Registries since 1989. Before this year it was done directly through 
retrievals at all the cancer centers. 
The region is characterized by good access to medical care without financial obstacles. 
The distance to a hospital has always been less than 30 kilometres. The population in 
the area is increasingly aging, with an increased proportion of elderly women (from less 
than 5% to more than 10%), and since 1965 a decreasing number of children. 
 
Staging 
Stage of the adenocarcinomas was categorized according to the TNM-classification 
IUCC for all patients. No major changes in the classification occurred since the mid-
1970s which could have led to a shift in stage distribution 41.  
 
Histological classification 
Colorectal tumours were classified based on topography and histology, according to the 
WHO International Classification of Diseases for Oncology (ICD-O)42. In the studies 
presented in this thesis, patients with unclassified malignant neoplasms, sarcomas, 
lymphomas, carcinoids, and melanomas located in the colorectum were excluded (≈5% 
of total) (Table 3). 
 
Table 3: Classification of histology (morphology) according to the WHO ICD-O42 
 
Histological group Morphology code according to 
ICD-O a 
Proportional distribution 
of histology of tumours 
located within the 
colorectum b 
Neoplasm, NOS 8000-8005 2% 
Epithelial neoplasm, NOS 8010-8046 1% 
Carcinoid 8240-8249 0.6% 
Adenocarcinoma c 8140-8231, 8260-8384, 8440, 
8470, 8480, 8481, 8490 
95% 
Sarcoma  8800-8990 0.12% 
Melanoma 8720-8790 0.03% 
Lymphoma 9590-9729 0.5% 
Other (squamous cell neoplasm, 
ductal and lobular neoplasm, acinar 
cell neoplasm, complex epithelial 
neoplasm) a 
8050, 8070, 8500-8576 0.1% 
No microscopical confirmation 9990 0.5% 
NOS = not otherwise specified 
a
 List not exhaustive; non-incident codes (Eindhoven Cancer Registry, 1975-2004) excluded 
b
 Eindhoven Cancer Registry, 1975-2004 
c
 Including cystic, mucinous and serous adenocarcinoma 
  
 
 
Topographical codes of colorectal cancer were used to divide the colorectum into 
subsites (Table 4). Tumours of the anus and the anal canal were excluded throughout 
the thesis unless stated otherwise. 
 
Table 4: Classification of localisation (topography) according to the WHO ICD-O42 
 
Localisation ICD-O Proportional distribution a 
Caecum  C18.0 13% 
Appendix  C18.1 0.5% 
Ascending colon C18.2 9% 
Hepatic flexure C18.3 4% 
Transverse colon C18.4 5% 
Right colon 
Splenic flexure C18.5 3% 
Descending colon C18.6 3% Left colon Sigmoid colon C18.7 25% 
 Overlapping lesions C18.8 
Colon 
 Colon, NOS C18.9 1% 
 Rectosigmoid junction C19.9 8% 
Colorectum 
Rectum 
 Rectum C20.9 28% 
a
 Incidence, Eindhoven Cancer Registry, 1990-2004 
 
 
Comorbidity 
Since 1993 the registry also recorded comorbidity according to a slight adaption of the 
list of serious diseases drawn up by Charlson and colleagues 43. In short, the following 
important conditions were recorded: chronic obstructive pulmonary diseases (COPD), 
cardiovascular and cerebrovascular diseases, other malignancies (excluding basal cell 
carcinoma of the skin), and diabetes mellitus. Furthermore, hypertension, connective 
tissue diseases, rheumatoid arthritis, kidney, bowel, and liver diseases, dementia, 
tuberculosis and other chronic infections were also recorded 44. In chapters 2.1, 2.2, 
2.3, and 3.2 of this thesis, a table containing the recorded comorbid conditions can be 
found. 
 
Data-analysis 
Incidence and mortality 
Because the age-distribution varies over time, and to enable international comparisons, 
age-adjustment was performed by direct standardization according to the European 
Standard Population (European Standardised Rates, ESR). 
Annual incidence and mortality rates were calculated as 3-year moving averages. 
Trends in incidence and mortality were estimated by calculating the estimated annual 
percentage change (EAPC). This was done by fitting a regression line to the natural 
logarithm of the rates using calendar year as a regressor variable, i.e., y=mx + b 
where y=ln(rate) and x=calendar year. Then EAPC=100x (em -1). This calculation 
assumes that the rates increased or decreased a a constant rate over the entire period. 
 
 
 
Survival 
  
Information on the vital status of all patients was obtained initially from the municipal 
registries and since 1998 the Central Bureau for Genealogy. These registers provide 
virtually complete coverage of all deceased citizens. 
Crude survival analyses were performed. Cox regression models were used to compute 
multivariable rates. 
Relative survival (the ratio of the observed to the expected rates) is an estimation of 
disease-specific survival, which reflects survival of cancer patients adjusted for survival 
in a background population with the same age structure 45. Expected survival rates 
were calculated from life tables for regional populations with the same 5-year age 
distribution. Generalized linear models with a Poisson structure were used, based on 
collapsed data and exact survival times 46. 
 
 
Outline 
 
The main objectives of the studies described in this thesis were: 
1. To investigate clinical care for the growing proportion of elderly patients with 
colorectal cancer, with an emphasis on the influence of comorbidity on treatment, 
treatment-related complications, and survival. 
2. To explore adherence to colorectal cancer treatment guidelines within the 
Eindhoven Cancer Registry area. 
3. To study the trends in incidence, treatment, stage distribution, and survival of 
colorectal cancer in a large population-based setting. 
 
 
In chapter 2.1 an overview is given of the prevalence of comorbidity among patients 
with colorectal cancer, and its influence on treatment and long-term survival. This is 
the first population-based study in literature to give insight in the impact of specific 
combinations of comorbid conditions on adjuvant treatment and 5-year survival of 
colorectal cancer. In chapter 2.2, it is investigated whether the previously noticed 
status quo in survival for elderly rectal cancer patients could be due to a lower 
effectiveness of new treatment regimens in this group 47. Chapter 2.3 deals with the 
unanswered question whether, and if yes, which comorbid conditions predict 
complications after surgery for colorectal cancer. 
An overall overview of the adherence to treatment guidelines for colorectal cancer in 
the Eindhoven Cancer Registry area is presented in chapter 3.1. In-depth studies 
concerning adjuvant chemotherapy for stage III colon cancer patients and lymph node 
examination for colon cancer are described in chapter 3.2 and chapter 3.3.  
The trends in incidence, treatment, stage distribution, and survival of colorectal cancer 
are dealt with in chapter 4.1. The consequences of the trends described here, an 
overview of the international population-based literature on the management and 
survival of colorectal cancer in the elderly, unsolved issues concerning the role of 
comorbidity, and the meaning of non-adherence to clinical guidelines is discussed in 
chapter 5.1 to 5.5. In chapter 5.6, future perspectives for research and clinical 
management of colorectal cancer are discussed. 
  
 
 
 
 
 
 
  
Chapter 2 
 
Clinical care: 
Influence of age and comorbidity
  
 
 
  
Chapter 2.1  
 
Comorbidity leads to altered treatment and 
worse survival of elderly patients with colorectal 
cancer 
 
Reprinted from British Journal of Surgery 92(5): Lemmens VEPP, Janssen-Heijnen MLG, 
Verheij CDGW, Houterman S, Repelaer van Driel OJ, Coebergh JWW: Comorbidity leads 
to altered treatment and worse survival of elderly patients with colorectal cancer. 
Pages 615-623. © 2005, British Journal of Surgery Society Ltd. Reproduced with 
permission. Permission is granted by John Wiley & Sons Ltd on behalf of the BJSS Ltd. 
 
 
Summary 
 
BACKGROUND: The aim of this study was to evaluate the effects of comorbidity on the 
treatment and prognosis of elderly patients with colorectal cancer. METHODS: The 
independent influence of age and comorbidity on treatment and survival was analysed 
for 6931 patients with colorectal cancer aged 50 years or more diagnosed between 
1995 and 2001 in the southern part of the Netherlands. RESULTS: Comorbidity had no 
influence on resection rate. The use of adjuvant chemotherapy in patients with stage 
III colonic cancer was influenced by comorbidity, especially a previous malignancy 
(odds ratio (OR) 0.2 (95 per cent confidence interval (c.i.) 0.1 to 0.6); P = 0.002) or 
chronic obstructive pulmonary disease (COPD) (OR 0.3 (95 per cent c.i. 0.1 to 0.9); P = 
0.043). Comorbidity also influenced use of adjuvant radiotherapy in patients with rectal 
cancer, especially the presence of hypertension in combination with diabetes (OR 0.5 
(95 per cent c.i. 0.2 to 0.9); P = 0.031). Comorbidity influenced survival (hazard ratio 
up to 1.6), when adjusted for age, sex, tumour stage and treatment. The greatest 
influence on survival of patients with colonic cancer was previous malignancy, 
cardiovascular disease and COPD, and that of patients with rectal cancer was COPD, 
hypertension, and hypertension in combination with diabetes. CONCLUSION: Elderly 
patients with comorbidity were treated less aggressively and had a worse survival than 
those with no concomitant disease. 
   
 
Introduction 
 
Colorectal cancer is the second most common cause of cancer death in industrialized 
countries 9, 48. Seventy-five per cent of incident tumours occur in persons aged 65 years 
or more. Colorectal tumours affect a large number of people who, because of their age, 
are likely to have other chronic disabling conditions (comorbidity) 49. In patients with 
serious comorbidity, the practitioner might decide to alter standard oncological 
treatment because of increased risk of side-effects or limited life expectancy. Few data 
are available for treatment outcome in elderly patients with colorectal cancer who are 
also suffering from serious comorbid conditions, as these patients are generally 
ineligible for clinical trials. Surgical, sometimes endoscopic, resection of the tumour is 
the only primary curative treatment for colorectal cancer. Total mesorectal excision 
(TME) and preoperative radiotherapy for stage II and III rectal cancer, and adjuvant 
chemotherapy for stage III colonic cancer, improve both disease control and patient 
survival 47, 50-53. These treatments have been recommended in the Netherlands since 
the mid-1990s. In this population-based study, carried out in medium to large general 
hospitals and two radiation therapy centres, the effect of comorbidity on choice of 
treatment and survival of patients with colorectal cancer was investigated in association 
with other prognostic determinants. 
 
Patients and methods 
 
Analyses were based on data for all 6931 patients aged 50 years or more diagnosed 
with colorectal cancer from 1995 to 2001 in the registration area of Eindhoven Cancer 
Registry. This registry serves a large part of the southern Netherlands, with 2·4 million 
inhabitants; it is notified by six pathology departments, the hospital medical records 
departments of ten community hospitals, and two radiation therapy institutes. Despite 
lack of access to death certificates, the organization of Dutch healthcare facilities and 
notification procedures has enabled cancer registries to attain a completeness of data 
exceeding 95 per cent 54. Prognostically relevant concomitant conditions were recorded 
from the medical records according to a slightly adapted version of the Charlson Index 
(Table 1) 43; sources used included correspondence between specialists, medical 
history and preoperative reports. A patient's medical record is regarded as the most 
complete source of information on past and current health status 55.  
Tumour site, stage and morphology were classified according to the International 
Classification of Diseases for Oncology. Patients with tumour stages I and II were 
considered as one group, because differences in treatment and 10-year survival were 
relatively small 56. 
Primary treatment of colonic cancer was classified as surgery, surgery followed by 
chemotherapy, and other (palliative, radiotherapy alone, chemotherapy alone, 
radiotherapy plus chemotherapy) or no therapy. Rectal cancer treatment was classified 
as conventional surgery (without TME), surgery including TME (with or without 
radiotherapy), conventional surgery with radiotherapy, and other (palliative, 
radiotherapy alone, chemotherapy alone, radiotherapy plus chemotherapy) or no 
therapy. No differentiation was made between TME with and TME without radiotherapy 
  
because a large national trial comparing these two treatments was being conducted 
during the study period, and included a large proportion of patients in the region. 
 
Table 1. Classification of comorbidity according to an adapted version of the Charlson Index 43 
 
Previous malignancy (except basal skin carcinoma 
and carcinoma in situ of the cervix) 
Chronic obstructive pulmonary disease (COPD) 
Cardiovascular disease (myocardial infarction, 
cardiac decompensation, angina pectoris, 
intermittent claudication, abdominal aneurysm, 
peripheral arterial disease) 
Cerebrovascular disease (cerebrovascular accident, 
hemiplegia) 
Hypertension 
Diabetes mellitus 
Digestive tract disease (stomach diseases, Crohn's 
disease, ulcerative colitis, liver cirrhosis, hepatitis) 
Other (connective tissue disease, severe 
rheumatoid arthritis, kidney disease, dementia, 
tuberculosis, chronic infection) 
 
 
It was not possible to differentiate between curative and palliative surgery; in stage IV 
disease, surgery was expected to be palliative. Chemotherapy given to patients with 
stage IV disease was classified as chemotherapy, not as palliative treatment. 
To avoid bias due to changing guidelines, only recent data on therapy (1997-2001) 
were used when determining the influence of age and comorbidity on adjuvant 
chemotherapy in patients with stage III colonic cancer, and adjuvant radiotherapy in 
patients with rectal cancer. 
The prevalence of comorbidity was analysed according to age (50-64, 65-79 and 80 or 
more years), sex and tumour site (colon or rectum). The independent influence of 
comorbidity on adjuvant chemotherapy in patients with stage III colonic cancer, and 
adjuvant radiotherapy in patients with rectal cancer, was examined in a logistic 
regression analysis, controlling for age, sex and tumour stage (only for rectal cancer). 
The influence of comorbidity on TME was also examined by logistic regression. The 
influence of age (50-64, 65-79 and 80 or more years) and number of comorbid 
diseases on the rate of permanent stoma formation was analysed using the Chi2 test 
(excluding patients who had excision of the rectum). 
The survival of patients at 1 January 2004 was assessed through civil municipal 
registries and the Central Bureau for Genealogy, which collects data on all Dutch 
citizens who die. Patients who left the Netherlands (estimated as 0.2 per cent) were 
lost to follow-up. A total of 3486 patients (50.3 per cent) died and 3445 (49.7 per cent) 
were still alive; the latter were censored at 1 January 2004. Crude survival was 
determined from date of diagnosis to death or end of study. The log rank test was used 
to compare survival between groups of patients. Multivariable proportional hazards 
regression methods were used to calculate hazard ratios adjusted for probable 
   
 
confounders. The likelihood ratio method was used to determine hazard ratios for 
death. The effects of comorbidity were first evaluated in a model with the number of 
comorbid conditions, age, tumour stage and sex, without treatment. Treatment was 
then included in the model, in order to investigate whether the prognostic effects of 
age and comorbidity could be fully explained by less aggressive treatment. This 
procedure was repeated for each comorbid condition (or combinations of conditions) in 
place of the number of comorbidities. Patients who coded positive for a pair of 
conditions did not code positive for each condition singly. Univariate survival analysis 
(modelling a single explanatory variable) was stratified according to age at diagnosis. 
For facilitated application of the results in clinical practice, patients aged 65-79 years 
were stratified into 5-year age groups (50-64, 65-69, 70-74, 75-79 and 80 or more 
years). 
Multivariable survival analysis was stratified according to tumour site (colon and 
rectum). All data analysis was performed using SAS/STAT® software, version 8 (SAS 
Institute, Cary, North Carolina, USA). 
 
Results 
 
The 6931 patients newly diagnosed with colorectal cancer between 1995 and 2001 had 
a mean age of 70 (maximum 98) years. Characteristics according to tumour site and 
age are shown in Table 2. Stage was more often unknown for older patients, especially 
those with rectal cancer. The number of comorbid conditions increased with age. For all 
age groups the most frequent single concomitant diseases were hypertension (9.4 per 
cent of patients, decreasing with age), previous malignancy (7.1 per cent of patients, 
increasing with age) and cardiovascular disease (5.6 per cent of patients, increasing 
with age). The prevalence of COPD was 4.0 per cent, that of diabetes mellitus 3.4 per 
cent and digestive tract disease 1.9 per cent. The most frequent combination of 
comorbid conditions was cardiovascular disease plus hypertension (3.3 per cent of 
patients). Combinations of hypertension with diabetes (2.1 per cent), previous 
malignancy with cardiovascular disease (up to 1.8 per cent of patients aged 80 years or 
more) and cardiovascular disease with COPD (up to 2.4 per cent of patients with rectal 
cancer aged 80 years or over) were also common. Women suffered more often from 
hypertension than men, and less often from concomitant cardiovascular disease and 
COPD. The prevalence of comorbidity was similar in patients with colonic and rectal 
cancer. However, previous malignancy was more frequent in patients with colonic 
cancer aged 80 years or more (9.1 per cent versus 5.3 per cent of patients with rectal 
cancer), and COPD was more frequent in patients with rectal cancer aged 80 years or 
more (5.2 per cent versus 3.1 per cent of patients with colonic cancer). Previous 
malignancy consisted mainly of colorectal, genital and breast tumours (in women). The 
prevalence of comorbidity was not related to tumour stage.  
Most patients with stage I-II colonic cancer received surgical treatment only (Figure 1); 
less than 2 per cent of patients with stage II disease had adjuvant chemotherapy. For 
stage III colonic cancer, surgery followed by adjuvant chemotherapy was the most 
frequently used treatment for patients younger than 65 years (82.8 per cent). Adjuvant 
chemotherapy was given to 42.4 per cent of patients with stage III disease aged 65-79 
  
years, but to only 1.2 per cent of those aged 80 years or more. For stage IV disease, 
the proportion receiving chemotherapy decreased from 41.3 per cent of patients aged 
50-64 years to 1.8 per cent of those in the oldest age group.  
 
Table 2. General characteristics of patients with colorectal cancer according to tumour site and 
age (1995-2001). 
 
Frequency (%)  
 
Colonic cancer  
 
Rectal cancer  
 
 
50-64 
years (n 
(n=1226) 
65-79 
years 
(n=2331) 
80+ 
years 
(n=842) 
50-64 
years 
(n=865) 
65-79 
years  
(n=1265) 
80+ 
years 
(n=402) 
 
Sex 
   M 54·2 50·9 39·0 62·6 60·0 45·3 
   F 45·8 49·1 61·0 37·4 40·0 54·7 
Stage 
   I-II 47·8 55·3 55·2 50·0 56·5 47·2 
   III 26·5 23·9 22·1 24·0 18·2 17·3 
   IV 23·4 16·8 13·6 17·1 15·2 11·5 
   Unknown 2·3 4·0 9·1 8·9 10·1 24·0 
No. of comorbid conditions* 
   0 55·5 33·9 26·2 60·2 35·7 29·7 
   1 30·0 35·4 33·8 27·0 35·8 34·0 
   2 9·8 19·1 24·4 9·5 17·4 22·0 
   3 3·4 7·8 10·0 2·7 8·4 10·4 
   4+ 1·3 3·8 5·6 0·6 2·7 3·9 
   Unknown 10·8 8·2 9·9 8·5 7·0 9·1 
Treatment 
   Surgery alone 63·6 79·1 86·5 35·0 42·4 44·5 
   Surgery 
including TME ± 
radiotherapy 
   
22·0 20·8 11·0 
   Surgery + 
adjuvant  
therapy a 
29·5 12·3 0·2 34·3 23·5 11·1 
   Other or no 
therapy b 
6·9 8·6 13·3 8·8 13·3 33·4 
 
*
 Proportion of patients excluding unknown comorbidity.  
a
 Adjuvant chemotherapy for colonic and adjuvant radiation therapy for rectal cancer.  
b
 Other treatment comprises therapy not otherwise specified and metastasis-directed   
   therapy such as metastasectomy and metastasis-directed radiotherapy, but not  
   metastasis-directed chemotherapy, which is classified as chemotherapy.  
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In patients with stage I-II and III rectal cancer, surgery alone or in combination with 
radiotherapy was the most common treatment (Figure 2). TME was performed in 20.1 
per cent of patients with stage I-II disease and in 28·0 per cent of those with stage III. 
Most patients with stage IV rectal cancer received palliative therapy alone. For all 
stages of disease, the proportion receiving adjuvant radiotherapy decreased with 
increasing age.  
 
Figure 1. Choice of therapy for patients with colonic cancer according to stage and age (1997-
2001)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Choice of therapy for patients with rectal cancer according to stage and age (1997-2001)  
      Stage I/II                         Stage III                            Stage IV 
                       Stage I                   Stage II                  Stage III                 Stage IV 
  
The proportion of patients with stage II and III rectal cancer who received adjuvant 
chemoradiotherapy increased from 3.9 per cent in 1995-1999 to 15.9 per cent in 2001 
(data not shown). Owing to small numbers in 1995-1999, adjuvant chemoradiotherapy 
was not taken into account in further analyses. 
In logistic regression analysis of patients with stage III colonic cancer, controlling for 
age and sex, comorbidity was associated with a lower probability of receiving adjuvant 
chemotherapy (Table 3). Previous malignancy (odds ratio (OR) 0.2 (95 per cent 
confidence interval (c.i.) 0.1 to 0.6); P = 0.002) and COPD (OR 0.3 (95 per cent c.i. 0.1 
to 0.9); P = 0.043) were mainly responsible for this effect (subanalysis; data not 
shown). Older age was also clearly related to less frequent administration of adjuvant 
therapy. Patients with rectal cancer and comorbidity had a lower probability of 
receiving adjuvant radiotherapy; previous malignancy and the combination of 
hypertension and diabetes had the greatest effect on treatment (OR 0.5 (95 per cent 
c.i. 0.2 to 0.9); P = 0.031). The use of adjuvant radiotherapy decreased with age. 
Elderly patients with rectal cancer and patients with comorbidity were less likely to 
have TME (Table 4). The effect of comorbidity was largely due to previous malignancy. 
The rate of permanent stoma formation increased with age, from 16.7 per cent of 
patients aged 50-64 years to 26.7 per cent of those aged 80 years or more (P = 
0.001), but was not influenced by comorbidity (P = 0.298; data not shown).  
 
For colonic cancer, patients aged 50-64 years without recorded concomitant disease 
had a crude 5-year survival rate of 58.4 per cent. In patients aged 65-79 years without 
comorbidity the survival rate was 58·4 per cent (age 65-69 years, 56.1 per cent; 70-74 
years, 59.9 per cent; 75-79 years, 57.3 per cent), and in those aged 80 years and older 
39.2 per cent (Table 5). Survival decreased with the number of comorbid conditions. In 
a multivariable analysis, comorbidity was a significant predictor of death even when 
adjusted for age, sex and disease stage. The inclusion of treatment in the model did 
not affect the significance of comorbidity. Patients with previous malignancy, 
cardiovascular disease, COPD, the combination of previous malignancy and COPD 
(hazard ratio (HR) 1.8 (95 per cent c.i. 1.1 to 1.7)), and the combination of 
hypertension and diabetes (HR 1.6 (95 per cent c.i. 1.2 to 2.0)) had a worse survival.  
 
For rectal cancer, patients without recorded comorbidity aged 50-64 years had a crude 
5-year survival rate of 60.0 per cent (Table 6). In patients without comorbidity aged 
65-79 years the survival rate was 53.9 per cent (age 65-69 years, 52.8 per cent; 70-74 
years, 55.9 per cent; 75-79 years, 52.4 per cent), and in those aged 80 years or more 
32.9 per cent. Survival decreased with number of concomitant diseases. In a 
multivariable analysis, age, stage and comorbidity were prognostic factors in patients 
with rectal cancer; these factors remained significant after the inclusion of treatment in 
the model. Patients with COPD, hypertension, and the combination of hypertension and 
diabetes (HR 1.8 (95 per cent c.i. 1.2 to 2.7)) had a worse survival.  
   
 
Table 3. Administration of adjuvant therapy for patients with stage III colonic cancer or rectal 
cancer diagnosed between 1995 and 2001; logistic regression model including all listed variables 
 
 
                                        Odds ratio P* 
 
Colonic cancer 
   Age (years) 
      50-64 1·0 
 
      65-79 0·2 (0·1, 0·3) < 0·0001 
      80+ 0·01 (0·001, 0·02) < 0·0001 
   Sex 
      M 1·0 
 
      F 0·7 (0·5, 0·9) 0·045 
   No. of comorbid conditions 
      0 1·0 
 
      1 0·8 (0·6, 1·1) 0·057 
      2+ 0·5 (0·3, 0·8) 0·001# 
Rectal cancer 
   Age (years) 
      50-64 1·0 
 
      65-79 0·7 (0·5, 0·9) 0·041 
      80+ 0·4 (0·2, 0·5) < 0·0001 
   Sex 
      M 1·0 
 
      F 1·0 (0·8, 1·2) 0·970 
   Stage 
      I-II 1·0 
 
      III 1·3 (0·9, 1·6) 0·071 
      IV 0·5 (0·4, 0·7) < 0·0001 
   No. of comorbid conditions 
      0 1·0 
 
      1 0·9 (0·7, 1·2) 0·535 
      2+ 0·7 (0·5, 0·9) 0·040# 
Values in parentheses are 95 per cent confidence intervals. 
* Wald Chi2 test 
# Chi2 test for trend 
 
 
 
 
 
 
 
 
  
Table 4. Total mesorectal excision for patients with rectal cancer diagnosed between 1995 and 
2001; logistic regression model including all listed variables 
 
 
Odds ratio P* 
 
Age (years) 
   50-64 1·0 
 
   65-79 1·0 (0·8, 1·3) 0·898 
   80+ 0·6 (0·4, 0·9) 0·038 
Sex 
   M 1·0 
 
   F 0·9 (0·7, 1·1) 0·762 
Stage 
   I-II 1·0 
 
   III 1·5 (1·2, 1·9) 0·016 
   IV 1·1 (0·8, 1·5) 0·294 
No. of comorbid conditions 
   0 1·0 
 
   1 0·7 (0·5, 0·9) 0·008 
   2+ 0·8 (0·6, 1·1) 0·192# 
Values in parentheses are 95 per cent confidence intervals. 
* Wald Chi2 test 
# Chi2 test for trend 
 
 
 
 
Discussion 
 
In this study of the influence of prognostically relevant comorbidity on choice of 
treatment and long-term survival of unselected patients with colorectal cancer, the 
proportion of patients with comorbidity varied from almost 40 per cent patients aged 
50-64 years to more than 70 per cent in those aged 80 years or older. The most 
common concomitant diseases were hypertension, cardiovascular diseases and 
previous malignancy. 
The proportion of patients undergoing surgery was not affected by age or comorbidity. 
This can be explained by the fact that resection is the only primary curative treatment 
for colorectal cancer, and is often necessary to prevent obstruction. This contrasts with 
resectable non-small cell lung cancer, for example, in which the proportion of patients 
undergoing surgery decreases with age 57. However, the rate of permanent stoma 
formation in the present study increased with rising age. 
Adjuvant chemotherapy is recommended in treatment guidelines for patients with stage 
III colonic cancer, whereas adjuvant radiotherapy is recommended for patients with 
stage II and III rectal cancer 51, 58. However, the use of adjuvant therapy decreased  
  
 
 
Table 5. Uni- and multivariable analyses for overall survival of colon cancer patients, according to age(1995-2001). 
 
 
50-64 yrs 65-79 yrs 80+ yrs  
 
Univariable1 Univariable1 Univariable1 Multivariable 
 
5 yrs % (SE) 5 yrs % (SE) 5 yrs % (SE) Hazard ratio (CI) p 
Age 
         
50-64 yrs 56  (1)          1.0   
65-79 yrs   46  (1)   1.3 (0.06) (1.2-1.5) <.0001 
80+ yrs     28  (2) 2.0 (0.07) (1.8-2.4) <.0001 
Sex          
Male 56  (2) 43  (1) 28  (3)      1.0   
Female 57  (2) 50  (1) 28  (2) 0.9 (0.04) (0.8-0.9) .008 
Stage 
         
I/II 80  (2) 63  (1) 39  (3)      1.0   
 III 55  (3) 39  (2) 25  (3) 2.1 (0.06) (1.9-2.3) <.0001 
 IV 9  (2) 4  (1) 4  (2) 5.2 (0.06) (4.7-5.9) <.0001 
Treatment 
         
Surgery  66  (1) 52  (1) 32  (2)      1.0   
Surgery + chemotherapy 46  (2) 41  (3) .  0.7 (0.07) (0.7-0.9) <.0001 
Other/none  . 2  (1) .  1.5 (0.08) (1.3-1.8) <.0001 
No. of comorbid conditions 
         
0 58  (2) 55  (1) 39  (4)      1.0   
1  55  (3) 44  (1) 27  (3) 1.2 (0.05) (1.1-1.3) .0003 
≥ 2  50  (4) 38  (2) 22  (3) 1.4 (0.05) (1.2-1.5) <.0001 
Type of comorbid condition(s) 2 
         
Previous malignancies 61  (6) 40  (3) 30  (6) 1.3 (0.08) (1.1-1.5) .002 
Cardiovascular  46  (7) 43  (4) 21  (6) 1.3 (0.09) (1.1-1.8) .008 
COPD 55  (9) 39  (5) 35  (11) 1.3 (0.12) (1.1-1.7) .010 
Diabetes 58  (11) 45  (5) 34  (11) 1.1 (0.13) (0.9-1.4) .386 
Hypertension 59  (5) 56  (3) 29  (7) 1.1 (0.08) (0.9-1.2) .074 
Cerebrovascular   . 32  (9) .  1.6 (0.19) (1.1-2.3) .018 
Digestive tract  59  (10) 45  (5) 31  (8) 0.9 (0.19) (0.7-1.4) .849 
Other single diseases  . 45  (7) .  1.5 (0.16) (1.1-2.1) .007 
 
  SE= standard error; CI=Confidence interval   
  1 Crude actuarial 5 year survival rates 
  2
 Reference category: no comorbidity 
 
        
 
Table 6. Uni- and multivariable analyses for overall survival of rectum cancer patients, according to age (1995-2001). 
 
 
50-64 yrs 65-79 yrs 80+ yrs  
 
Univariable1 Univariable1 Univariable1 Multivariable 
 
5 yrs % (SE) 5 yrs % (SE) 5 yrs % (SE) Hazard ratio (CI) p 
Age 
         
50-64 yrs 58 (2)     1.0   
65-79 yrs   45 (2)   1.4 (1.2-1.6) <.0001 
80+ yrs     24 (2) 2.1 (21.7-2.5) <.0001 
Sex          
Male 58 (2) 41 (2) 20 (3) 1.0   
Female 58 (3) 50 (2) 27 (3) 0.9 (0.8-1.0) .057 
Stage 
         
I 87 (2) 71 (3) 37 (6) 1.0   
II 63 (4) 52 (3) 37 (5) 1.7 (1.4-2.1) <.0001 
III 55 (4) 36 (3) 26 (6) 2.5 (2.1-3.0) <.0001 
IV 5 (2) 2 (1) 6 (4) 6.1 (5.0-7.5) <.0001 
Treatment 
         
Surgery  64 (3) 51 (2) 35 (4) 1.0   
Surgery + radiotherapy 60 (3) 50 (3) 24 (7) 1.0 (0.8-1.2) .889 
Surgery incl. TME +/- radiotherapy 65 (4) 55 (3) 44 (8) 0.8 (0.7-0.9) .009 
Other/none 8 (3) 6 (1) 3 (2) 1.9 (1.5-2.3) <.0001 
No. of comorbid conditions 
         
0 60 (2) 54 (2) 33 (5) 1.0   
1  61 (4) 44 (2) 20 (4) 1.3 (1.1-1.5) .001 
≥ 2  43 (5) 33 (2) 19 (4) 1.6 (1.4-1.9) <.0001 
Type of comorbid condition(s) 2 
         
Previous malignancies 46 (8) 54 (5) .  1.2 (0.9-1.6) .125 
Cardiovascular  65 (8) 37 (6) .  1.3 (0.9-1.6) .082 
COPD 59 (11) 41 (7) 17 (10) 1.4 (1.1-1.9) .021 
Diabetes 67 (11) 49 (9) .  1.1 (0.8-1.6) .554 
Hypertension 63 (7) 40 (5) 35 (11) 1.3 (1.1-1.6) .014 
Cerebrovascular  .  51 (11) .  1.1 (0.6-1.9) .763 
Digestive tract  60 (10) 35 (6) .  1.3 (0.8-2.1) .210 
Other single diseases 64 (12) 38 (8) .  1.3 (0.8-2.3) .283 
SE=standard error; CI=confidence interval 
1
 Crude actuarial 5 year survival rates 
2
 Reference category: no comorbidity 

  
strongly with increasing age for both colonic and rectal cancer, as has been shown 
previously 59-64, for several reasons. As well as comorbidity and the decrease in  
patients' general condition and cognitive ability, data on the efficacy of chemotherapy 
and radiotherapy in patients older than 70 years are limited. In addition, elderly 
patients are more likely to decline adjuvant treatment, especially in the absence of 
supportive caregivers 59, 65, 66. 
In agreement with previous studies, patients with comorbidity were less likely to be 
offered adjuvant therapy 59, 62-64. A history of previous malignancy contributed 
particularly to this effect, presumably because of a less favourable risk: benefit balance 
for patients with a second tumour. Patients with rectal cancer who also had a 
combination of hypertension and diabetes were less likely to receive adjuvant 
radiotherapy, which may be explained by the increased likelihood of radiotherapy-
related complications in patients with these conditions 67, 68. The combination of 
adjuvant chemoradiation in patients with stage II and III rectal cancer increased from 
3.9 per cent in 1995-1999 to 15.9 per cent in 2001. These rates contrast with the 
results of a SEER (Surveiliance, Epidemiology, End Results)-Medicare-based study 
(1992-1996), in which 37 per cent of patients aged 65 years or more with stage II and 
III disease received adjuvant chemoradiotherapy 69. 
TME-based surgical resection is strongly recommended for all resectable cancers of the 
mid or lower rectum 58. TME was performed less often in older patients and those with 
comorbidity, especially previous malignancy. The effect of comorbidity on TME surgery 
could be explained partly by the fact that a large national trial on the management of 
rectal cancer (the Dutch TME trial) was ongoing between 1996 and 1999; previous 
malignancy was an exclusion criterion for this study 70. 
Age and comorbidity were independent prognostic factors after adjustment for stage, 
sex and mode of treatment. Previous malignancy, cardiovascular diseases, COPD, the 
combination of previous malignancy and COPD, and the combination of hypertension 
and diabetes increased the risk of postoperative mortality in patients with colonic 
cancer. For patients with rectal cancer, increased mortality was associated mainly with 
COPD, hypertension, and the combination of hypertension and diabetes. 
The presence of concomitant disease had an impact on both crude and relative survival 
rates, an effect not mediated purely by changes in treatment 71. However, information 
was not available on possible dose reductions for adjuvant therapy in patients with 
comorbidity. A negative effect of comorbidity on survival of patients with colorectal 
cancer was demonstrated in an earlier population-based study in which 2-year survival 
was affected by high-impact cardiac-related comorbid conditions, COPD, renal failure 
and liver disease 72. 
The present population-based study has the advantage of avoiding selection bias, but 
detailed information on performance status of the patient (as measured by means of 
the Karnofsky scale 73), dosages of chemotherapy and radiotherapy, and treatment-
related complications was not available. Although performance status and comorbidity 
are both predictive factors for survival in patients with cancer, they are independent of 
one another 74, 75. These and other factors, such as socioeconomic status, cognitive 
disorders and frailty, also play a role in the selection of patients in terms of the 
administration of effective and safe treatment 76. 
  
 
The recording of comorbidity in patients with colorectal cancer diagnosed between 
1995 and 1999 and registered in the Eindhoven Cancer Registry was validated in a 
subset of 507 patients 77. Agreement of almost 70 per cent was found between the 
registry data and the findings of a medical doctor plus an epidemiologist; differences 
related mostly to minor comorbidity and to a lesser extent vascular diseases, which 
tended to be underscored in the registry. This may have led to an underestimation of 
the prognostic effects of comorbidity in the present study. 
Comorbidity did not affect the resection rate of patients with colorectal cancer, but led 
to less frequent use of adjuvant chemotherapy in patients with colonic cancer and of 
adjuvant radiotherapy in patients with rectal cancer, especially in those with previous 
malignancy. Comorbidity was also an independent negative prognostic factor, with 
previous malignancy and COPD having the greatest negative effect. Future studies on 
the treatment and outcome of elderly patients with colorectal cancer suffering from 
comorbidity should also take account of treatment dosages and complications, as well 
as broader geriatric assessment. 
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Elderly patients with rectal cancer have a higher 
risk of treatment-related complications and a 
poorer prognosis than younger patients: a 
population-based study 
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Summary 
 
It is likely that the shift from post- to preoperative radiotherapy and the introduction of 
total mesorectal excision (TME) surgery have contributed to the observed improved 
survival of rectal cancer in the south of the Netherlands. However, no improvement 
was seen for patients aged 70 or older. To investigate possible causes of this lack of 
improvement, we examined the risk of treatment-related complications and overall 
survival. Therefore, a random sample of 455 patients with rectal cancer aged 60 years 
or older, diagnosed between 1995 and 2001 was extracted from in the Eindhoven 
Cancer Registry database. Fifty-one percent of patients aged 60-69 years old had any 
complication within one year of diagnosis compared to 65% of patients aged 70 or 
older (p=0.007). Older patients were at higher risk of developing treatment-related 
complications (odds ratio (OR) 1.8; p=0.01), as were patients with comorbidity (OR 
1.7; p=0.07), and those who received preoperative radiotherapy (OR 1.8; p=0.02). In 
a multivariable analysis, age older than 70 (hazard ratio (HR) 2.2; p<0.0001), 
comorbidity (HR 1.7; p=0.03), and having two or more complications (HR=2.2; 
p=0.0002) had a negative effect on survival. The lack of improvement in the prognosis 
of elderly patients with rectal cancer might partially be explained by a higher risk of 
treatment-related complications and the high prevalence of comorbidity among these 
patients.  
  
 
Introduction 
 
The treatment of rectal cancer has changed during the last two decades. In the south-
east Netherlands, the shift from postoperative towards preoperative radiotherapy (5x5 
Gy) and the introduction of total mesorectal excision (TME) surgery have been the 
most important changes. It is very likely that these developments have contributed to 
the improved survival of patients with rectal cancer that was observed in this region. 47 
The decline in the relative risk of death in the period 19952000 versus 19801989 of 
patients with rectal cancer appeared to be related to age. Comparing both periods, the 
relative risk of death was 0.45 for patients under 60 years of age and 0.62 for those 
60-74 years old. However, no improvement in risk of death was found for patients over 
74 years of age. 47  
Current treatment guidelines for patients with rectal cancer include preoperative 
radiotherapy (5x5 Gy) for cT1-3 tumors, and prolonged chemoradiotherapy followed by 
resection and intraoperative radiotherapy (IORT) for cT4 tumors. Elderly patients are 
more likely to suffer from other chronic illnesses (comorbidity) which may contra-
indicate the standard treatment because of the fear of an increased risk of 
complications and death. 78-80 The results of a systematic review examining the 
outcome of surgery for colorectal cancer in elderly patients showed a progressive 
increase of postoperative morbidity and mortality with advancing age. 81 The 
contribution of age to this increased morbidity and mortality in elderly patients is not 
clear. The increased proportion of patients undergoing emergency surgery, together 
with more frequent comorbidity could contribute significantly to the increased risk of an 
adverse outcome in the elderly. 81-83 In this study, we investigated the influence of age 
and comorbidity on treatment related complications and survival of elderly patients with 
rectal cancer in the south-east of the Netherlands. 
 
Patients and methods 
 
Eindhoven Cancer Registry 
The Eindhoven Cancer Registry has been collecting data on patients with newly 
diagnosed cancer in a large part of southern Netherlands with a population of 2.3 
million inhabitants. The registry is notified by six pathology departments, 10 community 
hospitals and two radiotherapy institutes. Despite the lack of access to death 
certificates, the infrastructure of and good access to Dutch health care facilities in 
combination with the notification procedures used have made it possible to establish a 
completeness of the registry exceeding 95%. 54 
Information on diagnosis, staging, comorbidity at time of diagnosis, and treatment is 
routinely extracted from the medical records by the registrars usually 6 to 18 months 
after diagnosis. Prognostically relevant concomitant conditions are recorded from the 
medical records according to a slightly adapted version of the Charlson Index (Table 
1).43 In the original version used by Charlson and colleagues, not only the number but 
also the seriousness of the comorbid condition was taken into account. Within the 
framework of the cancer registry it was not feasible to register severity of comorbidity, 
but we only recorded serious comorbid conditions with possible prognostic impact. We 
  
also included hypertension, which has been shown to be a prognostic factor in some 
previous studies. In the analyses we classified comorbidity as no comorbidity, one 
comorbid condition, or two or more comorbid conditions. 
 
Table 1. Classification of comorbidity, according to an adapted version of Charlson et al. (1987) 
                                                                                                                                           
Previous malignancies (except basal skin carcinoma and  
carcinoma in situ of the cervix)       
   
   
Chronic Obstructive Pulmonary Diseases (COPD) 
    
Cardiovascular diseases (myocardial infarction, cardiac decompensation,  
angina pectoris, intermittent claudication, abdominal aneurysm,  
peripheral arterial disease)          
 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia)  
  
Hypertension 
          
Diabetes mellitus  
         
Digestive tract diseases (stomach diseases, Crohns disease,  
ulcerative colitis, liver cirrhosis, hepatitis)       
 
Other (connective tissue diseases, severe rheumatoid arthritis,  
kidney diseases, dementia, tuberculosis, chronic infections)     
 
 
 
Patient population 
The total number of patients with rectal adenocarcinoma aged 60 years or older 
diagnosed between 1995 and 2001 in the Eindhoven Cancer Registry area amounted to 
2094. Patients presenting with distant metastases (N=322) were excluded. Of the 
remaining patients, we randomly selected 455 patients, since the total patient 
population was too extensive to gather the additional information from the medical files 
(see below). The random selection procedure was carried out using SAS statistical 
software (SAS Institute Inc., Cary, North Carolina, USA, 1999). From the sample of 455 
rectal cancer patients, 29 clinical records could not be found in the hospitals due to 
migration, death or an unexplained reason. These 29 patients were excluded from the 
study. Fourteen of these patients (48%) died during the follow-up period completed on 
January 1st, 2005. 
 
Preoperative findings / social status 
Additional information on performance status, urgency of surgery, preoperative 
radiotherapy, and hemoglobin level, was recorded by two researchers (an 
epidemiologist and an experienced surgeon), with the approval and under supervision 
of the treating physicians. Performance status of patients was extracted from the 
medical record using the Karnofsky scale. For patients who underwent surgery we also 
recorded the American Society of Anesthesiologists (ASA) score. However, since 45% 
of the ASA score and 49% of the Karnofsky score were not mentioned in the medical 
  
 
files, we did not include these variables in our analyses. Patients with hemoglobin 
levels below 6.5 mmol per liter (before treatment or any transfusion) were assigned to 
the low hemoglobin group. 
Socio-economic status (SES) of the patient was defined at neighbourhood level (based 
on postal code of residence area, 17 households on average) combining mean 
household income (in 1998) and mean value of the house/apartment (in 2000), derived 
from individual fiscal data made available at an aggregated level. Postal codes were 
assigned to 3 SES categories: low (1st 3rd decile), intermediate (4th-7th decile), and 
high (8th-10th decile). Postal codes of institutions, such as nursing homes, were 
assigned to a separate category and were excluded from the logistic regression and 
survival analysis (19 patients, all aged 70 or older). 
 
Postoperative findings 
Serious complications occurring within one year of diagnosis were recorded. These 
were defined as minor infections (e.g. wound infections, urinary tract infections), major 
infections (e.g. abscess, peritonitis, anastomotic leakage), pulmonary complications 
(e.g. pneumonia), hemorrhage (requiring blood transfusion or surgery), thrombo-
embolic events, cardiac complications (e.g. cardiac failure, ischaemic heart disease), 
hematological complications, complications typically due to radiotherapy (e.g. radiation 
enteritis), stoma problems, death due to complications (stated in the medical file), and 
other complications (e.g. kidney failure, lymphoedema, fatigue, cerebral problems, 
ileus, incontinence, urine retention). 
Also the date of a local tumour recurrence was recorded. 
 
Follow-up 
Information on vital status of the patients was obtained from the hospital records, the 
civil municipal registries and the death register of the Central Bureau for Genealogy. 
The latter is an institution that registers all deceased Dutch citizens via the municipal 
civil registers. In this way, information on patients who had moved outside the registry 
area was also obtained. In total 201 (47%) colorectal cancer patients died during 
follow-up, which was completed on January 1st, 2005. The median follow-up in months 
was 48.5 (range 0-119). 
 
Statistical analyses 
The prevalence of complications was analysed according to age (dichotomised into <70 
and 70 years); significance was tested by means of a Chi square test. The 
independent influence of age, gender, stage, comorbidity, socioeconomic status, 
haemoglobin level and treatment on development of complications was analysed in a 
logistic regression analysis. Crude survival was computed with date of diagnosis as the 
starting point and death or end of study as endpoint. The log-rank test was used to 
compare univariable survival rates between groups of patients. Univariable survival 
analyses were stratified according to age at diagnosis (<70 and 70 years). 
Multivariable proportional hazards regression methods were used to discriminate 
independent risk factors for death. The likelihood ratio method was used to determine 
  
hazard ratios. The SAS computer package (version 8.2) was used for all statistical 
analyses (SAS Institute Inc., Cary, North Carolina, USA, 1999). 
 
Results 
 
The general characteristics are shown in table 2; 182 patients were between 60 and 69 
years old and 244 were aged 70 years or older. The male-female ratio was 1.8 among 
patients aged 60-69 and 1.0 among the elderly (p=0.004). Patients aged 70 years or 
older were more likely to have rectal cancer in an unknown stage than patients aged 
60-69 (12% vs. 7%, respectively), although there was no trend for older patients to be 
diagnosed in a more advanced stage of disease (p=0.3). Eighty-one percent of the 
patients aged 70 or older had one or more concomitant diseases compared to 64% of 
patients aged 60-69 (p<0.0001). Fourteen percent of patients aged 70 or older had low 
hemoglobin levels, in contrast to 7% of patients aged 60-69 (p=0.02). Of patients aged 
70 or older, 36% underwent preoperative radiotherapy, compared to 49% of younger 
patients (p=0.004); the proportion receiving other or no treatment was higher among 
the elderly. Four percent of patients underwent emergency surgery (2% of patients 
aged 60-69 vs. 5% of patients 70 or older, p=0.2; data not shown). 
 
Table 2. General characteristics of patients with rectal cancer diagnosed in 1995-2001 in the 
southern Netherlands, by age 
 
 
60-69 years 
(N=182) 
70+ years 
(N=244) 
  
 
N(%) N(%) 
 p-value* 
Gender  
      
Male  116 (64) 121 (50)  0.004 
Female 66 (36) 123 (50)   
Stage (TNM) 
      
I 56 (31) 69 (28)  0.3 
II 58 (32) 81 (33)   
III 55 (30) 64 (26)   
Unknown 13 (7) 30 (12)   
Comorbidity 
      
No comorbidity 61 (34) 41 (17)  <0.0001 
1 comorbid condition 55 (30) 64 (26)   
2 or more comorbid conditions 62 (34) 134 (55)   
Unknown comorbidity 4 (2) 5 (2)   
Socio-economic status       
High 63 (35) 81 (33)  0.0006 
Intermediate 61 (34) 88 (36)   
Low 58 (32) 56 (23)   
Institutionalized 0 (0) 19 (8)   
Haemoglobin level       
Normal (>6.5 mmol/l) 161 (89) 197 (81)  0.02 
Low (6.5 mmol/l) 13 (7) 34 (14)   
Unknown 8 (4) 13 (5)   
Treatment        
Surgery alone 78 (43) 115 (47)  0.004 
Preoperative radiotherapy 89 (49) 87 (36)   
Other/none 15 (8) 42 (17)   
* Chi-square test for equal proportions, the null hypothesis specifies equal proportions of the total 
sample size for each class. 
  
 
Fifty-one percent of patients aged 60-69 years old had any complication within one 
year of diagnosis compared to 65% of patients aged 70 or older (p=0.007) (figure 1). 
The most frequent complications within one year of diagnosis were minor infections, 
major infections, and pneumonia. Elderly patients suffered more from cardiac 
complications (8% vs. 2%, p= 0.01) and pneumonia (12% vs. 7%, p= 0.13) than 
younger patients, and there were also more deaths due to treatment complications 
(especially cardiac) among these patients (9% vs. 3%, p= 0.01).  
 
According to the results of the logistic regression analysis, the risk of developing 
complications was almost twice as high for patients aged 70 or older compared to 
younger patients (p=0.01, Table 3). Females appeared to have a lower risk of 
developing complications than males, whereas patients with stage III disease had a 
higher risk than those with stage I or II. The risk of developing complications was 
higher for patients with comorbidity compared to those without comorbidity, although 
not significantly (OR=1.7 for one concomitant disease; OR=1.5 for two or more 
concomitant diseases). This effect was more pronounced among patients aged 70 or 
older (OR=2.3, p=0.04 for one concomitant disease; OR=2.3, p=0.03 for two or more 
concomitant diseases; data not shown). Patients who underwent surgery plus 
radiotherapy had a significantly higher risk of developing complications (OR=1.8, 
p=0.02) compared to those who underwent surgery alone. 
 
 
Figure 1. Age-specific prevalence of complications during the first year after diagnosis among 
rectal cancer patients diagnosed between 1995 and 2001 
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Table 3. Risk of developing complications within one year after diagnosis for patients who 
underwent elective surgery for rectal cancer diagnosed between 1995 and 2001 in the southern 
Netherlands; multivariable logistic regression model including all variables listed* 
 
 
Odds ratio p-value 
Age  
  
60-69 years 1.0  
70+years 1.8 0.01 
Gender 
  
Male 1.0  
Female 0.7 0.08 
Stage (TNM) 
  
I 1.0  
II 1.1 0.7 
III 1.8 0.04 
Comorbidity 
  
No comorbidity 1.0  
1 comorbid condition 1.7 0.07 
2 or more comorbid conditions 1.5 0.2 
Socio-economic status 
  
High 1.0  
Intermediate 0.8 0.4 
Low 1.0 0.9 
Hemoglobin level 
  
Normal (>6.5mmol/l)  1.0  
Low (6.5mmol/l) 1.1 0.3 
Treatment  
  
Surgery alone 1.0  
Surgery + radiotherapy 1.8 0.02 
*Cases with missing values for any of the covariates were left out of the analyses 
 Reference category  
 
 
The rate of local recurrence was similar for patients who underwent surgery plus 
preoperative radiotherapy and for those who underwent surgery alone (6% vs. 8%, 
p=0.4; no difference by age). 
The crude 5-year survival rate was 70% for patients aged 60-69 years old and 44% for 
patients aged 70 or older (p<0.0001, table 4). These rates increased to 79% for 
patients aged 60-69 years without comorbidity and 60% for patients aged 70 or older 
without comorbidity. For both age groups the crude survival decreased with an 
increasing number of comorbid conditions, higher stage and number of complications. 
For patients aged 70 or older crude survival was also worse for those with a low 
hemoglobin level and for those receiving adjuvant radiotherapy or other/none 
treatment. In a multivariable analysis, higher age (hazard ratio (HR) =2.2), comorbidity 
(HR=1.7) and the development of 2 or more complications had a negative effect on 
survival. The receipt of preoperative radiotherapy had a borderline significant negative 
influence on survival (HR=1.4, p=0.10).  
  
 
Table 4. Uni- and multivariable analyses for overall survival of patients with rectal cancer 
diagnosed between 1995 and 2001 in the southern Netherlands.*                                  
 
 Univariable Multivariable 
 60-69 years 70+ years All ages 
 5 yrs% P-value 5 yrs% p-value Hazard 
ratio 
p-value 
Age  
      
60-69 years 70    1.0  
70+ years   44 <0.0001 2.2 <0.0001 
Gender 
      
Male 67  46  1.0  
Female 76 0.2 42 0.2 1.0 0.8 
Stage (TNM) 
      
I 82  63  1.0  
II 68  45  1.3 0.3 
III 59 0.03 30 0.001 2.0 0.002 
Comorbidity  
      
No comorbidity 79  60  1.0  
1 comorbid condition 71  47  1.7 0.05 
2 or more comorbid conditions 63 0.03 38 0.09 1.7 0.03 
Socio- economic status 
      
High 79  42  1.0  
Intermediate 65  52  0.7 0.10 
Low 66 0.3 42 0.6 0.9 0.6 
Hemoglobin level 
      
Normal (>6.5mmol/l) 71  46  1.0  
Low (6.5mmol/l) 58 0.7 34 0.01 1.1 0.2 
Treatment  
      
Surgery alone 70  56  1.0  
Surgery + radiotherapy 71  42  1.4 0.10 
Other/none   18 0.002   
Complications 
      
No complication 81  58  1.0  
1 complication 69  50  1.1 0.8 
2 or more complications 54 0.007 29 0.0003 2.2 0.0002 
*Cases with missing values for any of the covariates were left out of the analyses 
1 Reference category  
 Analyses could not be completed due to small numbers  
 
 
Discussion 
 
Patients aged 70 years or older underwent surgery in combination with preoperative 
radiotherapy (36%) less often than patients aged 60-69 years (49%). Elderly patients 
and those who underwent surgery plus radiotherapy had a significantly higher risk of 
developing complications, especially pneumonia, cardiac complications and death due 
to complications. Independent prognostic factors were higher age, comorbidity, higher 
stage, and having two or more complications.  
 
Previous population-based studies already described the influence of age on the receipt 
of adjuvant radiotherapy for rectal cancer patients. 59, 79 The physician might decide not 
to refer elderly patients for radiotherapy because of advanced age or serious 
comorbidity, but other factors might also play a role, such as a decreased general 
  
mental and physical condition, refusal of the patient, the absence of caregivers in the 
family situation, and distance to the radiotherapy institute. 59, 79 It is likely that the 
influence of these factors is more important in the longer-term postoperative setting 
than in the relatively short (5x5 Gy) preoperative setting. Since 1995, postoperative 
radiotherapy has been largely replaced by preoperative radiotherapy in the south of the 
Netherlands; the rate of postoperative radiotherapy has dropped to 4%.47 
The current study showed that elderly patients developed more treatment related 
complications, especially pneumonia and cardiac complications, and were at a higher 
risk of dying due to a complication. The effect of age on postoperative morbidity and 
mortality has already been described in a number of other studies. 84-87 A recent 
prospective multicenter study in France found age older than 70 years and neurologic 
and cardiorespiratory comorbidity to be independent risk factors of morbidity after 
colorectal surgery, and age older than 70 years and neurological comorbidity were 
preoperative risk factors of mortality. 88 In a review of 28 studies on colorectal cancer 
surgery in the elderly, an increased frequency of postoperative morbidity and mortality 
with advancing age was reported. 81 Pooled data suggested an age-related increase for 
pneumonia/respiratory failure, cardiovascular complications, cerebrovascular accident, 
and thromboembolism. There was no increased frequency of anastomotic leaks in the 
elderly. Overall 5-year survival decreased by age, although there was only little 
difference in cancer-specific survival. Unfortunately, in this retrospective population-
based study we did not have data on cause of death at our disposal. 
Preoperative radiotherapy reduces the risk of a local recurrence; it tends however to 
increase the risk of developing complications, including impaired wound healing and 
bowel dysfunction. 50, 84, 89-92 Some authors considered preoperative radiotherapy as a 
risk factor for anastomotic leakage. 93, 94 Also in our study, patients who underwent 
surgery plus preoperative radiotherapy developed more complications than patients 
undergoing surgery alone. Minor infections such as delay of wound healing were the 
most frequent complications after adjuvant radiotherapy (18%). Prognosis was 
negatively affected by age and comorbidity, in line with previous studies. 72, 81, 95-97 The 
Stockholm II Trial reported that both the increase in postoperative mortality and the 
higher incidence of intercurrent death after radiotherapy were mainly caused by 
cardiovascular disease. 98 The cause of the increased cardiovascular mortality is not 
known. One explanation is that, in addition to a local effect on the vascular bed, there 
is also a systemic effect that may result in thromboembolic and cardiovascular 
complications developing with time. 99, 100 In the current study the risk of local 
recurrence for the group as a whole was low and was similar for patients receiving 
preoperative radiotherapy and for those undergoing surgery alone. However, 
regardless of having recurrence or survival as an endpoint, comparison of treatment 
outcome in a retrospective population-based study may be biased due to selection of 
patients by the treating physician. 
Unfortunately, ASA and performance score were not mentioned in the majority of the 
medical files, so that these important variables could not be included in our study. 
Performance score is found to have a prognostic impact, independent of comorbidity. 74 
On the other hand, performance score is often amenable to the malignant disease and 
its treatment, in contrast to comorbidity. ASA score was found to be a predictor of 
  
 
mortality following surgery for colorectal cancer in some studies 101, 102; however, 
others did not find an independent effect of ASA on perioperative mortality or 
morbidity. 83, 88 This may be due to the considerable interobserver inconsistency of 
classification of ASA score. 103, 104   
In a previous study it was shown that survival of rectal cancer patients aged 75 or 
older did not improve in the south of the Netherlands between 1980 and 2000, 
whereas there was a clear improvement for the younger patients. 47 This observation 
seems to be partly explained by the results of the current study: elderly patients were 
at higher risk of developing treatment-related complications. Also the high prevalence 
of comorbidity is likely to contribute to the lack of improvement for the elderly patients. 
In order to optimize the risk/benefit ratio of elderly patients, individualization of 
treatment by means of a comprehensive geriatric assessment will be of critical 
importance. 
 
  
 
Chapter 2.3  
 
Which comorbid conditions predict complications 
after surgery for colorectal cancer? 
 
Reprinted from World Journal of Surgery 31(1): Lemmens VEPP, Janssen-Heijnen MLG, 
Houterman S, Verheij CDGW, Martijn H, van de Poll-Franse LV, Coebergh JWW: Which 
comorbid conditions predict complications after surgery for colorectal cancer? Pages 
192-199. © 2006, with permission from Springer.  
 
 
Summary 
 
Background: Accurate presurgical assessment is important to anticipate postoperative 
complications, especially in the growing proportion of elderly cancer patients. We 
defined which comorbid conditions at time of diagnosis predict complications after 
surgery for colorectal cancer.  
Patients: A random sample of 431 patients recorded in the population-based 
Eindhoven Cancer Registry who underwent resection for stage I-III colorectal cancer, 
newly diagnosed between 1995 and 1999.  
Methods: The influence of specific comorbid conditions on the incidence and type of 
complications after surgery for colorectal cancer was analysed.  
Results: Overall, patients with comorbidity did not develop more surgical 
complications. However, patients with a tumour located in the colon who suffered from 
concomitant chronic obstructive pulmonary disease (COPD) more often developed 
pneumonia (18% vs. 2%; p=0.0002) and haemorrhage (9% vs. 1%; p=0.02). Patients 
with colon cancer who suffered from deep vein thrombosis (DVT) at the time of cancer 
diagnosis more often had surgical complications (67% vs. 30%; p=0.04), especially 
more minor (44% vs. 11%; p=0.002) and major infections (56% vs. 10%; p<0.0001), 
pneumonia (22% vs. 2%; p=0.01), and thromboembolic complications (11% vs. 3%; 
p=0.02). Patients with a tumour located in the rectum who suffered from COPD more 
frequently had any surgical complication (73% vs. 46%; p=0.04), and presence of DVT 
at time of cancer diagnosis was predictive of thromboembolic complications (17% vs. 
4%; p=0.045).  
Conclusions: Among patients undergoing surgery for colorectal cancer, development 
of complications was especially predicted by presence of COPD and DVT. In the latter, 
regulation of the pre- and postsurgical haemostatic balance needs full attention.
  
 
Introduction 
 
Colorectal cancer (CRC) is the second most common cause of cancer death in 
industrialized countries 105. Seventy-five percent of incident tumours occur in persons 
aged 65 years or older. Because of their age, these patients are likely to suffer from 
other chronic illnesses in addition to the colorectal malignancy (comorbidity). In the 
Netherlands, 60% of patients with CRC over the age of 70 suffer from comorbidity 80. 
Resection rates however remain at a high level among these patients, explained by the 
fact that resection is the only primary curative treatment for CRC, and often necessary 
to prevent obstruction. In the last decades, the safety of surgery for CRC has improved 
by advances in surgical technique, anaesthesia, intensive care therapy, antibiotic 
treatments, thromboprophylaxis, and other supportive measures 106, 107. Especially in 
patients suffering from comorbidity, an accurate presurgical assessment is important in 
planning surgery and supportive treatment. In order to stratify patients into groups 
with varying risks of complications based on their comorbidity, we evaluated the 
influence of specific comorbid conditions on incidence and type of complications after 
surgery for CRC, using data from the population-based Eindhoven Cancer Registry in 
the Netherlands. 
 
Patients and methods 
 
The Eindhoven Cancer Registry (ECR) collects data on all patients with newly 
diagnosed cancer in a large part of the southern Netherlands with a population of 2.4 
million. The registry is notified by 6 pathology departments, 10 community hospitals 
and 2 radiotherapy institutes. There are no university hospitals in the region. 
Registration takes place 6 to 18 months after diagnosis. Despite the lack of access to 
death certificates, the infrastructure of and good access to Dutch health care facilities 
in combination with  the notification procedures used have made it possible to establish 
a completeness of the registry of more than 95% 54.  
Between 1995 and 1999, 5352 patients were diagnosed with primary CRC in the ECR 
area. Since it was not feasible to review the medical records of all patients in order to 
collect additional data, a random sample of 545 patients aged 40 years and older with 
colorectal adenocarcinoma diagnosed between 1995 and 1999 was extracted. The 
randomisation procedure was run by a computer program (SAS statistical software, 
SAS Institute Inc., Cary, North Carolina, USA, 1999). Colon tumours were defined as 
C18.0-C18.7 and rectal tumours as C19.9-C20.9, according to ICD-O-3. For the random 
sample of 545 colorectal cancer patients, 31 clinical records could not be found in the 
hospitals (i.e. patients moved to another area or country) and 8 clinical records were 
incomplete. These 39 patients were excluded from the study. They did not differ from 
the study population according to age or stage (the latter known for 29 out of 39 
excluded patients) at diagnosis. Next, we excluded patients who presented with distant 
metastasis (n=27), patients with unknown stage of disease (n=40), and patients who 
did not undergo a resection (n=21). 
Information on diagnosis, staging, comorbidity at time of diagnosis, and treatment is 
routinely extracted from the medical records by the registrars. Comorbidity was 
  
recorded according to a slightly adapted version of the Charlson Index (table 1). In the 
original version used by Charlson and colleagues, not only the number but also the 
severity of the comorbid condition was taken into account. Within the framework of the 
cancer registry it was not feasible to register severity of comorbidity; the comorbid 
conditions as listed in table 1 were recorded if they were present at the time of cancer 
diagnosis. We also included hypertension, which has been shown to be a prognostic 
factor in some previous studies. Additional information was recorded by two 
researchers (an epidemiologist and an experienced surgeon, always working together), 
with the approval and under supervision of the treating physicians. Performance status 
of patients was extracted from the medical record using the Karnofsky scale 108. Also 
the American Society of Anaesthesiologists (ASA) physical score was recorded 109. 
However, due to incomplete documentation of performance status (87% missing) and 
ASA scores (65% of the scores for resected patients missing), these variables could not 
be included in our analyses. 
 
Table 1. Classification of comorbidity, according to an adapted version of Charlson et al. (1987)43 
                                                                                                                                           
Previous malignancies (except basal skin carcinoma and  
carcinoma in situ of the cervix)       
   
   
Chronic Obstructive Pulmonary Diseases (COPD) 
    
Cardiovascular diseases (myocardial infarction, cardiac decompensation,  
angina pectoris, intermittent claudication, abdominal aneurysm,  
peripheral arterial disease)          
 
Deep vein thrombosis (DVT) 
 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia)  
  
Hypertension 
          
Diabetes mellitus  
       
Other (digestive tract disease, connective tissue diseases, severe rheumatoid arthritis,  
kidney diseases, dementia, tuberculosis, chronic infections)     
 
 
Blood haemoglobin level (before any transfusion) was extracted from the medical 
record; patients with haemoglobin levels below 6.5 mmol per litre were assigned to the 
low haemoglobin group 110.  
Preoperative radiotherapy was recorded as yes vs. no. Timing (elective vs. emergency) 
and type of surgery was also recorded.  
Serious surgical complications as described in the medical records, occurring within 60 
days of diagnosis were recorded. Complications registered were minor infection (e.g. 
wound infections, wound dehiscence, urinary tract infections), major infection (e.g. 
abscess, peritonitis, anastomotic leakage), pulmonary complications (e.g. pneumonia), 
haemorrhage (requiring blood transfusion or reoperation), thrombo-embolic events, 
cardiac failure (e.g. cardiac insufficiency), kidney failure, stoma problems (e.g. stomal 
necrosis), and other complications. Also death due to complications was recorded, 
  
 
judged from the information in the medical record whether the patients death could be 
directly linked to a preceding complication. 
The association between comorbidity and complications was analysed using a chi-
square test. Then, the association between comorbidity and complications was 
evaluated in a logistic regression model; first, a model including age, gender, stage, 
tumour site, haemoglobin level, timing of surgery, preoperative radiotherapy, and 
presence of comorbidity (yes vs. no) was built. No interaction term reached statistical 
significance. Thereafter, the model was run again with presence of comorbidity 
replaced by presence of the respective comorbid condition (having no comorbidity as a 
reference). All variables were included in the model without the use of a forward or 
backward procedure, in order to conclude about the effects of the all included variables 
on the development of complications. The SAS computer package (version 8.2) was 
used for all statistical analyses (SAS Institute Inc., Cary, North Carolina, USA, 1999). 
 
Results 
 
The general characteristics of the 418 patients are depicted in table 2. The use of 
preoperative radiotherapy for patients with rectal cancer increased during the study 
period, from 24% in 1995 to 53% in 1999. 
The most frequent comorbid conditions at the time of the colorectal cancer diagnosis 
were cardiovascular disease, hypertension, and a previous malignancy, for both colon 
and rectal cancer (table 3).  
 
In table 4 the frequency of surgical complications are depicted. Minor and major 
infections were the most frequent complications for both colon and rectal cancer 
patients. 
Thirty percent of patients with colon cancer who did not suffer from comorbidity 
developed surgical complications (table 5). Patients with thrombosis present at the time 
of cancer diagnosis were at higher risk of developing any surgical complication 
(p=0.04). Especially minor infections (p=0.002), major infections (p<0.0001), 
pneumonia (p=0.01), and thrombo-embolic complications (p=0.02) more frequently 
developed among these patients. Among patients who suffered from COPD at time of 
cancer diagnosis, pneumonia (p=0.0002) and haemorrhage (p=0.02) were more 
frequent than among patients without comorbidity. Patients with COPD also seemed to 
develop more major infections, although this relation did not reach statistical 
significance (p=0.07).  
 
Forty-six percent of patients with rectal cancer not suffering from comorbidity 
developed a surgical complication (table 6). Patients presenting with COPD more 
frequently developed any surgical complication (p=0.04), and patients with thrombosis 
at time of cancer diagnosis developed more often thrombo-embolic events 
postoperatively (p=0.045).  
Eight percent (n=22) of patients with colon cancer and 7% (n=9) of patients with 
rectal cancer died within 60 days of diagnosis, following a surgical complication (mainly 
after cardiac complications and deep infections). Thirty-six percent (n=11) of the 
  
deceased patients underwent an emergency operation. The presence of comorbidity 
increased the risk of dying following a complication (3% of patients without 
comorbidity vs. 10% of patients with comorbidity, p=0.04) 
 
 
Table 2. Patient characteristics and treatment of 418 patients who underwent resection for 
colorectal cancer between 1995 and 1999 in the southern Netherlands. 
 
 
Colon Rectum 
 (n=279) (n=139) 
Mean age (range in yrs.) 70 (41-92) 67 (42-86) 
     
 
n (%) n (%) 
Gender 
    
  Male 133 (48) 84 (60) 
  Female 146 (52) 55 (40) 
Stage 
    
  I 51 (18) 46 (33) 
  II 134 (48) 50 (36) 
  III 94 (34) 43 (31) 
Site of tumour 
    
  Colon ascendens 109 (39)   
  Colon transversum 62 (22)   
  Colon descendens 108 (39)   
  Rectosigmoid   31 (22) 
  Rectum   108 (78) 
Number of comorbid conditions 
    
  0 77 (28) 53 (38) 
  1  87 (31) 38 (28) 
  2+ 103 (37) 45 (32) 
  Unknown 12 (4) 3 (2) 
Type of surgery 
    
  Surgery, not specified 13 (5) 6 (4) 
  Total procto-colectomy 1 (0.4) 2 (1) 
  Subtotal colectomy 12 (4)   
  Hemicolectomy, right / ileocoecal resection 135 (48)   
  Hemicolectomy, left 33 (12)   
  Sigmoid resection with primary anastomosis 85 (31)   
  Rectosigmoid resection with Hartmann-procedure   10 (7) 
  Low anterior resection with  primary anastomosis   78 (57) 
  Abdominoperineal resection   43 (31) 
Timing of surgery     
  Elective operation 227 (81) 125 (90) 
  Emergency operation 37 (13) 5 (4) 
  Unknown 15 (5) 9 (6) 
Pre-operative radiotherapy 
  55 (40)a 
a
 Ranging from 24% in 1995 to 53% in 1999. 
 
 
After adjustment for age, gender, stage, tumour site, haemoglobin level, timing of 
surgery, and preoperative radiotherapy, patients with comorbidity in general did not 
have a higher risk of developing any surgical complication (odds ratio (OR) 1.1, p=0.2) 
(table 7). However, presence of DVT at time of cancer diagnosis increased the risk of 
developing a complication compared to patients without comorbidity (OR 9.0; p=0.04). 
The risk of developing a complication also seemed to be increased for patients with 
  
 
COPD (OR 1.8, p=0.2), and decreased for patients with diabetes (OR 0.6, p=0.2), 
although both effects did not reach statistical significance. Furthermore, age older than 
70 years, a tumour located in the rectum, and emergency surgery all independently 
increased the risk of developing a surgical complication.  
 
Table 3. Prevalence of comorbidity at time of diagnosis according to tumour site, among patients 
who underwent resection for colorectal cancer diagnosed between 1995 and 1999 in the southern 
Netherlands.a,b 
 
 Colon 
(n=267) 
n (%) 
Rectum 
(n=136) 
n (%) 
No comorbidity 77 (29) 53 (39) 
Previous malignancy 54 (20) 18 (13) 
Cardiovascular disease 90 (34) 38 (28) 
COPD 36 (13) 12 (9) 
Diabetes mellitus 26 (10) 13 (10) 
Hypertension 68 (25) 37 (27) 
DVT 9 (3) 6 (4) 
Other c 51 (19) 20 (15) 
a
 Excluding patients with unknown comorbidity (n=15) 
b
 More than one condition per patient possible 
c Including digestive tract diseases, connective tissue diseases, severe rheumatoid arthritis, kidney 
diseases, dementia, tuberculosis, and chronic infections 
 
 
Table 4. Postoperative complications within 60 days of diagnosis according to tumour site, among 
patients with colorectal cancer diagnosed between 1995 and 1999 in the southern Netherlands.a,b 
 
 
Colon 
(n=270) 
n (%) 
Rectum 
(n=136) 
n (%) 
Any complications 96 (36) 63 (46) 
Minor infections c 33 (12) 18 (13) 
Major infections d 27 (10) 17 (13) 
Pneumonia 13 (5) 8 (6) 
Haemorrhage 7 (3) 8 (6) 
Thrombosis 5 (2) 4 (3) 
Cardiac failure 24 (9) 8 (6) 
Kidney failure 6 (2) 5 (4) 
Stoma problems 4 (1) 7 (4) 
Death due to complication 20 (7) 9 (7) 
Other e 5 (2) 5 (4) 
a
 Excluding patients with unknown complications (n=12). 
b
 More than 1 complication per patient possible. 
c
 Including wound infections, wound dehiscence, urinary tract infections. 
d
 Including abscess, peritonitis, anastomotic leakage. 
 
 
Discussion 
 
Unsurprisingly, a large proportion of the colorectal cancer (CRC) patients in our study 
presented with one or more comorbid conditions at the time of cancer diagnosis.80 
Overall, comorbidity was not associated with postoperative morbidity after surgery for 
CRC, but several specific comorbid conditions were related to a more frequent 
  
development of complications. Especially patients suffering from deep vein thrombosis 
(DVT) or chronic obstructive pulmonary disease (COPD) at time of diagnosis were at 
higher risk. 
Operative morbidity clearly depends on patient selection and underlying pathology. 
Many studies have therefore attempted to link presurgical risk factors to morbidity and 
mortality.81, 83, 88, 93, 106, 111-115 Most of these were single-hospital studies; only few 
population-based studies have been able to stratify patients into groups with varying 
risks of complications based on their comorbid conditions.88, 93, 106, 114 One of the 
advantages of using population-based data is the avoidance of several potential 
sources of bias, such as referral bias and exclusion of emergency cases. Also, inclusion 
of non-academic hospitals of different size, subspecialties, and levels of surgical 
experience may provide a more realistic image of every-day practice, including 
postoperative morbidity.106 The complication rate of 39% in the current study is higher 
than that found in most other studies, which could partly be explained by the more 
accurate reflection of postoperative morbidity than in other, mostly single-hospital 
studies.81, 83, 88, 93, 106, 111-115 However, the higher rate of complications in our study was 
probably also caused by the fact that we scored all surgical complications within 60 
days of diagnosis (due to the lack of the date of operation) instead of the commonly 
used period of 30 days within operation. Unfortunately, performance status and ASA 
score were in many instances not adequately documented in the medical records, so 
this information could not be used in our analysis.  
We found that patients with colon cancer and presence of deep vein thrombosis (DVT) 
at time of cancer diagnosis were at higher risk of developing complications. These 
patients especially had more infections, pneumonia, and postoperative thrombo-
embolic events. The complex relation between cancer and DVT has been well-
established.116, 117 Besides the fact that cancer patients are at high risk of DVT, surgery 
for malignant disease increases the risk development of DVT, further enhanced by the 
presence of central venous catheters and prolonged bed rest.107, 117 There is evidence 
that a hypercoagulable state may contribute to the development of anastomotic 
leakage by facilitating formation of microthromboses in the perianastomotic region.118 
It seems plausible that in patients with clinically evident DVT at time of cancer 
diagnosis, major abdominal surgery will further stress the haemostatic balance. This 
consequently leads to impaired wound healing and a higher risk of developing surgical 
complications.116 To our knowledge, only one population-based study has described the 
relation between preoperative haemostatic balance and postoperative morbidity after 
surgery for colorectal cancer.106 Using data from the National Veterans Affairs Surgical 
Quality Improvement Program, the authors found preoperative prothrombin times of 
less than 12 seconds to be predictive of three of the most frequently occurring 
complications after colectomy. The management of DVT in the presence of malignancy 
is complex, due both to the effects of the cancer itself and its treatment. Recent 
research indicates that the use of low molecular weight dalteparin, instead of vitamin K 
antagonists such as warfarin, offers an effective alternative in the management of DVT, 
free from the practical problems associated with the use of vitamin K antagonists, and 
without increasing the risk of bleeding.116, 117, 119, 120 
  
 
 
 
 
Table 5. Development of postoperative complications within 60 days of diagnosis according to comorbid condition, among patients with colon cancer diagnosed  
between 1995 and 1999 in the southern Netherlands. 
 
  
Surgical complication 
Comorbid condition n Any surgical 
Complication 
(n=96) 
Minor 
Infections 
(n=33) 
Major 
Infections 
(n=27) 
Pneumonia 
(n=13) 
Haemorrhage 
(n=7) 
Thrombosis 
(n=5) 
Cardiac failure 
(n=24) 
Kidney 
failure (n=6) 
Stoma 
problems (n=4) 
No comorbidity 77 30% 11% 10% 2% 1% 3% 6% 3% 1% 
Previous malignancy 54 47%* 16% 10% 10%*  6% 0% 10% 2% 2% 
Cardiovascular disease 90 
 
39% 11% 11% 7% 5% 1% 13% 1% 1% 
COPD 36 42% 15% 18%* 18% ** 9%** 0% 15% 0% 3% 
Diabetes 26 21%* 8% 0%*  4%  4% 0% 0%* 4% 0% 
Hypertension 68 33% 10% 11% 3% 2% 0% 8% 2% 0% 
DVT  9 67% **  44%**  56%**  22%**  11% 11%** 22% 0% 0% 
Percentages depict the proportion of patients which developed the respective complication in presence of the respective comorbid condition. 
** p < 0.05 (chance of developing a complication in presence of the respective comorbid condition vs. chance of developing a complication in absence of comorbidity). 
* p < 0.10 (chance of developing a complication in presence of the respective comorbid condition vs. chance of developing a complication in absence of comorbidity). 
 
 
Table 6. Development of postoperative complications within 60 days of diagnosis according to comorbid condition, among patients with rectal cancer diagnosed  
between 1995 and 1999 in the southern Netherlands. 
 
  
Surgical complication 
Comorbid 
condition 
 
n 
Any surgical 
Complication 
(n=63) 
Minor 
Infections 
(n=18) 
Major 
Infections 
(n=17) 
Pneumonia 
(n=8) 
Haemorrhage 
(n=8) 
Thrombosis 
(n=4) 
Cardiac 
failure 
(n=8) 
Kidney 
failure 
(n=5) 
Stoma 
problems 
(n=7) 
No comorbidity 53 46% 13% 10% 8% 10% 4% 4% 2% 6% 
Previous 
malignancy 
18 
 
50% 22% 17% 6%  11% 0% 6% 11% 0% 
Cardiovascular 
disease 
38 
 
53% 15% 9% 3% 6% 0% 6% 6% 3% 
COPD 12 73%** 9% 18% 9%  0% 0% 18%* 0% 18%* 
Diabetes 13 62% 15% 15%  0%  0% 8% 0% 8% 8% 
Hypertension 37 53% 14% 19% 6% 6% 0% 8% 6% 11%* 
DVT 6 67%   33%*  17%  0%  0% 17%** 17% 0% 0% 
Percentages depict the proportion of patients which developed the respective complication in presence of the respective comorbid condition. 
** p < 0.05 (chance of developing a complication in presence of the respective comorbid condition vs. chance of developing a complication in absence of comorbidity). 
* p < 0.10 (chance of developing a complication in presence of the respective comorbid condition vs. chance of developing a complication in absence of comorbidity)
  
Table 7. Risk of developing a surgical complication among patients with colorectal cancer 
diagnosed between 1995 and 1999 in the southern Netherlands, calculated by means of a logistic 
regression analysis. a 
 Odds ratio  p-value 
Age  
   
   <70 years b 1.0   
   70+ years 1.8  0.02 
Gender 
   
   Male b 1.0   
   Female 1.1  0.8 
Stage 
   
   I b 1.0   
   II 1.0  0.9 
   III 1.2  0.6 
Tumoursite 
   
   Colon b 1.0   
   Rectum 1.9  0.03 
Haemoglobin level 
   
   Normal (>6.5 mmol/l) b 1.0   
   Low (≤ 6.5 mmol/l) 1.2  0.6 
Timing of surgery 
   
   Elective surgery b 1.0   
   Emergency surgery 3.2  0.005 
Preoperative radiotherapy 
   
   No b 1.0   
   Yes 1.5  0.18 
Comorbidity 
   
   No comorbidity b 1.0   
   Any comorbidity 1.1  0.2 
   -Previous malignancy 1.2  0.5 
   -Cardiovascular disease 0.9  0.6 
   -COPD 1.8  0.2 
   -Diabetes 0.6  0.16 
   -Hypertension 0.7  0.4 
   -DVT 9.0  0.04 
a
 Adjusted for all listed variables 
b
 Reference category 
 
 
The presence of COPD was predictive of development of pneumonia and haemorrhage 
among patients with colon cancer in our study. Cardiopulmonary comorbidity was also 
associated  with a higher risk of postoperative morbidity after colorectal surgery in a 
French prospective multicenter study,88 while a history of COPD was an independent 
predictor of postoperative 30-day morbidity in patients after colectomy for colon cancer 
in a large US population-based study.106 Surprisingly, COPD was not predictive of 
pneumonia in that study, opposite to being a current cigarette smoker. COPD was 
found to be related to the development of major infections in two studies;106, 114 among 
the colon cancer patients in our study, this effect did not reach statistical significance. 
Among rectal cancer patients, COPD was predictive for development of any surgical 
complication. The effect of COPD might be distorted by smoking status; smoking may 
have an independent negative effect on the development of complications.121 Smoking 
is associated with microvascular disease, which in turn predisposes to anastomotic 
breakdown. This effect may in part be due to vasospasm in the diseased vessels, which 
are hypersensitive to serotonin, a vasoactive amine known to be present in increased 

  
 
quantities in the serum of smokers. Treatment with serotonin antagonists in the 
perioperative period may therefore be beneficial to anastomotic healing, helping to 
maintain microvascular flow.121 In the logistic regression analysis, COPD did not have a 
significant effect on the development of complications, probably due to the relatively 
small sample size used in our study and the resulting lack of power. 
To conclude, we found that among patients undergoing surgery for colorectal cancer, 
development of complications was especially predicted by presence of COPD and DVT. 
The effect of DVT on postoperative complications will have to be addressed in larger, 
prospective studies. Meanwhile, regulation of the pre- and postsurgical haemostatic 
balance in these patients needs full attention.  
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Summary 
 
Aims: Population-based cancer registries can provide excellent data for insight in 
disease management practice. This study examines the extent to which the consensus-
based national clinical guidelines (version 2000-2001) for colorectal cancer (CRC) had 
been implemented in the diagnostic and treatment approach in the southern 
Netherlands in 2002. 
Methods: Data were gathered from the medical records for a random sample from the 
Eindhoven Cancer Registry of 308 patients with colorectal cancer. Adherence to clinical 
guidelines was determined for diagnostic assessment, pathology, and treatment during 
the first year after diagnosis.  
Results: Surgical procedures and referral for preoperative radiotherapy were carried 
out largely conform the recommendations. The number of performed colonoscopies 
among colon cancer patients amounted to 60%; contrast enemas after incomplete 
colonoscopy were performed in only 27% of patients. The median number of examined 
lymph nodes was only 6 for patients with colon and 5 for patients with rectal cancer; 
the administration of adjuvant chemotherapy for patients with stage III colon cancer 
decreased from 95% of patients younger than 70 years to 48% of patients over 70. 
Conclusions: Adherence to clinical guidelines was not optimal. Feedback to surgeons 
and pathologists should improve adherence, especially with respect to nodal retrieval 
and assessment.  
  
 
Introduction 
 
Colorectal cancer (CRC) is the second most common cause of cancer in industrialized 
countries 105. In the year 2001, over 9200 patients were diagnosed with CRC in the 
Netherlands; almost 4300 patients died of their disease 122. Over a period of more than 
20 years, a clear improvement in survival of patients with CRC was attained by earlier 
detection (e.g. by low barrier endoscopy), better staging, improved surgery and 
combined modality treatment 47, 123, 124. Promoted by concerns regarding practice 
variations, the standard of care for CRC in the Netherlands is formulated in clinical 
practice guidelines since the mid 1990s. Clinical practice guidelines are defined as 
systemically developed statements to assist both practitioner and patient decisions 
about appropriate health care for specific clinical circumstances125. Explicit guidelines 
improve clinical care including patient survival 126, 127. However, recommendations 
made in guidelines are not always followed; important variations in clinical practice are 
well documented in the Netherlands and elsewhere 128, 129. Reasons for non-compliance 
may be high complexity of recommended procedures, high age of the patient, 
disagreement with guidelines, new developments described in recent literature, and a 
lack of manpower, money, space or equipment 130, 131. 
Population-based cancer registries can provide excellent data for drawing an accurate 
picture of disease management practice. The objective of this study was to determine 
the extent to which the guidelines for CRC had been implemented in the diagnostic and 
treatment approach of general hospitals in the Eindhoven Cancer Registry area in the 
southern Netherlands, in 2002. 
 
Patients and methods 
 
The Comprehensive Cancer Centre South is one of nine regional cancer centers in the 
Netherlands with a policy of improving the quality of oncological care in a broad sense, 
thereby using the data of the Eindhoven Cancer Registry for studies on the 
effectiveness of care. The Registry records data on all patients newly diagnosed with 
cancer in the southern part of the Netherlands, comprising an area of 2.3 million 
inhabitants. The registry is notified by six pathology departments, hospital medical 
records offices in 10 community hospitals, and two radiotherapy institutes. There are 
no university hospitals in the region. Information on diagnosis, staging, comorbidity 
and treatment is routinely recorded from the medical records by trained registrars. The 
medical records contain letters from and to other specialists, the medical history, 
pathology reports, information on previous admissions, current medication, and 
preoperative screening. For this study additional data were gathered for a random 
sample of 170 patients newly diagnosed with colon cancer in 2002, and for a random 
sample of 138 patients who underwent surgery for a primary rectal tumor in 2002. 
Colon cancer was defined as C18, rectal cancer as C19-C20 according to ICD-O-3. 
Patients with cancer diagnosed at autopsy were not selected. The additional data were 
retrospectively extracted from the medical records by an experienced medical doctor 
(C.D.G.W.V.), on request and under supervision of the treating physicians. Additional 
data concerned diagnostic assessment, treatment, and pathology, covering all  
  
 
Table 1. Summary of the consensus-based national clinical guidelines (2000-2001) for colon and 
rectal cancer. 
Colon Rectum 
Diagnostics 
Assessment of family history Assessment of family history 
Documentation of comorbidity Documentation of comorbidity 
Physical examination  Physical examination 
Assessment of Hb and alkaline phosphatase Assessment of Hb and alkaline phosphatase 
Colonoscopy; if not complete: contrast enema Colonoscopy. Suspicion of extended or fixed 
tumor: pelvic CT or MRI 
Liver ultrasound and thoracic X-ray Liver ultrasound and thoracic X-ray 
Tumor biopsy, unless specific radiological image Tumor biopsy 
Treatment 
Resectable tumors: resection with 
lymphadenectomy; if necessary en bloc  
Mobile tumors: if well differentiated tumor (T1), 
then local excision (transanal endoscopic 
microsurgery); else resection (TME for tumors 
in middle or lower rectum). Preoperative 
radiation (5 x 5 Gy), followed by resection 
within 1 week 
Irresectable tumors: palliative resection can be 
considered. Induction chemotherapy followed by 
evaluation of tumor response, with option for 
resection with or without radiotherapy. Palliative 
chemotherapy. In case of obstruction: formation 
of stoma. 
Fixed tumors: (chemo)radiation (50 Gy), 
followed by resection (TME) after 4-6 weeks, 
possibly IORT. In case of obstruction or 
incontinence: formation of stoma with use of 
biologic spacer. 
Irresectable metastases: palliative resection 
unless extensive metastases or severe 
comorbidity. Palliative chemotherapy.  
Irresectable metastases: palliative resection 
can be considered for vital patients. Palliative 
chemotherapy. In case of hemorrhage or pain: 
radiotherapy.  
(Adjuvant) treatment after initial treatment: stage 
III: 6 months 5-FU/Leucovorin. Stage IV: 
palliative chemotherapy 5-FU-Leucovorin, if 
necessary followed by second-line 
chemotherapy. 
(Adjuvant) treatment after initial treatment: 
stage III: adjuvant chemotherapy is not 
considered standard treatment. In case of 
resection margin less than 1 mm, and no 
preoperative radiotherapy: postoperative 
radiotherapy (50 Gy). Stage IV: palliative 
chemotherapy 5-FU-Leucovorin, if necessary 
followed by second-line chemotherapy. 
Pathology 
The pathologist has to report at least: histology, 
differentiation grade, resection margin expressed 
in mm, a conclusion regarding radicality, the 
number of examined (minimum 12) and positive 
lymph nodes, localization of lymph nodes. 
The pathologist has to report at least: 
histology, differentiation grade, resection 
margin expressed in mm, a conclusion 
regarding radicality, the number of examined 
(minimum 12) and positive lymph nodes, 
localization of lymph nodes. 
 
recommendations from the clinical guidelines for colon and rectal cancer, version 2000-
2001 (table 1). Data on diagnostic assessment included a reported family history (for 
patients < 60 years), a physical examination, a colonoscopy or sigmoidoscopy, X-ray of 
the abdomen/thorax, abdominal computed tomography (CT), magnetic resonance 
imaging (MRI), ultrasound examination, biopsy, and laboratory tests (hemoglobin (HB), 
alkaline phosphatases (AP), carcinoembryonic antigen (CEA)).  
  
 
Additional treatment data (performed vs. not performed) included intent of treatment 
(curative resection with no microscopic evidence of positive margins, palliative 
resection, palliative radio- or chemotherapy, or adjuvant chemotherapy), type of rectal 
cancer surgery (low anterior resection (LAR), abdominal perineal resection (APR), 
Hartmann procedure, total mesorectal excision (TME)), and radiotherapy (intra-
operative radiotherapy, preoperative radiotherapy). Emergency of surgery was 
recorded for colon cancer. Pathological data consisted of tumor differentiation grade, 
the number of lymph nodes examined, the number of positive lymph nodes, indication 
of histological type, indication of lymph node localization, and indication of radicality. 
Diagnostic and treatment data for colon cancer patients who underwent urgent surgery 
(N=35) were assessed separately. The association between age (<70 years vs. 70+ 
years), stage and diagnostic and treatment items was analysed using a chi-square test 
(SAS system 8.2, SAS Institute, Cary, NC). P-values below 0.05 were considered 
statistically significant. 
 
Results 
 
The mean age at diagnosis of the 308 patients was 70 years for patients with colon 
cancer, and 64 years for patients with rectal cancer (ranging from 41 years to 91 years, 
and from 33 years to 86 years, respectively).  
 
Diagnostic assessment 
Colon cancer 
An accurate family-anamnesis was reported in the medical record for 88% of colon 
cancer patients younger than 60 years (100% of patients younger than 50 years) 
(table 2). 60% of the patients underwent colonoscopy (ranging from 81% of patients 
with stage I disease to 42% of patients with stage III disease, p=0.03; no difference 
by age). 30% of the performed colonoscopies were documented to be incomplete 
(ranging from 8% of patients with stage I disease to 54% of patients with stage II 
disease, p=0.05). Of the patients who did not have a complete preoperative 
colonoscopy, an obvious reason for not performing this procedure postoperatively was 
present for half of the patients (e.g. all colon proximal of tumour removed, death of the 
patient, palliative treatment only). Eighteen percent of the remaining patients 
underwent complete postoperative colonoscopy. 
Rectal cancer 
A family-anamnesis was documented for 75% of rectal cancer patients younger than 
60 years (83% of patients <50 years). The proportion of patients who received 
colonoscopy decreased with increasing stage of disease: from 39% of patients with 
stage I to 21% of patients with stage IV disease (p=0.07).  
 
 
 
 
 
 
  
 
Table 2. Diagnostic assessment of patients with colorectal cancer in the southern Netherlands, 
2002 (excluding patients with urgent surgery).  
 
     Management according to guidelines 
 
Colon Rectum  
 
Yes No  Unknown   Yes  No  Unknown  
Assessment of family history 
(age <60 yrs) 
88% 6% 6%  75% 18% 7% 
Documentation of comorbidity 96% 4% 0%  92% 7% 1% 
Assessment  of Hb level  95% 1% 4%  93% 1% 6% 
Assessment  of alkaline 
phosphatase level 
88% 6% 6%  78% 13% 9% 
Assessment of CEA level  24% 62% 14%  23% 67% 10% 
Colonoscopy 60%a 40% 0%  31% 67% 2% 
Contrast enema in case of 
incomplete colonoscopy 
27% 70% 3%  n.a.   
Abdominal ultrasound +  
thoracic X-ray 
73% 11% 16%  82% 8% 10% 
Tumor biopsyb 80% 1% 19%  97% 0% 3% 
 
a
 Of which 70% complete. 
b
 Recommended for patients with colon cancer unless radiological image is specific. 
 
Treatment 
Colon cancer 
95% of the colon cancer patients received radical surgical treatment. In the remaining 
patients, surgery was not performed for reasons of comorbidity, old age, and advanced 
cancer extension (not shown). Of patients with resectable tumors, 89% underwent a 
curative resection (no difference by age) (table 3). The use of adjuvant chemotherapy 
for patients with stage III disease decreased by age: 95% to patients younger than 70 
vs. 48% of patients over 70; p=0.0004.  
Of the 35 patients who underwent urgent surgery, 23 underwent a resection with 
curative intent. Fourteen of these patients appeared to have positive lymph nodes; 11 
of them received adjuvant chemotherapy. Seven patients undergoing urgent surgery 
had distant metastasis; 4 of them received palliative chemotherapy.  
Rectal cancer 
76% of the rectal tumors was considered to be mobile (table 4). The proportion of 
patients undergoing a total mesorectal excision (TME) did not differ by age. 58% of 
patients underwent a low-abdominal resection, 37% an abdominoperineal resection, 
and 5% underwent a Hartmann procedure (not shown). The proportion of patients 
receiving preoperative radiotherapy did also not differ by age. 
 
Pathology report 
Colon cancer 
The histological tumor type and the differentiation grade were reported for nearly all 
patients (table 5). The median number of lymph nodes examined was 6.0 (table 6). 
78% of the patients had less than 12 lymph nodes examined. In 10% of the pathology 
reports the number of lymph nodes examined could not be found.  
  
 
Table 3. Primary treatment of 128 patients with colon cancer in the southern Netherlands, 
diagnosed 2002 (elective surgery only). 
 
 
 
Management according to guidelines 
 
Yes No Unknown  
 
Resectable tumors      
 -resection with curative intent 89% 11% 0%  
Irresectable tumors      
 - chemotherapy 19% 81% 0%  
Irresectable metastases     
 -palliative chemotherapy 37% 62% 1%  
Adjuvant chemotherapy stage III 
disease  
71% 
 
37% 2%  
Chemotherapy stage IV disease 65% 35% 0%  
 
 
 
Table 4. Treatment of 138 patients who underwent surgery for rectal cancer in the southern 
Netherlands, 2002. 
 
 
Management according to guidelines 
 
Yes No  Unknown  
Mobile tumors     
 -TME a 90% 4% 6% 
 -preoperative radiotherapy 78% 20% 2% 
Fixed tumors     
 -TME a 45% 21% 34% 
 -preoperative radiotherapy 97% 3% 0% 
 -preoperative chemo 93% 7% 0% 
Irresectable metastases    
 -palliative chemotherapy 22% 78% 0% 
a
 Percentage of patients with a tumour of the middle or lower part of the rectum. 
 
 
Rectal cancer 
The median number of examined lymph nodes was 5.0 (table 6). 91% of rectal cancer 
patients had less than 12 lymph nodes examined.  
 
Discussion 
 
This study demonstrates a diverse overall concordance of practice with the clinical 
guidelines for CRC. The relatively low rate of performed and completed colonoscopies 
among patients with colon cancer in the current study may partly be explained by the 
absence of the intention to achieve pancolonoscopy. This is indicated by the relatively 
large proportion of colon cancer patients undergoing a sigmoidoscopic procedure. 
Furthermore, completion rates are reported to be lower among patients with colonic 
symptoms than among relatively young asymptomatic individuals or as part of colon 
cancer screening programmes 132. A study conducted in an asymptomatic American 
population reported rates of total colonoscopy of over 95%, with minimal sedation, 
little patient discomfort, and low complication rates 133. 
  
 
Table 5. Documentation of items in the pathology report of resected patients with colorectal cancer 
in the southern Netherlands, 2002. 
 
Documented according to guidelines 
 
Colon Rectum 
 
Yes  No  Yes  No  
Histological tumor type  98% 2% 99% 1% 
Differentiation grade  97% 3% 99% 1% 
Localization of examined lymph 
nodes 
25% 75% 17% 83% 
Circumferential margin 73% 27% 69% 31% 
Conclusion of radicality  10% 90% 48% 52% 
 
 
 
Table 6. Number of examined and positive lymph nodes of resected patients with colorectal cancer 
in the southern Netherlands, 2002. 
 
 
Colon Rectum 
 
Median  Range Median Range 
Number of lymph nodes 
examined 
6.0 0-27 5.0 0-28 
Number of positive lymph nodes 1.2 0-10 1.0 0-15 
 
 
 
In an English study complete colonoscopy rates were 77% among patients undergoing 
the procedure for surveillance and various diagnostic and therapeutic reasons 35, but 
this proportion dropped to only 54% among patients with a tumour, and to 20% 
among patients with a malignant stricture. In line with this, the rate of complete 
colonoscopy among patients with colon cancer in the present study was highest among 
patients with stage I disease (T1 and T2 tumours), and lowest among patients with 
stage II disease (T3 and T4 tumours). Nevertheless, pancolonoscopy is proclaimed to 
be the aim in all patients 132 and when visualization is incomplete, a contrast enema 
should be performed to detect all polyps and tumours. This happened in only one 
quarter of the patients in the current study. However, the presence of a malignant 
stricture may also be good reason not to perform a contrast enema. 
The high resection rate of colon cancer patients in our study was in agreement with 
other European studies, remaining at a high level until old age 80, 134, 135. Selecting only 
rectal cancer patients who underwent tumour resection kept the resection rate for this 
group of patients unknown. However, from the cancer registry we can derive it to be 
85%. The proportion of 90% of patients receiving TME surgery is in concordance with 
TME rates reported in literature 136, 137. 
A large age-related decrease in administration of adjuvant chemotherapy for stage III 
colon cancer patients was observed in this study. Elderly patients are less likely to 
undergo adjuvant treatment due to the presence of comorbidity and a decrease in the 
patients general condition and cognitive abilities 138, 139. Also more patient refusal 
among the elderly and a shortage of supportive caregivers self-evidently results in a 
lower use of adjuvant treatment 59. Moreover, limited data on chemotherapy efficacy 
exist among patients older than 70 years 66, 140. Most of the available studies however 
present evidence of tolerance and efficacy of chemotherapy among both selected and 
  
 
unselected elderly colon cancer patients, thus counteracting the persisting ageism in 
colon cancer care 141, 142.   
There was a large discrepancy between everyday practice and clinical guideline with 
respect to the number of lymph nodes examined. This is of importance since previous 
research reported a more than 20% increase in overall, cause-specific, and disease-
free survival of colorectal cancer patients upon examination of an increased number of 
lymph nodes 143-146. It is unknown to what degree adequate staging and subsequent 
therapy, or the therapeutic effect of a complete lymphadenectomy itself may explain 
the positive effect on prognosis 147. Yet, a less adequate lymph node evaluation may 
have several causes. It is depending on anatomic subsite, since a specimen of right-
sided resections often contains a larger amount of mesentery; there can also be 
variations in the extent of the dissection by the surgeon, and in the applied 
thoroughness by the pathologist 146-149. The biologic behaviour of the tumour and the 
immune response of the patient can also explain a lower number of evaluated lymph 
nodes 146. Nonetheless, the median number of lymph nodes evaluated in the current 
study is low compared to most other studies 143, 146, 147, 149. An educational intervention 
targeted at surgeons and pathologists seems undoubtedly warranted. The effectiveness 
of such an intervention was shown in a Canadian single institution study, where the 
median number of evaluated lymph nodes increased from 8 to 18 within 30 months of 
the intervention 150.  
Sometimes the reason for not complying with clinical guidelines may be clear and 
legitimate, such as not performing a complete colonoscopy in case of a malignant 
structure, or refraining from chemotherapy for frail elderly patients. Often, the situation 
is more complex. For example, the threshold of 12 lymph nodes required for optimal 
staging is not accepted universally. The Royal College of Pathologists in the United 
Kingdom recommends that all lymph nodes identified in the resection specimen should 
be examined histologically but does not specify an arbitrary minimum number151. On 
might argue whether lymph node examination is not optimal, or that the guidelines are 
not realistic. However, as stated earlier, comparison with the results of other studies 
indicates that there is room for improvement of the quality of nodal retrieval and 
assessment. 
This study demonstrated a mixed adherence to the clinical practice guidelines for CRC 
in 2002. Currently, the present consensus-based guidelines are being exchanged for 
evidence-based guidelines. Feedback to and discussions with surgeons and pathologists 
should improve adherence to these guidelines, with special attention to nodal retrieval 
and assessment.  
 
 
 
  
 
Chapter 3.2  
 
Adjuvant treatment for elderly patients with 
stage III colon cancer in the southern 
Netherlands is affected by socioeconomic status, 
gender, and comorbidity 
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Summary 
 
Background: Adjuvant 5-fluoruracil-based chemotherapy significantly decreases 
mortality among patients with stage III colon cancer, but is less prescribed with rising 
age. We were interested in the pattern of adjuvant treatment and possible effects on 
survival among elderly patients. 
Patients & Methods: All resected patients aged 65-79 with stage III colon 
carcinoma, diagnosed between 1995 and 2001 in the Comprehensive Cancer Centre 
South registry area in the Netherlands were included (n=577). We examined 
determinants of receipt of adjuvant chemotherapy, and their relation to survival.  
Results: The proportion of elderly patients receiving adjuvant chemotherapy increased 
from 19% in 1995 to 50% in 2001, but a large inter-hospital variation remained. In a 
multivariable analysis, females (odds ratio (OR) 0.5, p=0.006), patients with 
comorbidity (OR 0.5, p=0.005), and patients with a low socio-economic status (OR 0.5 
p=0.02) received less adjuvant therapy. Between 1995 and 2001 survival of elderly 
patients improved (hazard ratio 0.8, p=0.04). 
Conclusion: Although an increasing proportion of elderly patients with colon cancer is 
treated with adjuvant chemotherapy, many elderly patients still do not receive this 
treatment. As expected, receipt of adjuvant treatment decreased in presence of 
comorbidity, but the clinical rationale for undertreatment of women and patients with 
low socio-economic status is not clear. 
  
Introduction 
 
The prognosis for elderly patients who have undergone resection of a stage III 
colon carcinoma remains relatively poor; the relative 5-year survival proportion of 
patients aged 65 years or older diagnosed between 1995 and 1999 in the south of 
the Netherlands was 30% 56. Several trials have established 5-fluorouracil (5-FU)-
based chemotherapy as the standard adjuvant treatment for patients with stage III 
disease 51, 53, 142, 152. However, retrospective analyses showed such adjuvant 
chemotherapy to be administered less with increasing age. Also presence of 
comorbidity, higher refusal rates among elderly patients, hospital volume, and 
socioeconomic factors are reported to influence administration of adjuvant 
chemotherapy 59, 61, 63, 141. 
Since the mid 1990s, administration of adjuvant chemotherapy is recommended in 
Dutch treatment guidelines 153. In order to evaluate adherence to these guidelines 
for elderly patients with stage III colon cancer in the south of the Netherlands, we 
determined the proportion of patients receiving adjuvant chemotherapy. We 
assessed factors associated with receipt of chemotherapy, and to what extent these 
factors were related to survival. 
 
Patients and methods 
 
Data collection 
The Comprehensive Cancer Centre South (Eindhoven Cancer Registry) covers a 
large part of the south Netherlands with approximately 2.4 million inhabitants. This 
population-based registry is notified by six pathology departments, the hospital 
medical records offices in -at time of the study- 15 community hospitals and two 
radiotherapy institutes. There are no university hospitals in the registry area. 
Registration takes place between 6 and 18 months after diagnosis. Despite the lack 
of access to death certificates, the infrastructure of and good access to Dutch health 
care facilities, together with the notification procedures used, have made it possible 
to establish cancer registries with a completeness exceeding 95% 54.  
Colon tumours were defined as C18.0-C18.7 according to ICD-O-3. All patients aged 
65 years or older diagnosed in the period 1995-2001 who had been operated on for 
stage III colon adenocarcinoma were selected from the database of the Eindhoven 
Cancer Registry (n=772). Only one patient older than 80 years received adjuvant 
chemotherapy. Therefore, we restricted our analyses to patients aged 65-79 
(N=577). 
Trained registrars recorded the following patient characteristics: age at time of 
diagnosis, gender, and serious comorbidity, the latter according to a slightly 
modified version of the Charlson classification (table 1) 43. Socio-economic status 
(SES) of the patient was defined at neighbourhood level (based on postal code of 
residence area, 17 households on average) combining mean household income (in 
1998) and mean value of the house/apartment (in 2000), derived from individual 
fiscal data made available at an aggregated level. Postal codes were assigned to 3 
SES categories: low (1st 3rd decile), intermediate (4th-7th decile), and high (8th-
  
 
10th decile). Postal codes of institutions, such as nursing homes, were assigned to a 
separate category and were excluded from the logistic regression and survival 
analysis (33 patients). These excluded patients had a median age of 76,5 years, 
compared to a median age of 72 years of the total study population. 
The following tumour characteristics were recorded: tumour grade (low grade (well 
or moderately differentiated) vs. high grade (poorly or undifferentiated tumours)), 
postoperative extent of disease (T1/T2, T3, T4), and lymph node involvement (N1, 
N2). The stage III patients were classified into three subgroups (IIIA: T1-2/N1, IIIB: 
T3-4/N1, IIIC: any T/N2) according to the International Union Against Cancer 
(UICC) TNM Classification of Malignant Tumours (6th edition) 154. The N3 
designation, as used by prior editions of the UICC TNM classification of Malignant 
Tumours, was incorporated into the N1 or N2 categories, according to the number 
of tumour positive lymph nodes.  
Also adjuvant chemotherapy (yes vs. no; information on type and dose was not 
available), year of diagnosis (periods 1995-1998 and 1999-2001), and hospital of 
surgery were recorded. 
Vital status of all patients on 1st of January 2004 was assessed through the Central 
Bureau for Genealogy, the institution where all deceased persons in The Netherlands 
are registered. Patients who had moved abroad (estimation: 0.2%) were possibly 
wrongly considered as being alive. At the end of follow-up (January 2004) 219 
patients (38%) were still alive. 
 
Table 1. Classification of comorbidity, according to an adapted version of Charlson et al. 
(1987). 
 
___________________________________________________________________________
__                                                                                                                                           
Previous malignancies (except basal skin carcinoma and carcinoma in situ of the cervix) 
 
Chronic Obstructive Pulmonary Diseases 
 
Cardiovascular diseases (myocardial infarction, heart failure, angina pectoris, intermittent 
claudication, abdominal aneurysm, peripheral arterial disease)   
 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia) 
 
Hypertension 
 
Diabetes mellitus 
 
Digestive tract diseases (stomach diseases, Crohns disease, ulcerative colitis, liver cirrhosis, 
hepatitis) 
 
Other (connective tissue diseases, severe rheumatoid arthritis, kidney diseases, dementia, 
tuberculosis, chronic infections) 
___________________________________________________________________________
__ 
 
Analyses 
  
Differences in adjuvant treatment between subgroups were tested by means of a 
chi2 test (gender and tumour grade) or a Cochran-Armitage trend test (number of 
comorbid conditions, SES, stage group, and year of diagnosis). 
The independent influence of the patient and tumour characteristics on 
administration of adjuvant chemotherapy was evaluated by means of a logistic 
regression analysis (LOGISTIC procedure). A log rank test was used to compare 5-
year survival proportions (LIFETEST procedure). Multivariable proportional hazards 
regression analysis (PHREG procedure) was used to discriminate independent risk 
factors for death. Since the numbers of patients treated with adjuvant 
chemotherapy were very low in some hospitals, we did not incorporate hospital of 
treatment in the logistic regression or survival analysis. 
For all analyses the SAS/STAT® statistical software (SAS system 8.2, SAS Institute, 
Cary, NC) was used.  
 
Results 
 
Among the 577 patients with stage III colon cancer aged 65-79, administration of 
adjuvant chemotherapy decreased with rising age (in 2001: 80% of patients aged 
65-69 vs. 28% of patients aged 75-79, ptrend<0.0001) (table 2). Overall, the 
proportion of elderly patients receiving adjuvant chemotherapy increased from 19% 
in 1995 to 50% in 2001 (ptrend <0.0001). In all age groups, adjuvant chemotherapy 
was administered more often to males (p=0.03) and patients with high grade 
tumours (p=0.04). Chemotherapy was administered less often to patients with 
comorbidity (from 50% of patients without comorbidity to 33% of patients with 2 or 
more comorbid conditions, ptrend=0.0006) and to those with a lower SES (from 29% 
of patients with a low SES to 49% of patients with a high SES, ptrend<0.0001). The 
proportion of patients who received adjuvant chemotherapy clearly increased 
between 1995 and 2001 (from 46% to 80% of patients aged 65-69, ptrend<0.0001; 
from 16% to 48% of patients aged 70-74, ptrend=0.02; and from 5% to 28% of 
patients aged 75-79, ptrend=0.02). A large hospital variation in the administration of 
adjuvant therapy could be observed. This variation was not related to the size of the 
hospital. Twenty-three percent of the excluded institutionalised patients with a 
median age of 76,5 years received adjuvant chemotherapy. Among the excluded 
patients, also females (21% vs. 27% of male patients) and patients with comorbidity 
(16% vs. 36% of patients without comorbidity) were less likely to receive adjuvant 
chemotherapy (results not shown). 
In a multivariable logistic regression analysis, age independently influenced the odds 
of receiving adjuvant chemotherapy, as did comorbidity (table 3). Previous 
malignancies (mostly colorectal tumours) (odds ratio=0.2; p=0.001) and COPD 
(odds ratio 0.3; p=0.03) in particular contributed to this effect. Females were 
significantly less likely to receive chemotherapy than males, while patients with a 
high SES were twice as likely to receive adjuvant treatment compared to patients 
with a low SES. Patients with a high grade tumour and patients with substage IIIB 
disease received chemotherapy more often. Patients diagnosed between 1999 and 
  
 
2001 were 2.4 times more likely to receive chemotherapy compared to patients 
diagnosed between 1995 and 1998. 
In a proportional hazards regression analysis adjusting for age, gender, number of 
comorbid conditions, SES, substage, tumour grade, and period of diagnosis, 
adjuvant chemotherapy was associated with a 50% lower mortality risk (hazard) 
than patients who did not receive adjuvant treatment. Patients aged 70 years or 
older exhibited a lower mortality risk than patients aged 65 to 69 years. Survival was 
worse for patients with comorbidity (hazard ratio 1.4) and patients diagnosed with a 
more advanced substage (hazard ratio 1.8). Patients diagnosed more recently had a 
more favorable  
 
Table 2. Stage III colon cancer patients diagnosed between 1995 and 2001 in the southern 
Netherlands; proportion of patients who received adjuvant chemotherapy according to age.  
 
 
 Proportion of patients treated with chemotherapy 
 
 65-69 years 
(n=181) 
70-74 years 
(n=196) 
75-79 years 
(n=200) 
 n % % % 
Gender     
Male  284 62 41 23 
Female 293 56 37 17 
No. of comorbid conditions  
   
0 184 72 44 28 
1 194 58 34 16 
2+ 159 49 41 15 
Unknown 40 33 30 27 
SES     
High 148 67 45 28 
Intermediate 205 43 41 19 
Low 191 19 34 16 
Stage group a 
    
IIIA (T1-2 N1) 28 88 22 18 
IIIB (T3-4 N1) 438 62 42 20 
IIIC (any T N2) 107 44 32 19 
Tumour grade  
   
Low 386 54 39 18 
High 148 73 44 27 
Unknown 33 62 13 8 
Year of diagnosis     
1995 52 46 16 5 
1996 77 41 35 8 
1997 75 41 40 35 
1998 75 61 40 19 
1999 86 57 48 17 
2000 103 73 35 22 
2001 109 80 48 28 
Hospital of treatment b 
 
    
#1 74 79 44 20 
  
#2 51 65 40 0 c 
#3  51 77 42 32 
#4  54 70 40 45 
#5 41 57 25 0 d 
#6 44 63 73 2 
#7 37 50 31 31 
#8 53 32 11 13 
a Four patients with Tx were not assigned to a substage; none of them received adjuvant 
chemotherapy. 
b Only the 8 largest (according to treated number of stage III patients) out of 15 hospitals are 
shown here. 
c Out of 14 patients. 
d Out of 18 patients. 
prognosis (hazard ratio 0.8). There was no significant difference in adjusted survival 
between males and females, SES categories, and tumour grade. 
 
Discussion 
 
In our study of 577 patients with stage III colon cancer aged 65 to 79 years we 
found that adjuvant chemotherapy was administered less often with increasing age. 
Also females, patients with comorbidity, and patients with a low social-economic 
status received adjuvant therapy less often. There was a clear rise in administration 
of chemotherapy between 1995-1998 and 1999-2001, but a large inter-hospital 
variation remained.  
 
 
Table 3. Stage III colon cancer patients diagnosed between 1995 and 2001 in the southern 
Netherlands; odds of administration of adjuvant chemotherapy, as calculated from a logistic 
regression model which included all listed variables.a 
 
  
 
 
 
a
 Cases with missing values for any of the covariates were left out of the analyses.
 
b
 Reference category. 
c
 Adjusted for all variables listed. 
Table 4. All stage III colon cancer patients diagnosed between 1995 and 2001 (follow-up until 
January 2004) in the southern Netherlands; crude and multivariable analysis for overall 
survival, model including all listed variables.a 
 
Covariate Crude 5 year 
survival (%) 
Hazard 
ratioc 
p-value 
Adjuvant chemotherapy 
   
Nob 32 1.0  
Yes 51 0.5 <.0001 
Age 
   
65-69b 31 1.0  
70-74 48 0.6 .0008 
75-79 37 0.6 .007 
Gender 
   
Maleb 41 1.0  
Female 37 0.9 .7 
No. of comorbid conditions 
   
0b 49 1.0  
1 32 1.4 .02 
2+ 33 1.4 .04 
Covariate Odds 
ratioc 
p-value 
Age 
  
65-69b  1.0  
70-74 0.4   .001 
75-79 0.1 <.0001 
Gender 
  
Maleb  1.0  
Female 0.5 .006 
No. of comorbid conditions   
0b 1.0  
1 0.5 .005 
2+ 0.4 .004 
SES 
  
Highb 1.0  
Intermediate 0.7 .2 
Low 0.5 .02 
Stage group 
  
IIIA (T1-2 N1) 0.5 .3 
IIIB (T3-4 N1)b 1.0  
IIIC (any T N2) 0.5 .02 
Tumour grade 
  
Lowb 1.0  
High 1.6 .07 
Period of diagnosis 
  
1995-1998b 1.0  
1999-2001 2.4 .0003 
  
SES 
   
Highb 44 1.0  
Intermediate 39 1.1 .8 
Low 38 1.0 .9 
Stage group 
   
IIIA (T1-2 N1) 62 0.7 .3 
IIIB (T3-4 N1)b 41 1.0  
IIIC (any T N2) 27 1.8 .0001 
Tumour grade    
Lowb 40 1.0  
High 33 1.3 .06 
Period of diagnosis    
1995-1998b 38 1.0  
1999-2001 39 0.8 .04 
 
a
 Cases with missing values for any of the covariates were left out of the analyses.
 
b
 Reference category. 
c
 Adjusted for all variables listed. 
 
Survival was better for patients receiving adjuvant chemotherapy, for patients aged 
70 to 79 years compared to 65-69 years, and for patients diagnosed more recently, 
and worse for patients with comorbidity or a more advanced substage.  
The lower probability of receiving adjuvant treatment for elderly patients with colon 
cancer had already been shown previously 60-64, 141, 155. The reason why these 
patients are less likely to receive adjuvant treatment is multifactorial. In addition to 
the presence of concomitant diseases, more patient refusal among the elderly, the 
absence of supportive caregivers, a decrease in the patients general condition and 
cognitive abilities, and especially frailty could result in lower chemotherapy rates 59, 
65, 138, 156. Most of the available studies present evidence of tolerance and efficacy of 
chemotherapy among both selected and unselected elderly colon cancer patients 59, 
61, 141, 157, thus counteracting the persisting ageism in colon cancer care. However, 
there are probably still uncertainties about the risk-benefit ratio of aggressive 
treatment, as is suggested by the observed inter-hospital variation. 
The reported higher intolerance among females for 5-fluoruracil-based (5-FU) 
chemotherapy due to a lower level of dihydropyrimidine dehydrogenase, together 
with a higher refusal rate among elderly women, may partly be responsible for the 
finding that they were less likely to receive adjuvant treatment than men 63, 158, 159. 
However, higher intolerance among females may have been overcome in most cases 
by alternative 5-FU doses or schedules, and the magnitude of the observed effect in 
our study seems too large to be explained by a higher refusal rate among elderly 
women. In view of the good access to health care facilities and the Dutch health 
insurance system with a coverage of approximately 99% 160, our finding that 
patients with a low SES are two times less likely to be treated with adjuvant 
chemotherapy than patients with a high SES is remarkable. Socio-economic status 
has previously been reported to influence adjuvant treatment of colorectal cancer 
patients 59, 63, although the impact was much smaller than that observed in the 
present study. A possible explanation of the effect of SES on adjuvant treatment 
may be that patients with a higher SES have a more active behavior, in terms of 
  
 
seeking more aggressive treatment or making and keeping appointments with 
specialists. SES could be associated with education as well, which might influence 
acceptance rates. Patients with a higher SES also have a more positive self-rated 
health 161, 162, which in turn may affect treatment decision-making 69. The 
institutionalised patients who were excluded from the analyses received adjuvant 
chemotherapy as often as the included patients with the same age and gender. As 
we do not expect that the average socio-economic status of nursing home residents 
differs significantly from the average socio-economic status of other patients, we 
consider the possible impact of excluding the 33 institutionalised patients to be 
relatively small.  
Patients presenting with comorbidity received adjuvant chemotherapy less often, in 
agreement with previous retrospective studies 59, 62-64. Few prospective studies have 
reported the effect of comorbidity on the safety and efficacy of chemotherapy, and, 
as a result, few guidelines exist for patients with specific comorbid conditions.  
We do not have a clear explanation for our finding that patients with stage IIIB 
disease (T3-4, N1) received adjuvant chemotherapy more often than patients with 
stage IIIC disease (any T, N2); perhaps these elderly patients with stage IIIC 
disease were considered to have a less favorable risk-benefit ratio regarding 
adjuvant treatment. 
As reported in several other population-based studies, adjuvant chemotherapy had a 
marked independent prognostic impact 62, 157. Due to the population-based nature of 
our data, we do not know the extent to which this positive prognostic impact was 
caused by selection of the fitter patients for adjuvant chemotherapy, or by other 
factors associated with treatment allocation besides those controlled for in our 
analysis (e.g. performance status). Very likely, frail elderly less often receive 
adjuvant chemotherapy. The worse prognosis of these frail patients has probably 
biased the prognostic impact of adjuvant chemotherapy in the current study. This is 
supported by the fact that the survival difference between treated and non-treated 
patients was larger than found in randomized clinical trials 141.  
A possible explanation for the improved survival between 1995-1998 and 1999-2001 
may be more accurate staging due to a more thorough search for positive lymph 
nodes by the pathologist, promoted by the presence of effective adjuvant treatment 
for lymph node-positive cancers 143. Moreover, staging may also have been 
improved by a better identification of distant metastases. 
Our finding that patients aged 70 or older had a better prognosis than patients aged 
65-69 years is odd, but in line with the results of a large single-hospital study where 
patients with stage III colon cancer aged 65 years or older had an overall 5-year 
survival of 74%, compared to 54% for patients younger than 65 years. 163. A 
possible explanation for this finding might be a selection of the more robust 
individuals living long enough to develop colon cancer, or a potential decrease in 
aggressiveness of the tumour with rising age. 
Data extraction from the patients medical record is regarded as the most complete 
source of information on the patients past and current health status 55. Yet, 
performance status could not be included in our study, since this is not mentioned in 
the medical records routinely. Performance score and comorbidity are both 
  
predictive factors of treatment and survival for cancer patients, independent of each 
other 74, 75. However, performance status is often amenable to the malignant disease 
and its treatment, in contrast to comorbidity. 
 
Although the proportion of elderly patients with colon cancer receiving adjuvant 
chemotherapy is increasing, many elderly patients still do not receive or accept this 
treatment. Development of age-based guidelines and increased awareness among 
both physicians and patients through education is important to prevent 
undertreatment of (subgroups of) elderly patients who are eligible for 
chemotherapy. With decision making becoming more individualized with the rise of 
age, the use of a comprehensive geriatric assessment may be helpful in choosing 
the most adequate treatment for these patients. 
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Summary 
 
Purpose: There is a positive association between the number of lymph nodes 
examined and prognosis for patients with colon cancer. However, there is a large 
variation in the number of nodes examined between patients, departments of 
pathology, hospitals, and regions. We studied the extent to which this variation 
could be attributed to patient and tumour characteristics versus local patterns in 
surgical and pathology practice.  
Patients and methods: All patients who underwent resection for stage I-III 
(pTanyNanyM0) colon carcinoma diagnosed between 1999 and 2002 (N=2168) in the 
Eindhoven Cancer Registry area were included. Determinants of lymph node 
evaluation and their relationship to survival were assessed, including variation 
between the 6 departments of pathology. 
Results: A median number of 6 lymph nodes per specimen had been examined. The 
median number for each department of pathology ranged from 3 to 8 (p<0.0001). 
After correction for age, gender, socio-economic status, comorbidity, tumour site, 
depth of invasion, lymph node involvement, and tumour grade, the large variation 
between the departments of pathology remained. This resulted in differences in the 
proportion of N+ tumours between departments from 29% to 41% (p<0.0001). The 
number of nodes examined was positively associated with survival, among both 
node-negative and node-positive patients. Survival for node negative patients 
differed between the departments of pathology (up to hazard ratio (HR) 1.5; 
p=0.02).  
Conclusion: There was a large variation in lymph node evaluation between the 
departments of pathology, leading to differences in stage distribution and survival. 
Intervention strategies should be directed at nodal assessment. 
   
Introduction 
 
Colorectal cancer (CRC) is the second most common cause of cancer in industrialized 
countries.164, 165 Yearly, over 9200 patients are diagnosed with CRC in the Netherlands, 
1300 of whom live in the area covered by the Eindhoven Cancer Registry.122 Resection 
of the tumour with adequate margins and associated mesentery, including draining 
lymph nodes, remains the primary modality of treatment for CRC. Patients with positive 
lymph nodes may also benefit from adjuvant chemotherapy.51, 53, 142, 152, 166 Therefore, 
lymph node analysis is one of the critical factors for therapeutic decision-making. 
Several studies have not only described a positive association between the number of 
lymph nodes evaluated and prognosis for CRC patients but also a large variation in the 
number of lymph nodes examined between patients, departments of pathology, 
hospitals, regions, and countries.134, 143, 146, 147, 167, 168 This variation, which influences 
staging and subsequent therapy, may be explained by several mechanisms: firstly, the 
thoroughness of the surgical lymphadenectomy in order to remove all potential lymph 
node metastases; secondly, the extent and diligence of the pathologists examination; 
and thirdly, inter-individual differences in the biological behavior of the tumour and/or 
host, such as immune response, which may affect the number of traceable lymph 
nodes.146, 147 In the current study of patients who had a colectomy for stage I-III 
(TanyNanyM0) colon carcinoma, we determined the variation in lymph node examination 
and its relationship to stage distribution and survival in the southern Netherlands, and 
the extent to which this variation could be attributed to local patterns in surgical and 
pathology practice or patient and tumour characteristics. 
 
Patients and methods 
 
Data collection 
The Comprehensive Cancer Centre South (Eindhoven Cancer Registry) covers a large 
part of the southern Netherlands with approximately 2.4 million inhabitants. This 
population-based registry is served by ten hospitals, six departments of pathology, and 
two radiotherapy institutes. There are no university hospitals in the registry area. 
Between 6 to 18 months after diagnosis the patients are registered by the trained 
administrators. The completeness of registration is estimated to be >95%.54  
All patients who had a colectomy for stage I-III (pTanyNanyM0) colon carcinoma in the 
4-year period 1999  2002 were selected from the database of the Eindhoven Cancer 
Registry (N=2168). The patients age at diagnosis, gender and comorbidity according 
to a slightly modified version of the Charlson classification were recorded. Also, tumour 
site (right sided: colon ascendens (C18.0-C18.2) and colon transversum (C18.3-C18.5); 
left sided: colon descendens and sigmoid (C18.6-C18.9)), grade of tumour 
differentiation (low grade (well or moderately differentiated) vs. high grade (poorly or 
undifferentiated tumours)), depth of invasion, and nodal involvement were recorded. 
Furthermore, the number of lymph nodes examined, adjuvant chemotherapy (yes vs. 
no), hospital of surgery, and the department of pathology were registered. Socio-
economic status (SES) of the patient was defined at neighbourhood level (based on 
postal code of residence area, 17 households on average) combining mean household 
  
income (in 1998) and mean value of the house/apartment (in 2000). The latter was 
derived from individual fiscal data made available at an aggregated level. Postal codes 
were assigned to one of 3 SES categories: low (1st 3rd decile), intermediate (4th-7th 
decile), and high (8th-10th decile).  
Vital status of all patients on 1st January 2005 was assessed through the Central 
Bureau for Genealogy, where all deceased persons in the Netherlands are registered. 
Patients who had moved abroad (estimation: <0.3%) were possibly incorrectly 
considered as being alive.  
Analyses 
Differences between the departments of pathology according to the number of lymph 
nodes evaluated and the postoperative nodal status were tested by means of a chi2 
test. The independent influence of pathology practice or patient and tumour 
characteristics on the number of lymph nodes evaluated was analysed by means of 
logistic regression analysis (LOGISTIC procedure). A Cochran-Armitage trend test was 
used to investigate whether there has been an increase or decrease in the number of 
nodes evaluated during the study period. To examine the hypothesis that the number 
of lymph nodes examined is related to survival, a multivariable proportional hazards 
regression analysis (PHREG procedure) was used to discriminate independent risk 
factors for death, stratified by nodal involvement. A model was built with and without 
the number of lymph nodes evaluated to investigate the hypothesis that the prognostic 
differences between the pathology departments can be fully explained by the number 
of lymph nodes evaluated (after adjustment for age, gender, SES, the number of 
comorbid conditions, tumour site, tumour size, and adjuvant chemotherapy). Cases 
with missing values for any of the covariates were left out of the logistic and regression 
analyses. All statistical tests were two-sided. For all analyses the SAS/STAT® statistical 
software (SAS system 8.2, SAS Institute, Cary, NC) was used.  
 
Results 
 
At the end of follow-up (1st of January 2005), 1381 patients (64%) were alive.  
The coverage of the six departments of pathology for the colon cancer resection 
specimens is depicted in table 1. Three departments serve one hospital, while two 
departments cover 3 hospitals. All hospitals are community hospitals. 
 
Table 1. Coverage of the departments of pathology for colon carcinoma resection specimens. 
 
Path. laboratory Patients (N) Hospitals (N) a 
#1 154 1 
#2 460 2 
#3 270 1 
#4 421 3 
#5 608 3 
#6 255 1 
 a
 One hospital is covered by 2 pathology departments: department #3 and #4. 
 
The general characteristics of all 2168 patients are shown in table 2. For 24% of 
patients 0 to 3 lymph nodes had been examined; for another 24% 4 to 6 nodes were 
   
examined, versus 7 to 9 nodes for 16%, 10 or 11 lymph nodes for 6%, and 12 or more 
nodes for 13%.  
In figure 1a and 1b, the numbers of lymph nodes evaluated among node-negative and 
node-positive patients are depicted. For all patients, the median number of lymph 
nodes examined was 6 (table 3); for patients with pN0 and pN1/2 colon carcinoma it 
was 5 and 6, respectively. The median number of lymph nodes examined in each 
department of pathology ranged from 3 to 8 (p<0.0001).  
In table 4 the odds of having 6 or more nodes examined, as calculated by means of a 
multivariable logistic regression analysis, are listed. The number of lymph nodes 
examined clearly decreased with increasing age. Also patients with comorbidity were 
less likely to have had 6 or more lymph nodes examined. The chance was also lower 
for patients with left-sided tumours, as well as patients with pT1 tumours, male 
patients, and patients with nodal negative disease. There was a large variation 
between the departments of pathology; patients whose lymph nodes were evaluated in 
department nr. 1 were 1.6 times more likely to have a minimum of 6 nodes examined, 
compared to the reference department. Especially in departments nr. 2 and nr. 6, 
patients had a lower chance of having 6 or more nodes evaluated.  
Overall, there was no significant change in the number of lymph nodes evaluated 
between 1999 and 2002.   
There was no difference in the number of lymph nodes examined between the 
hospitals which were covered by one and the same department of pathology. 
The postoperative stage distribution (pTNM) according to department of pathology is 
depicted in figure 2. In department nr. 1, there was a relatively large proportion of T4 
tumours (32%). The proportion of T2/T3N0 tumours varied from 43% in department 
nr. 1 to 62% in department nr. 2. 
The proportion of patients with lymph node metastases (pN1 or pN2; stage III) ranged 
from 29% in department nr. 6 and 32% in department nr. 2 to 41% in departments nr. 
1 and 5 (p<0.0001) (figure 3).  
After adjustment for relevant patient and tumour characteristics, the risk of death 
(hazard ratio (HR)) among node-negative patients differed between the departments of 
pathology, by up to HR 1.47 (table 5). Inclusion of cases with a missing value for the 
covariate number of nodes evaluated did not alter the variation between the 
departments. After adding the number of lymph nodes examined to the model, the 
differences between the reference department and the other departments became 
insignificant. The risk of death decreased clearly with increasing number of lymph 
nodes examined, for both patients with negative lymph nodes and patients with 
positive lymph nodes (to HR 0.56 and HR 0.68, respectively).  
 
 
 
 
 
 
Table 2. General characteristics of all 2168 patients who underwent resection for stage I-III colon 
carcinoma, diagnosed between 1999 and 2002 in the southern Netherlands. 
 
  
 
Age (years) 
  
Median (range) 70.5 (23-100) 
 
 
 
  N   (%) 
Gender   
Male 1064 (49) 
Female 1104 (51) 
Socio-economic status 
  
Low 634 (29) 
Intermediate 772 (36) 
High 617 (28) 
Unknown 145 (7) 
Comorbidity 
  
No comorbidity 698 (32) 
One comorbid condition 640 (30) 
Two or more comorbid conditions 612 (28) 
Unknown 218 (10) 
Tumour site 
  
Left-sided 978 (45) 
Right-sided 1179 (54) 
Unknown 11 (0.5) 
Stage 
  
pT1-2N0 280 (13) 
pT3-4N0 1081 (50) 
pT1-4N+  798 (37) 
Unknown 9 (0.4) 
Tumour grade 
  
Moderately/well differentiated 1635 (75) 
Poorly differentiated 405 (19) 
Unknown 128 (6) 
Adjuvant chemotherapy 
  
Yes 480 (22) 
No 1688 (78) 
No. of lymph nodes evaluated  
  
0-3 513 (24) 
4-6 513 (24) 
7-9 342 (16) 
10-11 130 (6) 
≥ 12 291 (13) 
Unknown 379 (17) 
   
   
Table 3. Median number of lymph nodes evaluated, according to department of pathology. 
 
Dep. of pathology Median number of nodes 
evaluated 
Range 
1 7 0-24 
2 3 0-26 
3 6 0-40 
4 8 0-33 
5 7 0-29 
6 4 0-19 
Total 6 0-40 
 
 
 
 
 
 
Figure 1a. Number of lymph nodes evaluated among all resected patients with node negative 
(stage I-II) colon cancer diagnosed between 1999 and 2002 in the Eindhoven Cancer Registry 
area. 
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Figure 1b. Number of lymph nodes evaluated among all resected patients with node positive 
(stage III) colon cancer diagnosed between 1999 and 2002 in the Eindhoven Cancer Registry 
area. 
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(for figure 2, see two pages ahead) 
Figure 3. Postoperative nodal status of patients with colon carcinoma, according to department of 
pathology a. 
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a
 Difference of postoperative nodal status between departments of pathology: chi-square 48.58, 
p<0.0001. 
1-3       4-6       7-9     10-12   13-15    16-18    19-21   >22 
N0 
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Table 4. Odds of having 6 or more lymph nodes evaluated by the pathologist; calculated by means 
of a multivariable logistic regression analysis (model including all listed variables). a 
 
 
Odds ratio p-value 
Age 
  
19-49 years b 1.00  
50-69 years 0.72 0.047 
70+ years 0.64 0.004 
Gender  
  
Male b 1.00  
Female 1.29 0.02 
Socio-economic status 
  
High b 1.00  
Intermediate 1.00 0.74 
Low 0.85 0.34 
No. of comorbid conditions 
  
0 b 1.00  
1 0.73 0.021 
2+ 0.61 0.0005 
Tumour site 
  
Left-sided tumours b 1.00  
Right-sided tumours 2.07 <0.0001 
Depth of invasion 
  
pT1  0.10 0.003 
pT2 b 1.00  
pT3 1.31 0.10 
pT4 0.91 0.66 
Lymph node involvement 
  
pN0 b 1.00  
pN+ 1.51 0.0004 
Tumour grade 
  
Well/moderately differentiated b  1.00  
Poorly differentiated 1.09 0.55 
Dep. of pathology 
  
1 1.62 0.034 
2 0.12 <0.0001 
3 0.49 <0.0001 
4 1.02 0.89 
5 b 1.00  
6 0.20 <0.0001 
a
 Cases with missing values for any of the covariates were left out of the analyses. 
b
 Reference category.  
 
  
Figure 2. Stage distribution according to department of pathology. 
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Discussion 
 
The availability of increasingly effective postoperative chemotherapeutic agents for 
patients with nodal metastasis stresses the importance of lymph node analysis in colon 
carcinoma. In this population-based study in the southern Netherlands, the median 
number of lymph nodes examined among patients who underwent resection for stage 
I-III (pTanyNanyM0) colon carcinoma was 6. Other population-based studies reported 
median numbers of lymph nodes examined of 7 to 9,147, 167, 169 while single-hospital 
studies reported median numbers up to 17.149, 170 A low number of lymph nodes 
evaluated in the Netherlands has already been reported by a Eurocare study among 
patients diagnosed in 1990, covering 11 European cancer registries.134 The Dutch 
registries had the smallest proportion of patients with 12 or more lymph nodes 
examined: 5% in the Dutch Eindhoven Cancer Registry and 2% in the Dutch Rotterdam 
Cancer Registry. In a large US population-based study, geographic location was an 
important predictor of adequate lymph node evaluation, indicating that surgical and 
pathological practice probably play an important role.147 This was recently confirmed by 
a Swedish population-based study, where the median number of lymph nodes 
examined varied from 6 to 12 between the 7 departments of pathology.167 
Also in the current study there was a large variation between the departments of 
pathology. The absence of a difference in the number of lymph nodes evaluated 
between the hospitals covered by one and the same department of pathology indicated 
that pathology practice patterns probably played a more important role than surgical 
practice patterns. The significance of the variation in pathology practice is emphasized 
by the differences in nodal status and survival between the departments of pathology. 
In addition to different degrees of diligence, the technique used by the pathologist can 
influence lymph node assessment. Techniques such as xylene or alcohol fat clearance, 
cytokeratin immunohistochemistry, and multilevel step sectioning can increase the 
number of nodes identified.171-173 These techniques are considered too expensive and 
time-consuming for standard use or are as yet of unproven clinical significance. 
However, a single-hospital study reported a mean number of over 20 lymph nodes 
evaluated with standard manual dissection methods of pathology evaluation, without 
clearing solutions or ancillary techniques.170 An example of a straightforward way of 
improving adequacy of nodal harvest is a longer duration of specimen fixation. This 
may significantly upstage colon carcinoma from node-negative to node-positive after an 
additional 24 hour fixation in formaldehyde prior to specimen dissection.174, 175 In a 
Canadian study, reinforcing strategies aimed at surgeons and pathologists, including 
the use of a pathology reporting template, increased the median number of lymph 
nodes evaluated from 8 to 18, in a 30-month period.150  
The Dutch colorectal cancer treatment guidelines, in agreement with the American 
Joint Committee on Cancer (AJCC) and the Tumour, Node, Metastasis Committee of the 
International Union Against Cancer, require a minimum of 12 nodes to be examined for 
adequate staging.153 However, this threshold of at least 12 nodes is not universally 
accepted. The recommendation of the Royal College of Pathologists in the UK is that all 
lymph nodes identified in the resection specimen should be examined histologically but 
  
does not specify an arbitrary minimum number since it is recognised that the number 
of lymph nodes identifiable in a specimen varies according to several factors, as 
indicated also by the results of this and other studies.151, 175-178  
The number of lymph nodes evaluated may also be related to the immune response of 
the patient; size and morphology of lymph nodes are modified by immune responses 
against neoplastic cell products.146, 178, 179 Older patients probably have a diminished 
immune response, which would explain the effect of age on the number of lymph 
nodes examined in this and other studies.146-148 Table 5. Multivariable proportional 
hazards regression analyses of survival of patients who underwent resection for colon 
cancer, diagnosed between 1999-2002 in the southern Netherlands (follow-up until 
January 1st 2005), according to nodal involvement. a 
However, since the immune response is expected to be evenly distributed 
geographically among patients with colon cancer (especially after adjustment for age 
and other possible relevant factors), this does not explain the variation between the 
departments of pathology. In agreement with previous studies we also found an effect 
of gender on the adequacy of node evaluation.146, 147 The observation that a larger 
number of lymph nodes was examined with more advanced stage of disease can partly 
be explained by the fact that retrieval of a higher number of nodes logically increases 
the possibility that existing positive lymph nodes will be detected. Furthermore, positive 
lymph nodes are generally slightly larger than negative lymph nodes, thus being more 
likely to be detected.149, 180  The presence of an inflammation in the surrounding lymph 
nodes in patients with T3 or T4 tumours, with subsequent enlargement of these nodes, 
explains the increased likelihood of an adequate lymph node evaluation among patients 
with stage II (pT3/4) disease compared to stage I (pT1/2).147 Another explanation may 
be a more thorough search by the surgeon or pathologist when a larger, penetrating 
tumour is present. Our finding that patients with right-sided colon cancer had more 
lymph nodes evaluated  is consistent with other studies and not unexpected, since 
larger amounts of mesentery are often found in right-sided resections and subtotal 
colectomy.146, 148, 181 However, the absence of a difference in the number of lymph 
nodes examined between the hospitals which were covered by the same department of 
pathology indicates that pathology rather than surgical practice patterns are 
responsible for the observed variation in lymph node evaluation. 
   
 
Table 5. Multivariable proportional hazards regression analyses of survival of patients who 
underwent resection for colon cancer, diagnosed between 1999-2002 in the southern Netherlands 
(follow-up until January 1st 2005), according to nodal involvement. a 
 
 Model not including 
number of lymph nodes 
evaluated b 
Model including number of 
lymph nodes  evaluated b 
 Hazard Ratio p-value Hazard Ratio p-value 
N0     
Dep. of pathology     
1 1.18 0.49 1.23 0.40 
2 1.47 0.024 1.26 0.20 
3 1.34 0.14 1.28 0.21 
4 1.13 0.49 1.18 0.38 
5 c 1.00  1.00  
6 1.34 0.12 1.19 0.38 
No. of nodes 
evaluated 
    
1-4 c   1.00  
5-7   0.74 0.047 
8-11   0.59 0.009 
≥12   0.56 0.016 
     
     
N1/2     
Dep. of pathology     
1 0.81 0.39 0.86 0.53 
2 1.35 0.083 1.22 0.28 
3 1.11 0.62 1.07 0.75 
4 1.36 0.063 1.39 0.049 
5 c 1.00  1.00  
6 1.00 0.98 0.90 0.64 
No. of nodes 
evaluated 
    
1-4 c   1.00  
5-7   0.97 0.85 
8-11   0.83 0.29 
≥12   0.68 0.048 
a
 Cases with missing values for any of the covariates were left out of the analyses. 
b
 Including the following variables: age, gender, socio-economic status, number of comorbid 
conditions, tumour site, depth of invasion, tumour differentiation grade, and adjuvant 
chemotherapy (yes vs. no). 
c
 Reference category.  
  
The current study also revealed differences in depth of tumour invasion between the 
departments of pathology, with one department showing a significant higher proportion 
of T4 tumours. An explanation for this might be the significantly larger proportion of 
patients with a low socio-economic status presenting in that hospital; possibly these 
individuals postpone seeking medical help after being confronted with unexplained 
symptoms. 
Our results confirmed the strong prognostic influence of an adequate lymph node 
examination, which may partly be related to the intensity of the patients immune 
response.134, 143, 146, 147, 167, 168, 182, 183 After adjustment for relevant factors such as stage 
and adjuvant therapy - but not the number of lymph nodes examined - there was a 
variation in patient survival between the departments of pathology. Among node-
negative patients, the departments of pathology with the lowest median number of 
examined nodes yielded the worst patient survival, reflecting that this group of node 
negative patients contained N1 patients wrongly staged as N0. Inclusion of the number 
of lymph nodes examined decreased the differences between the departments. This 
means that a reduction in mortality among these node-negative patients could be 
achieved by increasing the number of lymph nodes examined in the departments with 
the lowest numbers. The difference in survival among node-positive patients after 
adjustment for the number of nodes examined indicated that other relevant clinical 
features differ between institutions, in addition to the determinants we assessed in our 
analyses. For example, the surgical technique, the completeness of the resection, and 
the experience of the surgeon all may have a prognostic influence.184, 185 
In conclusion, we demonstrated a low number of lymph nodes examined among 
patients with colon cancer in the south of the Netherlands, with a large variation 
between the departments of pathology leading to differences in stage distribution and 
prognosis. This finding becomes more relevant with more frequent use of new, 
increasingly effective chemotherapeutic agents. In the future, lymphatic mapping might 
lead to inclusion of all tumour-draining lymph nodes and molecular tumour markers 
may provide diagnostic information that would preclude assessment of regional lymph 
nodes.171, 186-188 Until then, therapeutic decisions will be based on lymph node analysis, 
and intervention strategies should be directed at nodal assessment.  
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Summary 
 
Introduction: In the Netherlands, yearly 10,000 patients are diagnosed with 
colorectal cancer (CRC), of who about 4500 are expected to ultimately die of the 
disease. Investigating long term and recent trends will help predict future 
developments, which is important for planning prospective investments in clinical 
cancer care.  
Methods: The 19,099 cases of primary CRC (C18.0-C20.9) diagnosed between 1975 
and 2004 in the Eindhoven Cancer Registry area were included. We analysed trends in 
incidence, prevalence, stage distribution, treatment, survival, and mortality. 
Results: The epidemiology of CRC has changed strikingly in the south of the 
Netherlands during the period 1975 to 2004. First of all, there has been a gradual 
increase in incidence, which was most marked among males and for proximal tumours. 
Furthermore, survival increased dramatically, especially among rectal cancer patients 
and patients younger than 70 years. This went together with changes in treatment; 
particularly since the mid-1990s, a growing proportion of predominantly younger 
patients underwent adjuvant chemo- or radiotherapy. The advances in survival led in 
turn to decreased mortality rates, and consequently to increased prevalence rates. The 
changes toward an increased proportion of stage III tumours suggested improved 
staging procedures over time, without evidence that patients diagnosed more recently 
are diagnosed at an earlier stage of the disease.  
Conclusions: The results of our study showed that the workload of all clinicians 
involved in CRC care will keep increasing considerably in the near future. The steady 
increase in age-adjusted incidence, the demographic changes of the Dutch population 
and the likely future implementation of CRC mass screening will necessitate 
investments with relation to education, recruitment, materials, and infra-structure. In 
many other European countries, the situation is presumably the same. Nevertheless, 
this study demonstrated large improvements in management and survival of CRC 
patients between 1975 and 2004. The increase in survival of rectal cancer was the 
largest seen among all adult tumours in the Netherlands. Progress can however still be 
made, principally regarding management of older patients and early detection of CRC. 

  
Introduction 
 
Based on data from registries assembled in the European Network of Cancer Registries, 
colorectal cancer (CRC) was estimated to be the most frequent cancer in the European 
Union in 2004 189. In the Netherlands, yearly 10,000 patients are diagnosed with CRC, 
of who about 4500 are expected to ultimately die of the disease 1. It constitutes 2-3% 
of total mortality above the age of 40. During the last 35 years, earlier detection, 
improvements in endoscopy and imaging, advances in surgery and pathology, better 
pre- and postoperative care, and more frequent use of adjuvant therapies have led to 
improvements in survival of patients with CRC 47, 50, 53, 152, 190, 191. However, besides 
implementing all those changes, the clinicians of today face new challenges: one of 
them is the rising age of the Western population will lead to an increase in cancer 
patients, with a higher mean age at presentation.  
Investigating long term and recent trends will help predict future developments, which 
is important for planning prospective investments in clinical cancer care. Also, it is 
useful for clinicians and policy makers to evaluate the impact of all the changes that 
have taken place in the past. In this study, we focus on trends in incidence, stage 
distribution, treatment, survival and mortality among patients diagnosed with CRC 
between 1975 and 2004 in the south of the Netherlands, and we discuss the likely 
effects of the most important trends on clinical practice in the near future.  
 
Patients and methods 
 
The Eindhoven Cancer Registry collected data on all patients with newly diagnosed 
cancer in a large part of the southern Netherlands. The registry area grew from an area 
covering 850.000 to about 2.3 million inhabitants. This population-based registry was 
notified by 6 pathology departments, 10 community hospitals (20 at the beginning of 
the study period but many of them have merged) at 17 locations, and 2 radiotherapy 
institutions.  
Between 1975 and 2004, 19,099 cases of primary CRC (C18.0-C20.9) were diagnosed 
in the Eindhoven Cancer Registry area, excluding patients with unknown site of primary 
tumour within the colorectum (1.5% of total). Information on diagnosis, staging, and 
treatment is routinely extracted from the medical records by specially trained 
administrators of the cancer registry. Registration took place 6 to 18 months after 
diagnosis. By means of an independent case ascertainment method, the completeness 
of the registration is estimated to exceed 95% 54. Vital status of all patients diagnosed 
until 1st of January 2004 was assessed on 1st of January 2006 through merging with the 
Municipal Administrative Databases, where all deceased and emigrated persons in the 
Netherlands are registered.  
 
Analyses 
Differences in patient/tumour characteristics between different periods were analysed 
using a two-sided Cochran-Armitage trend test. Incidence/mortality rates are shown as 
the 3-year moving average of the number of new patients/deaths per 100,000 
inhabitants per year. The trends are age standardised, using the European 
  
 
 
Standardised Rate (ESR). Trends in detection and stage are shown as the proportional 
distribution of the Tumour Node Metastasis (TNM) stage in the respective period (1985-
1989, 1990-1994, 1995-1999 and 2000-2004). Stage is postoperative, except for cases 
where postoperative stage was unknown, then preoperative stage was used. Relative 
survival was used as an estimation of disease specific survival. It reflects survival of 
cancer patients, adjusted for survival in the general population with the same age 
structure. Relative survival is calculated as the ratio of the observed rates in cancer 
patients to the expected rates in the general population 192. Expected survival rates 
were calculated from life tables for regional male and female populations with the same 
5 year age distribution. In order to examine any changes in survival between the 
periods of diagnosis, a multivariable proportional hazards regression analysis stratified 
by tumour site (colon vs. rectum) was used to discriminate independent risk factors for 
death. This model was first built without the variable therapy, which was added later 
in order to investigate to what degree any prognostic effects of period of diagnosis 
could be explained by changes in treatment. Prevalence of patients with CRC up to 10 
years before 1984, 1994, and 2004 was expressed as the age-standardised number of 
patients alive per 100,000 inhabitants at the respective date.  
 
Results 
 
The age distribution shifted between 1975-1984 and 2000-2004 towards a higher 
proportion of patients diagnosed between age 65 and 79 years (ptrend<0.0001) (table 
1). The male-female ratio of incidence increased from 1.04 to 1.17 (ptrend 0.05), and a 
shift occurred towards a more proximal tumour site (colon vs. rectum) (ptrend <0.0001).  
The age-standardised incidence of colon carcinoma among males gradually increased 
between 1975 and 2004 from 24 to 38 patients per 100,000 inhabitants (figure 1). The 
incidence of colon carcinoma among females increased from 23 to 30. The incidence of 
rectal carcinoma remained more or less stable among males (about 25 per 100,000 
inhabitants) and females (about 15). 
 
Table 1. Age, gender, and tumour site distribution of the 19.099 patients diagnosed with colorectal 
cancer in the south of the Netherlands between 1975 and 2004, by period of diagnosis.1 
 
Period of diagnosis 
 
1975-1984 1985-1994 1995-1999 2000-2004 
Age (years)         
  19-49  278 (9) 377 (8) 352 (7) 414 (6) 
  50-64 952 (32) 1329 (31) 1495 (28) 1877 (29) 
  65-79 1447 (48) 2048 (47) 2585 (49) 3240 (50) 
  80+ 336 (11) 623 (14) 835 (15) 951 (15) 
Gender         
  Male 1523 (51) 2281 (53) 2802 (53) 3485 (54) 
  Female 1490 (49) 2056 (47) 2465 (47) 2997 (46) 
Tumour site         
  Colon 1819 (60) 2672 (62) 3265 (62) 4152 (64) 
  Rectum 1194 (40) 1665 (38) 2002 (38) 2330 (36) 
1
 Data are absolute numbers with percentages between parentheses. 
 
  
Figure 1. Age-standardized incidence of CRC in the south of the Netherlands, according to gender 
and tumour site (3-year moving average; ESR= European Standardised Rate).  
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The subsite-specific incidence rates showed a marked increase for carcinomas situated 
in the colon ascendens, among both males and females, and for carcinoma situated in 
the colon descendens and colon sigmoideum (figures 2a and 2b). 
 
Figure 2a. Age-standardized incidence of colon cancer among males in the south of the 
Netherlands, according to subsite (3-year moving average; ESR= European Standardised Rate).  
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Figure 2b. Age-standardized incidence of colon cancer among females in the south of the 
Netherlands, according to subsite (3-year moving average; ESR= European Standardised Rate).  
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The proportional stage distribution of patients with colonic carcinoma showed a slightly 
decreasing proportion of stage I patients, and an increased proportion of stage III 
(TanyN1-2M0) patients since 1984-1989 (p<0.0001) (figure 3). The proportion of 
patients with unknown stage remained stable for both colon (2.4%) and rectal cancer 
(3.5%) between 1985-89 and 2000-2004 (results not shown). Among patients without 
lymph node metastases (N0), the proportion of patients with T1 tumours decreased 
from 11% to 5%, the proportion T2 decreased from 28% to 17%, and the proportion 
T3 increased from 54% 69% (p<0.0001). 
Almost all patients with stage I-III (TanyNanyM0) colon carcinoma underwent resection, 
regardless of period of diagnosis and age (ranging from 92% to 100%) (table 2a). 
Since mid 1990s, adjuvant chemotherapy was increasingly administered among all age 
groups of stage III colon carcinoma patients, but the increase in the older age groups 
was much less marked. Only 4% of patients aged 80 years or older received adjuvant 
chemotherapy in the most recent period. In that period among stage II (T3-4N0M0) 
patients, 10% of patients younger than 50 years received adjuvant chemotherapy. 
While resection rates increased over time among patients younger than 50 years with 
colon carcinoma stage IV (TanyNanyM1), these rates decreased among the older age 
groups. Chemotherapy was increasingly administered to stage IV patients, except for 
patients over 80 years of age. 
Patients with rectal carcinoma increasingly underwent surgery, except for the most 
recent period, where surgery rates remained stable or even seemed to decrease 
somewhat among the oldest patients (table 2b). The use of radiotherapy among stage 
II/III patients increased between 1980-1989 and 1990-1994 (postoperative 
radiotherapy), decreased in the subsequent period (transition to preoperative 
radiotherapy), and increased again in the most recent period (preoperative  
  
 
 
Figure 3. Trends in stage distribution of CRC in the south of the Netherlands (excluding unknown 
stage). 
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radiotherapy). With rising age, the use of radiotherapy decreased. The combination of 
chemo- and radiotherapy was administered mostly to patients younger than 70 years 
old in the most recent period. The youngest stage IV patients increasingly underwent 
resection, contrasting the older patients. The use of chemotherapy among stage IV 
patients rose clearly, but less pronounced among the older patients. 
Unadjusted relative survival rates increased markedly for colon and for rectal cancer 
patients during the 30 year period (figures 4a-4n), especially among patients with 
stage III colon cancer and stage III rectal cancer.  Among stage I and II colon cancer  
  
 
 
Table 2b. Trends in primary treatment for patients with colon cancer in the south of the 
Netherlands, according to age a. 
 
  
Period of diagnosis 
Treatment age 1980-89 1990-94 1995-99 2000-04 
  % % % % 
Resection, stage I-III      
 19-49 99 99 92 99 
 50-59 100 99 95 98 
 60-69 99 99 98 98 
 70-79 97 99 97 97 
 80+ 96 98 97 97 
Adjuvant chemotherapy, 
stage II 
     
 19-49 0 14 2 10 
 50-59 0 5 5 5 
 60-69 1 6 2 4 
 70-79 0 0 1 2 
 80+ 0 0 0 0 
Adjuvant chemotherapy, 
stage III 
     
 19-49 2 47 72 93 
 50-59 1 34 60 83 
 60-69 0 32 52 76 
 70-79 0 8 25 36 
 80+ 0 0 1 4 
Resection (any), stage IV      
 19-49 76 69 85 83 
 50-59 80 78 73 70 
 60-69 82 83 70 70 
 70-79 78 75 71 68 
 80+ 78 71 69 64 
Chemotherapy, stage IV      
 19-49 17 38 60 68 
 50-59 11 33 44 63 
 60-69 5 20 28 50 
 70-79 2 3 12 32 
 80+ 0 0 1 3 
a
 Percentages of patients who underwent the respective treatment. 
 
patients, survival improved markedly since 1974-1985, but remained stable afterwards. 
Among stage II patients, survival kept improving throughout the whole period. An 
improvement in survival can be noted since 111995-99 among stage IV patients, but 
only for survival up to 2 years. Survival of stage I and II rectal cancer patients 
improved drastically during the 1970s and 80s, but remained stable afterwards, 
although in the most recent period an improvement among stage I rectal cancer 
patients can be noted up to 4-year survival. The improvements among stage III rectal 
cancer patients are comparable to the improvements seen among stage III colon 
cancer patients, with large improvements in the 2 most recent periods. There was also 
a noteworthy improvement among stage IV rectal cancer patients, especially in the 
period 2000-2004. The unadjusted cancer survival rates for both colon and rectal 
cancer and for both patients younger and older than 70 years of age did not show a 
clear improvement since the period 1985-1994. An exception was the unadjusted 
survival rate among rectal cancer patients younger than 70 years, which improved up 
  
to the period 1995-1999. Five-year survival of all colon cancer patients improved from 
45% in 1975-1984 to 56% in 2000-2004; 5-year survival of all rectal cancer patients 
improved from 39% to 57% in that period. 
 
Table 2b. Trends in primary treatment for patients with rectal cancer in the south of the 
Netherlands, according to age a. 
 
  
Period of diagnosis 
Treatment age 1980-89 1990-94 1995-99 2000-04 
  % % % % 
Resection, stage I-III      
 19-49 96 95 94 98 
 50-59 99 97 97 97 
 60-69 98 99 97 96 
 70-79 96 96 94 95 
 80+ 89 96 93 88 
Pre/postoperative 
radiotherapy b, stage II/III 
     
 19-49 55 63 58 77 
 50-59 67 61 54 73 
 60-69 46 57 47 71 
 70-79 31 43 37 58 
 80+ 15 20 19 42 
(Neo-) adjuvant 
chemotherapy plus 
radiotherapy, stage II/III 
     
 19-49 0 11 14 37 
 50-59 2 6 11 27 
 60-69 0 2 4 22 
 70-79 0 1 1 9 
 80+ 0 0 0 1 
Resection (any), stage IV      
 19-49 53 50 57 66 
 50-59 72 54 69 56 
 60-69 75 55 63 60 
 70-79 63 63 55 42 
 80+ 78 40 36 31 
Chemotherapy, stage IV      
 19-49 5 17 54 76 
 50-59 9 36 49 65 
 60-69 17 10 35 53 
 70-79 2 7 17 31 
 80+ 0 0 0 4 
a
 Percentages of patients who underwent the respective treatment. 
b
 Since mid-1990s, postoperative radiotherapy was replaced by preoperative radiotherapy. 
 
 
The multivariable analyses among stage III colon cancer patients aged younger than 
70 showed that without treatment added to the model, there is decreased risk of death 
over time (table 3a). However, with the addition of adjuvant treatment to the model, 
this effect disappeared. There was no significant improvement over time for the older 
age group. Among stage II and III rectal cancer patients, there was a significant 
reduction in death risk over time for both patients younger and older than 70 years, 
both without and with treatment in the model. Also among patients with stage IV 
  
 
 
colorectal cancer the risk of death decreased, only among younger patients, 
independent of treatment (table 3b).   
 
 
Figure 4a. Relative survival among patients with stage I colon cancer. 
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Figure 4b. Relative survival among patients with stage II colon cancer. 
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Figure 4c. Relative survival among patients with stage III colon cancer. 
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Figure 4d. Relative survival among patients with stage IV colon cancer. 
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Figure 4e. Relative survival among patients with stage I rectal cancer. 
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Figure 4f. Relative survival among patients with stage II rectal cancer. 
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Figure 4g. Relative survival among patients with stage III rectal cancer. 
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Figure 4h. Relative survival among patients with stage IV rectal cancer. 
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Table 4i. Relative survival among patients with colon cancer, all stages, younger than 70 years. 
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Table 4j. Relative survival among patients with colon cancer, all stages, 70 years or older. 
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Table 4k. Relative survival among patients with rectal cancer, all stages, younger than 70 years. 
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Table 4l. Relative survival among patients with rectal cancer, all stages, 70 years or older. 
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Table 4m. Relative survival among patients with colon cancer, all stages and ages. 
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Table 4n. Relative survival among patients with rectal cancer, all stages and ages. 
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Age-standardised mortality from colon cancer among males fluctuated between 20 to 
25 deaths per 100,000 inhabitants during the whole study period (figure 5). Among 
females, colon cancer mortality rates showed a steady decrease from 22 deaths per 
100,000 inhabitants in 1975, to 16 in 2004. A similar trend could be observed for rectal 
cancer mortality rates; a decline from 13 deaths per 100,000 inhabitants to 7 among 
males, and from 8 to 4 among females.  
The 10-years prevalence of patients with CRC clearly increased between 1984 and 
2004, especially among males (table 4). Per community hospital, this means an 
increase from 800 colorectal cancer patients per hospital to almost 1300 patients. 
 
Discussion 
 
The epidemiology of CRC has changed strikingly in the south of the Netherlands during 
the period 1975 to 2004. First of all, there has been a gradual increase in incidence, 
which was most marked among males and for proximal tumours. Furthermore, survival 
increased dramatically, especially among patients younger than 70 years. This went 
together with changes in treatment; particularly since the mid-1990s, a growing 
proportion of predominantly younger patients underwent adjuvant chemo- or 
radiotherapy. The advances in survival led in turn to decreased mortality rates, and 
consequently to increased prevalence rates. The changes in stage distribution 
suggested improved staging procedures over time, without evidence that patients 
diagnosed more recently are diagnosed at an earlier stage of the disease.  
The rising age-standardised incidence of CRC in the south of the Netherlands, 
predominantly among males, is in concordance with patterns of incidence found in 
many other European countries 2, 193-195. Changes in major risk factors such as life style, 
including physical activity, diet and obesity may account for the rising trend (van 
Steenbergen et al, submitted for publication). These trends are however in contrast to 
patterns found in the USA, where overall incidence rates have been steadily declining 
over the past two decades 196. One explanation for this reversed trend may be the 
more extensive implementation of opportunistic CRC screening in the latter country 196. 
The trends in stage distribution as shown by the current study support this hypothesis; 
no clear shift towards an earlier stage at diagnosis was observed in the south of the 
Netherlands, which would be expected in case of higher uptake of screening activities. 
Added to that, one can only speculate about any effect on stage distribution of an 
increased polypectomy of premalignant adenomas over time.  
As in many Western countries, a shift towards more proximal tumour site was observed 
197-201. This has been related to the use of sigmoidoscopy (and related polypectomy) as 
a screening tool 197, 202. However, our data show that the shift towards proximal tumour 
site is the result of an increase in age-adjusted incidence of proximal tumours, and not 
merely a decline in distal tumour site. Possibly changes in diet and lifestyle, and maybe 
also the use of medications such as aspirin and non-steroidal anti-inflammatory drugs, 
and hormone replacement therapy in women, are responsible for the rightward shift in 
CRC incidence through differential effects of these risk factors on the respective 
subsites 15-20, 22, 27, 203-205. 
 
 
  
 
 
Table 3a. Multivariable survival analysis of patients with stage III colon and stage II/III rectal 
cancer. 
 
 
 
Model excl. treatment1 Model incl. treatment1 
 
 
Hazard 
ratio 
p-value Hazard 
ratio 
p-value 
Colon, stage III, 
<70 yrs 
 
Period of diagnosis 
    
 
  1975-1984 1.42 0.02 1.10 0.34 
 
  1985-1994 1.0  1.0  
 
  1995-1999 0.83 0.04 1.08 0.44 
 
  2000-2004 0.64 <0.0001 1.02 0.18 
 Treatment     
 
  Surgery -  1.0  
 
  Surgery + adjuvant   
  chemotherapy 
-  0.50 <0.0001 
Colon, stage III, 
70+ yrs 
 
Period of diagnosis 
    
 
  1975-1984 1.26 0.02 1.27 0.02 
 
  1985-1994 1.0  1.0  
 
  1995-1999 0.94 0.46 1.05 0.59 
 
  2000-2004 0.84 0.04 0.99 0.88 
 Treatment     
 
  Surgery -  1.0  
 
  Surgery + adjuvant  
  chemotherapy 
-  0.50 <0.0001 
 
     
Rectum, stage 
II/III, <70 yrs 
 
Period of diagnosis 
    
 
  1975-1984 1.37 0.0002 1.37 0.0003 
 
  1985-1994 1.0  1.0  
 
  1995-1999 0.70 <0.0001 0.70 <0.0001 
 
  2000-2004 0.58 <0.0001 0.54 <0.0001 
 Treatment     
 
  Surgery  -  1.0  
 
  Surgery + any adjuvant  
  therapy 
-  1.03 0.98 
Rectum, stage 
II/III, 70+ yrs 
 
Period of diagnosis 
    
 
  1975-1984 1.19 0.07 1.15 0.18 
 
  1985-1994 1.0  1.0  
 
  1995-1999 0.86 0.05 0.84 0.04 
 
  2000-2004 0.81 0.02 0.77 0.007 
 Treatment     
 
  Surgery  -  1.0  
 
  Surgery + any adjuvant  
  therapy 
-  0.93 0.33 
1
 Adjusted for age, gender, subsite, and variables shown 
 
There was a vast improvement in 5-year relative survival for both colon and rectal 
cancer, especially among stage III patients. The current study demonstrated that the 
increase in survival was more pronounced among patients younger than 70. For stage 
III colon cancer patients, the increased use of effective adjuvant chemotherapy 
regimens for these patients probably largely accounted for this improvement. Among 
elderly stage III patients, survival increased more moderately. Adjuvant chemotherapy 
was administered to only 36% of patients aged 70-79 years and only 4% of those aged  
  
 
 
 
Table 3b. Multivariable analysis of patients with stage IV colorectal cancer. 
 
  
Model excluding 
treatment1 
Model including 
treatment1 
  
Hazard 
ratio 
p-value Hazard 
ratio 
p-value 
Colorectum, 
stage IV, <70 yrs 
Period of diagnosis     
 
  1975-1984 1.17 0.03 1.18 0.03 
 
  1985-1994 1.0  1.0  
 
  1995-1999 0.84 0.006 0.90 0.09 
 
  2000-2004 0.68 <0.0001 0.76 <0.0001 
 Treatment     
 
  No systemic therapy -  1.0  
 
  Systemic therapy -  0.76 <0.0001 
Colorectum, 
stage IV, 70+ yrs 
Period of diagnosis     
   1975-1984 0.85 0.27 0.86 0.10 
   1985-1994 1.0  1.0  
   1995-1999 0.95 0.84 0.98 0.81 
   2000-2004 0.86 0.46 0.96 0.56 
 Treatment     
   No systemic therapy -  1.0  
   Systemic therapy -  0.64 <0.0001 
1
 Adjusted for age, gender, site, and variables shown 
 
80 or older in the period 2000-2004, although several studies have demonstrated the 
benefit of this therapy at higher ages 141, 206. Besides age as well as hospital, also 
comorbidity, gender, and socio-economic status influenced administration of adjuvant 
chemotherapy in the south of the Netherlands 139. Survival improved also among stage 
IV CRC patients, and among rectal cancer patients. Although a 2003 study did not 
detect a significant survival improvement among elderly rectal cancer patients in the 
south of the Netherlands, the present study shows an improvement in this group of 
patients 47. This may be explained by the fact that survival of elderly patients especially 
improved during the most recent years (2000-2004) which were not included in the 
previous study. Large changes in treatment have taken place among rectal cancer 
patients: implementation of Total Mesorectal Excision (TME) and a shift from post- to 
preoperative radiotherapy together with increased administration of (neo-adjuvant) 
chemotherapy 47, 89, 207. The increase in survival for rectal cancer in general was large, 
when also taking into account the survival in the period 1965-1974 (33%), the relative 
improvement in survival was the largest among all adult tumours 1. For stage IV CRC 
patients, higher resection rates and an increased use of and changes in chemotherapy 
could be noted. In most recent years, there has been a regionalisation of the surgical 
expertise for treating locally advanced rectal carcinoma and liver metastases. As 
opposed to stage III colon cancer patients, in our multivariable analyses the survival 
improvements for stage II/III rectal cancer patients could not be explained by the 
increased use of adjuvant treatment. Therefore, also changes in surgery, more 
accurate staging procedures by surgeon and pathologist, perioperative care, and the 
  
 
 
establishment of multidisciplinary teams have probably contributed to the improved 
survival of rectal carcinoma.  
 
Figure 5. Age-standardized mortality of CRC in the south of the Netherlands (3-year moving 
average), according to gender and tumour site.  
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Although adherence to clinical guidelines is generally considered a measure of quality 
of care, deviating from these guidelines in case of an elderly patient is not necessarily 
indicating inferior quality of care. The large proportion of elderly patients presenting 
with comorbidity, and the inherent lack of evidence-based guidelines for this group, 
often call for pragmatic individualised treatment 80. In view of the growing proportion 
of elderly CRC patients - partly because of the rising incidence rates but especially 
because of the aging population - clinicians will more and more often face difficult 
decisions regarding adjuvant therapy. However, specific knowledge of CRC care of the 
elderly, while lagging behind the treatment of younger patients, is beginning to 
emerge. Informed by recent trials, the approach towards elderly patients is shifting 
towards more aggressive treatment and multimodal therapy, as partly confirmed by our 
data.  
In recent years, the limited armamentarium of fluoruracil-based chemotherapy has 
been replenished by new systemic treatments agents 208. Oxaliplatin in combination 
with conventional 5-fluoruracil/leucovorin is now considered standard therapy for stage 
III colon cancer in the Netherlands. Targeted therapies directed at the vascular 
endothelial growth factor pathway and the epidermal growth factor pathway have also 
become key players in the treatment of CRC 209. However, the high costs of these new 
agents have to be taken into consideration, at the same time bearing in mind the rising 
number of CRC patients 209. Of importance to note here is that high-risk stage II colon 
cancer patients with a low number of lymph nodes examined, are nowadays also often 
offered adjuvant chemotherapy 210. Nevertheless, evidence confirming the benefit of 
this procedure among stage II patients stems from the preliminary results from one 
  
randomised study only, which to date has not published the complete results 211. 
Priority should be given to increase adequacy of nodal examination, which has been 
shown to be sub-optimal in the south of the Netherlands 212. 
The aging of the population and hence the rise in absolute numbers of patients with 
CRC together with the increased survival rates will also lead to a large number of 
individuals who were diagnosed with CRC 5 or more years ago. A report of the Dutch 
National Cancer Society estimated the prevalence of CRC patients in the Netherlands to 
increase from 60,000 in 2005 to 100,000 in 2015 4. These patients have to be followed-
up, which will further claim endoscopy capacity, and part of these patients will need 
extra care, i.e. because of a permanent stoma, and they have also an excess risk of 
developing a subsequent primary cancer 213.  
 
Table 4. Ten-years prevalence (ESR) of patients with CRC at 1st of January 1984, 1994, and 
2004, respectively, in the south of the Netherlands.1 
 
  
Prevalence (ESR) 
  
01-01-1984 01-01-1994 01-01-2004 
Males Colon 101 138 167 
 Rectum 70 104 128 
Females Colon 96 118 145 
 Rectum 51 59 75 
1
 Age-standardised number of patients alive, diagnosed with colorectal cancer up to 10 years 
before the respective date, per 100,000 inhabitants. 
 
The strength of the current study is the availability of long-term, high quality 
population-based data 54, 214. Studying long-term trends enables an evaluation of 
implemented care and eventual screening activities, and an anticipation of 
developments in the near future. The results of our study showed that the workload of 
all clinicians involved in the diagnosis, staging, treatment, and follow-up of CRC will 
keep increasing considerably in the near future. Not only the steady increase in age-
adjusted incidence, but especially the demographic changes of the Dutch population 
and the likely future implementation of CRC mass screening will necessitate 
investments with relation to education, recruitment, materials, and infra-structure. In 
many other European countries, the situation is presumably the same. Nevertheless, 
this study demonstrated large improvements in management and survival of CRC 
patients between 1975 and 2004. Progress can still be made, principally regarding 
management of older patients and early detection of CRC. 
 
 
  
 
 
Chapter 5 
 
Discussion
  
  
 
 
Chapter 5.1  
  
Introduction to the discussion 
 
 
This thesis described the clinical epidemiology of colorectal cancer in the South of the 
Netherlands, a region of 2.4 million people served by the Comprehensive Cancer Centre 
South (CCCS). The studies included in this thesis gave an overview of daily clinical 
practice, with results which were expected (comorbidity influencing treatment and 
survival), unexpected (the large variation in administration of adjuvant chemotherapy 
and of lymph node examination between institutions), and desirable (improvement in 
survival). It answered many questions, but even more questions were raised and 
remained unanswered. In this chapter, we will address several of these answered and 
unanswered questions in more detail; first we will address the trends in incidence and 
survival of colorectal cancer patients. Then we will focus on one of the main topics 
discussed in this thesis: treatment and survival of older colorectal cancer patients.  
Afterwards we will go deeper into the impact of comorbidity, and discuss guideline 
adherence and variation. We will end the discussion with a paragraph on future 
perspectives.
  
  
Chapter 5.2  
 
Incidence and survival 
 
 
The incidence of colon cancer increased since 1975 while rectal cancer incidence 
remained relatively stable (chapter 4.1). The differential increase in incidence for colon 
and rectal cancer in both genders is probably due to changed lifestyle factors. 
Epidemiological studies confirm the importance of lifestyle in colorectal cancer. 
Excessive intake of energy, red and processed meat, dietary fat, alcohol, smoking, as 
well as obesity and reduced physical activity are known risk factors for CRC 14-23. There 
was no major improvement in stage distribution during the last decades. Probably, this 
reflects the relatively low uptake of (opportunistic) screening activities. Currently 
available screening tests, if applied to the general population, could substantially reduce 
colorectal cancer incidence and mortality 215. Apart from this, there was already a large 
and continuing increase in survival in the south of the Netherlands, since the 1970s, for 
both colon and rectal cancer. The increase in rectal cancer survival was the largest of 
all tumours among adults. Changes in detection and treatment are largely accountable 
for the improvement for colorectal cancer survival: imaging techniques, surgery, and 
adjuvant chemo- and radiotherapy have all undergone major changes, as described in 
chapter 4.1. Survival increased more among patients younger than 75 years, but during 
more recent years also among elderly patients an improvement in survival could be 
noted. 
The increased incidence and survival rates led to a large increase in the prevalence of 
patients with colorectal cancer. Most of these patients will require follow-up, and part 
of these patients will need extra care, i.e. because of a permanent stoma or 
incontinence, and the excess risk of developing a subsequent primary cancer 213, 216, 217. 
This, together with increasing incidence rates, the demographic changes of the Dutch 
population, and the likely future implementation of colorectal cancer mass screening 
will necessitate enlarged provision of service.  
 
 
 
                                
 
Chapter 5.3  
 
Management and survival of colorectal cancer in 
the elderly; an overview of population-based 
studies 
 
Reprinted from European Journal of Cancer: J. Faivre, V.E.P.P. Lemmens, V. Quipourt, 
A.M. Bouvier. Management and survival of colorectal cancer in the elderly; an overview 
of population-based studies. Paper in press. © 2007, with permission from Elsevier.  
 
 
Summary 
 
Colorectal cancer is a major problem in elderly patients. Most data on the management 
and survival of colorectal cancer has been provided by specialised hospital units and as 
such cannot be used as reference because of unavoidable selection bias. Cancer 
registries recording data on treatment and survival at a population level represent the 
best valuable resource to assess the management of patients. However, there is a 
paucity of reports published in the literature due to the difficulty to routinely collect 
such data. Relative survival rates in the elderly were lower than in younger patients. 
However, the gap that has separated younger from elderly patients is closing. Stage at 
diagnosis remains the major determinant of prognosis. There is also large variation in 
survival within countries: survival rates being dramatically lower in Eastern European 
countries, compared to Western European countries. Comorbidity, which is particularly 
frequent in the elderly increases the complexity of cancer management and affects 
survival. 
Substantial improvement in the care of colorectal cancer in the elderly has been 
achieved (increase in the proportion of patients resected for cure, decrease in operative 
mortality, improvement in stage at diagnosis). Surgery should not be restricted on the 
basis of age alone. Further improvements can be made, in particular with respect to 
adjuvant therapy. 

                                
 
Introduction 
 
Colorectal cancer is predominantly a problem of the elderly: 30 to 40% of the cases 
occur in subjects aged 75 or older 2. The ageing of the population and the rise in life 
expectancy, as well as the increasing incidence of colorectal cancer, have led to a 
growing number of affected patients. Over the past 25 years important advances have 
occurred in the management of colorectal cancer 218. However, diffusion of treatment 
that has proven beneficial among elderly patients is not well known. Most data on 
management and survival of colorectal cancer in the elderly is provided by specialised 
hospital units and as such cannot be used as reference because of unavoidable 
selection bias. Furthermore, crude survival rates overestimate cancer-specific mortality 
among elderly patients since mortality due to other causes is high. Relative survival, 
defined as the ratio of observed survival to expected survival in a population of the 
same age and sex distribution, provides an estimation of patient survival which is 
corrected for non-colorectal cancer cause of death 192. Population-based studies, 
recording all cases diagnosed in a well-defined population, represent the best way to 
assess improvements in management or prognosis of colorectal cancer in the elderly 
(defined in this paper as patients aged 75 years or older). Such studies are rare, 
because they require accurate and detailed data collection, which is difficult to achieve 
for many cancer registries. The purpose of this report is to describe colorectal cancer 
management and survival in the elderly and to explore the factors involved using 
community-based statistics. 
 
 
Surgery for colorectal cancer 
 
Colorectal cancer is managed by surgical resection of the primary tumour whenever 
possible. This is the only possibility for cure of the cancer, with the exception of 
endoscopic polypectomy of a malignant adenoma, which by itself can be a sufficient 
treatment. A review of 28 independent studies, involving a total of 34,194 patients, has 
reported a lower resection rate in elderly patients compared to younger patients 81 
(Table 1). This difference between age groups is multifactorial. It may be because of 
later presentation, poor performance status, presence of comorbidities or an 
expectation of poorer outcome in elderly patients. However, the gap between age 
groups is closing.  
 
Table 1: Aggregate data on treatment and stage at diagnosis for colorectal cancer according to 
age, in 28 studies 
 
 
65-74 years 75-84 years  85 years 
    
Resection for cure 75% 73% 67% 
 No operation 6% 11% 21% 
 Emergency surgery 15% 18% 29% 
 TNM stage 1 15% 14% 10% 
 TNM stage 4 21% 22% 25% 
  
 
Recent data suggest that the resection rate for colon cancer is now similar in all age 
groups up until 85 and becomes lower only in the very old age group 81, 219. The age-
related decreased resection rate appears earlier among patients with rectal cancer, just 
after the age of 80 219. This can be explained by the fact that rectal surgery is generally 
more complex. Several reports from France indicate that there was a major 
improvement in the proportion of resected cases until the 1990s, after which it levelled 
out 123, 218, 220. A similar trend has also been reported in Denmark 221. The absence of a 
recent improvement in the proportion of resected cases can be related to the fact that 
it is not far from the optimum: 90% for colon cancer and 85% for rectal cancer up until 
85 years of age 219. The observed trend shows a change in the habits and opinions of 
surgeons and anaesthetists over the years. It is now well established that the quality of 
surgery is of particular importance in rectal cancer. Total mesorectal excision decreases 
local recurrence. However, it has been shown that total mesorectal excision was 
performed less often in elderly patients than in younger patients 80. This treatment 
must be recommended whatever the age. The importance of appropriate treatment 
does not diminish with age. Age in itself should not be a limiting factor in the treatment 
of patients with colorectal cancer. A comprehensive geriatric assessment for 
determining operative risk should assist in selection of patients who otherwise appear 
unlikely to benefit from surgery. 
It is important to underline that the increase in the proportion of patients resected from 
their cancer is associated with an improvement in the stage at diagnosis 222. Several 
explanations can be put forward: earlier consultation, more frequent and more rapid 
referral for investigations by general practitioners, a more forceful attitude of surgeons 
and also because among non-resected cases in the past, there were patients with 
early-stage disease which are now identified as such. 
The objectives of surgery in elderly patients are to improve life expectancy with a 
minimal risk of operative mortality and loss of autonomy.  A Canadian study compared 
quality of life of patients over 80 years old who had undergone surgery for colorectal 
cancer, with a younger group composed of patients under 70 223. Patients were 
surveyed by mail using the EORTC quality-of-life scales specific to cancer (EORTC  
C30) and colorectal cancer (EORTC  CR38). The two groups scored similarly except for 
physical functioning and stoma-related problems. Most patients did not require special 
assistance or alternative living arrangements after discharge from the hospital and 
were able to return to their preoperative level of functioning. This study suggests that 
elderly patients who are selected for surgery have a quality of life comparable to 
younger patients in most respects. It is well established that elderly patients have an 
increased frequency, compared with younger patients, of comorbid conditions such as 
diabetes, hypertension, chronic obstructive pulmonary disease or cardiovascular and 
cerebrovascular disease 80, 224. In a population-based study in the Netherlands the 
proportion of patients with comorbidity varied from almost 40% in patients aged 50-64 
years to more than 70% in those aged 80 years or older 80. However, the proportion of 
patients undergoing surgery was not affected by comorbidity. Elderly patients 
constitute a heterogeneous group. Post-operative morbidity increases progressively 
with age, as well as the duration of hospital stay. An increasing frequency of thrombo-
                                
 
embolism, respiratory and cardiovascular complications was reported in relation to age 
224. Some comorbid conditions at the time of diagnosis predict complications after 
surgery. This is particularly the case of chronic obstructive pulmonary disease and 
deep-vein thrombosis 225. However, anastomotic leak rates were unchanged.  
Available population-based data indicate that the outcomes of surgery, even in the 
oldest age groups, can be good. It can be concluded that if an elderly patient is 
believed to be fit for surgery, then a standard surgical procedure with primary 
anastomosis can be tolerated without excessive risk of surgical complications. 
 
 
Non-surgical treatments 
 
Randomized controlled trials published in the 1990s established that 5-FU-based 
chemotherapy reduces the crude risk of colon cancer recurrence and mortality by as 
much as 10% 53. These publications led to a progressive change in practices. In 
France, it took only 4 years in patients under 65, and 6 years in those aged 65-74, to 
reach almost optimum values (15). Although there was some improvement over time, 
few patients over the age of 75 received adjuvant chemotherapy for stage III colon 
cancer (24%, 1997-1998 period) (15). Data from Europe and Australia suggest that in 
the year 2000, only 20-25% of elderly patients received adjuvant chemotherapy (15-
20), in comparison to 40-50% in the US (21-29) (Table 2). More frequent use of 
adjuvant chemotherapy in elderly patients would reduce death from colorectal cancer. 
Data from the SEER program suggested that, in patients older than 65 years old, 
treatment with 5-FU in node positive colon cancer was associated with a 34% reduction 
in mortality, a difference similar to that described in randomized studies (30). Elderly 
patients have been under-represented in clinical trials, so it can be difficult to 
determine whether the benefits shown among trial participants pertain to older 
patients. However, a review of 7 randomised trials indicated that the benefits of 5-FU-
based chemotherapy in elderly people diminished only slightly with increasing age, and 
there was only a small increase in toxicity (in particular mucite) (31, 32). So, greater 
toxicity is an insufficient explanation for the decline in usage observed with advancing 
age. Elderly patients themselves may choose not to receive chemotherapy. However, 
when studied, older patients were just as likely as younger patients to accept 
chemotherapy, although after choosing to receive treatment they were less likely to 
accept major toxicity in exchange for added survival (33). Furthermore they have 
indicated that the primary determinant of their decision regarding chemotherapy was 
their physician's advice (34). The physician's attitude may explain the low utilisation of 
adjuvant chemotherapy, in particular in Europe. 
Some elderly patients may be unsuitable for chemotherapy due to pre-existing 
comorbidity. In a US study among patients 75 to 84 years of age, 53% received 
chemotherapy in the absence of co-morbidity, 47% if there was one-comorbid 
condition and 37% if there were two (25) (Table 2). The corresponding percentages 
for patients aged 85 and older were 19%, 9% and 2%. In the Netherlands, 28% of 
patients aged 75 to 79 years old without comorbidity received adjuvant chemotherapy, 
compared to 15% of patients in this age group with comorbidity (16). However, despite 
  
the fact that chronic conditions appear to be a strong barrier to the receipt of adjuvant 
chemotherapy, there is a paucity of studies that were able to link specific comorbid 
conditions to outcome for colorectal cancer. A recent cohort study did not find any 
between adjuvant chemotherapy and heart-failure, diabetes, and chronic pulmonary 
obstructive disease, regarding all-cause, condition-specific, or toxicity-related 
hospitalisation (28).  
 
 
Table 2: Proportions of elderly stage III colon cancer patients treated with adjuvant chemotherapy; 
population-based data a. 
 
 
a
 In 
square 
bracke
ts: rate 
of 
adjuva
nt 
chemo
therap
y 
compl
etion 
b
 Age 
group 
76-80 
y 
c
 Age 
group 
81-85 
y 
d
 Age 
group 
86+ y 
e
 Age 
group 
75-84 
y 
f
 Age group 85+ y 
g
 1-2 comorbid conditions 
h
 3+ comorbid conditions 
i
 Age group 80+ y 
j
 Age group 70-79 y 
k
 Age group 70+ y 
 
 
In view of the generally relatively low toxicity of chemotherapy in colon cancer and the 
increase in life expectancy, it can be concluded that a larger proportion of elderly 
patients, who are healthy enough to be operated on, could benefit from this treatment. 
The treatment decision for an individual patient should be based on the known benefit 
as opposed to the side effects and the impact on quality of life. In this context, 
discussion of the medical file within multidisciplinary consultancy meetings including a 
geriatrician is important. A recent survey in France indicated that multidisciplinary 
 Age group Comorbidity score 
Author All 
cases 
(75+ y) 
75-79 
y  
80-84 
y   
85+ y      0  1 2+ 
Morris et al 17% 
[64%] 
- - - - - - 
Phelip et al 18% - - - - - - 
Faivre-Finn et 
al 
24% 52% 10% 3% - - - 
Fietkau et al 29% - - - - - - 
Lemmens et 
al 
- 20% - - 28% 16% 15% 
Potosky et al 35% 47% 24%   - - 
Schrag et al 38% 58% 34% 8% - - 
- 
- 
Dobie et al - 56% 
[74%]b 
30% 
[68%]c 
8% 
[65%]d 
59% 
[79%] 
48% 
[77%] 
47% 
[74%] 
Sundararaya
n et al 
52% 58% 32% 15% 59% 57% 33% 
Ayanian et al 39% 48% 11% 53%e 
19%f 
47%e 
9%f 
Gross et al - 63%b 38%c 11%d 69% 55%g 
37%e 
2%f 
39%h 
Neugut et al - 54% 
[63%] 
21% 
[51%]i 
- 56% 
[68%] 
44% 
[61%] 
39% 
[57%] 
Cronin et al 52% - - - - - - 
Jessup et al - 69%j 39% - - - 
Bouchardy et 
al 
13%k - - - - - - 
                                
 
consultancy meeting has yet to be fully developed, particularly for the elderly (35). The 
importance that patients place on the physician's opinion makes it imperative for 
clinicians to fully inform their patients of the potential benefit of chemotherapy. 
Local recurrence, following curative resection for rectal cancer, remains a substantial 
problem. A population-based study has reported a 5-year local recurrence rate of 25% 
(1976-2000) (36). These results demonstrate the importance of effective adjuvant 
treatment in addition to surgery. Adjuvant radiotherapy for rectal cancer has been 
shown to reduce local recurrence, and preoperative radiotherapy was found to be more 
effective than postoperative radiotherapy. The effectiveness of preoperative 
radiotherapy has also been demonstrated after optimal surgery including total 
mesorectal excision (37). 
Current guidelines for patients with rectal cancer include adjuvant or neoadjuvant 
radiotherapy. Some data are available on the practice of radiotherapy in the elderly at 
a population level. They indicate that elderly patients are being undertreated compared 
to younger patients: 35% vs 79% in Burgundy over the 1994-1996 period (38). There 
were some variations between countries: treatment among elderly patients stood at 
36%-40% among SEER registries in the US (1992-1996 period) (25, 27, 39), 35% in 
France (1994-1996) (38), 36% in Germany (1999-2000) (20), and 20%-50% in the 
Netherlands (1980-2000, 2000-2004) (40-42, Lemmens, this thesis) (Table 3).  
 
 
Table 3: Proportions of elderly stage I-III rectal cancer patients treated with pre- or postoperative 
radiotherapy; population-based data  
 
  Age group 
Author All cases 
(75+ y) 
75-79 y 80-84 y  85+ y 
Faivre-Finn et al 35% 35% 36% 34% 
Fietkau et al 36% - - - 
Martijn et al 20% - - - 
Shahir et al 36%a - - - 
Vulto et al - 55%b,c 23% 
Lemmens et al - 58%d 42% 
Neugut et al 37% 48% 35% 17% 
Ayanian et al 40% 47%          14%  
Cronin et al 36% -  - - 
a
 Age group 70+ y 
b
 Age group 65-79 y 
c Declining from 65% in absence of comorbidity, to 45% in presence of 2 or more comorbid     
  conditions 
d
 Age group 70-79 y 
 
In the US, adjuvant treatment consisted of postoperative radiotherapy administered 
concurrently with chemotherapy. In France and in the Netherlands, preoperative 
radiotherapy has become the standard treatment regimen. Although radiotherapy is not 
always indicated in elderly patients because of severe comorbidity, it has not reached 
full implementation in this age group. The need for transportation between the home 
and the few radiotherapy centres can limit its use for elderly patients, although this 
aspect seems to be less important for patients receiving short-course preoperative 
radiotherapy (5 x 5 Gray). It has also been shown that elderly patients who underwent 
  
surgery plus operative radiotherapy develop more complications than patients 
undergoing surgery alone (especially pneumonia and cardiac complications). It is 
possible that after use of total mesorectal surgery, the added value of radiotherapy 
among the elderly is limited (41). In order to optimise the risk benefit ratio for elderly 
patients a comprehensive geriatric assessment is of critical importance.  
 
 
Survival 
 
In a review of the literature, postoperative mortality, i.e. mortality within 30 days of 
surgery, was 3 times higher in patients aged 75-84 and over 6 times more common in 
those aged 85 and over, compared with patients under 65 years of age (5). The 
increase in postoperative mortality with advancing age may be partly explained by 
comorbidity. An increasing frequency of respiratory, cardiovascular and tromboembolic 
complications has been reported in relation to age (9). However a steady reduction in 
operative mortality has been reported over time (43,44),  even though it is still higher 
than in younger patients. This is all the more noticeable as the proportion of patients 
who were offered surgery has increased. This has been achieved by improvement in 
the perioperative management of elderly patients, through evaluation and preoperative 
correction of associated medical conditions and by improvement of postoperative 
resuscitation. 
The 5-year mean relative survival rate for elderly patients, reported in the EUROCARE-3 
study, covering the period 1990-1994 (45), was 43%, higher for colon cancer (46%) 
than for rectal cancer (39%). The rate was similar in males (43%) and in females 
(44%). It was lower in younger patients since the 5-year relative survival rate was 57% 
in patients under 45, and 51% in patients aged 65 to 74. A slight improvement in 
survival in elderly patients was reported in the EUROCARE study. For colon cancer, the 
5-year relative survival rates were 40% (1983-1985) and 48% (1992-1994). The 
corresponding rates for rectal cancer were 35% and 40%. The gap that has separated 
younger from elderly patients is decreasing. In France, among patients over 80, 5-year 
relative survival rates for colon cancer increased from 27.0% (1978-1981) to 47.8% 
(1995-1997), and for rectal cancer from 18.1% to 41.7% (5). Also in the Netherlands a 
clear improvement in relative survival could be noted among these patients: from 39% 
(1975-1984) to 45% (2000-2004) for colon cancer, and from 29% to 49% for rectal 
cancer (Lemmens, personal communication). The improvement in survival can be 
attributed to the decrease in operative mortality and to the increase in proportion of 
patients resected for cure, which is associated with earlier diagnosis. The excess 
mortality rate is mainly observed during the first months after diagnosis (46, 47). The 
older persons who survive the first year have a prognosis similar to younger ones. Late 
diagnosis, and comorbidities or physiological impairment can explain an early 
prognostic disadvantage. These impose limits on the use of potentially curative 
treatment. Comorbidity was shown to be an independent prognostic factor (9). 
Previous malignancy, cardiovascular diseases, chronic obstructive pulmonary disease, 
hypertension and diabetes decreased 5-year survival. Comorbidity also led to less 
frequent use of adjuvant therapy, thus contributing to its impact on survival rates. In 
                                
 
contrast, older patients who are in good health, and who can undergo the same 
therapies as younger patients, have the same chances of survival.  
There were also large variations in survival between countries among elderly patients 
(Table 4). Survival rates were dramatically lower in Eastern European countries 
compared to Western European countries (46). Stage at diagnosis remained the major 
determinant of prognosis. In Burgundy, the 5-year relative survival rate in elderly 
patients was 85% for stage I, 65% for stage II, 35% for stage III and 4% for stage IV 
(1991-2000). This is probably the major determinant of survival differences between 
countries. In a study involving three European cancer registries, differences in rectal 
cancer survival were no longer significant after adjusting for stage (48). It has also 
been shown that survival is related to the level of health investment (49). Effective 
diagnosis and conditions of treatment depend on macroeconomic determinants, 
including total national expenditure on health. 
 
Table 4: 5-year relative survival rates for colon and rectum cancers in Europe 
(EUROCARE  3 data) 
 
 
COLON RECTUM 
 
all ages ≥ 75 y all ages ≥ 75 y 
     
France 59 52 58 45 
 
    
Switzerland 56 53 57 54 
 
    
Netherlands 54 51 55 53 
 
    
Sweden 53 53 55 48 
 
    
Finland 54 51 51 43 
 
    
Italy 53 45 49 36 
 
    
Portugal 47 45 43 44 
 
    
England 46 44 46 42 
 
    
Denmark 46 43 44 35 
 
    
Slovakia 43 41 31 19 
 
    
Slovenia 40 31 36 28 
 
    
Estonia 40 31 32 23 
 
    
Poland 30 21 29 21 
 
 
Conclusions 
 
There is growing interest in the management of CRC in the elderly. Although 
improvements have been achieved, in particular an improvement in resection rate and 
a decrease in operative mortality, there is evidence that there is still room for 
  
improvement in the use of adjuvant treatments. Comorbidities, which are particularly 
frequent in the elderly increase the complexity of cancer management and affect 
survival. The comprehensive geriatric assessment and multidisciplinary consultations 
need to be put in place to select those who can benefit from standard treatment. 
 
 
 
 
 
                                
 
Chapter 5.4  
 
Comorbidity 
 
 
 
As described in chapter 5.3, colorectal cancer affects a large number of people who, 
because of their age, are likely to have other chronic disabling, life-shortening 
conditions. This thesis showed that the proportion of Dutch patients with comorbidity 
varied from almost 40% among patients aged 50-64 years to more than 70% among 
those aged 80 or older (chapter 2.1). Using the registration of chronic conditions in the 
Eindhoven Cancer Registry (which required extensive training and validation), the most 
common concomitant conditions among all age groups together were cardiovascular 
diseases (15%), hypertension (13%), and previous malignancies (9%). Comorbidity did 
not influence the proportion of patients undergoing surgery for colorectal cancer. On 
the other hand, it did influence adjuvant treatment; the use of adjuvant chemotherapy 
in patients with stage III colon cancer was especially lower among patients with a 
previous malignancy and chronic obstructive pulmonary disease (COPD). Adjuvant 
radiotherapy among rectal cancer patients was negatively influenced by the presence 
of hypertension together with diabetes. From the treating physician point of view, the 
main reason for refraining from adjuvant therapy among these patients might be the 
perception of a short life-expectancy, or the fear of an increased risk of  potentially 
life-threatening- side effects/toxicity. However, one might argue why other serious 
concomitant diseases did not cause the physician to refrain from adjuvant treatment. 
There is yet no clear evidence to what degree it is beneficial or harmful for the patient 
with comorbidity to receive standard adjuvant treatment. These questions were not 
specifically addressed and therefore not answered by this thesis. More detailed 
information about the general condition of the patient, the seriousness and stage of the 
comorbid condition(s), treatment complications (prospectively), the exact reason why 
the physician chose not to treat certain patients, patient preferences, and social 
conditions has to be collected in order to provide any answer. In 2007, two 3-year 
projects funded by the Dutch Cancer Society will focus in the CCCS region on better 
implementation of new insights in daily treatments in this region served only by 
community hospitals, and on the differences that exist between patients older than 75 
years treated and non-treated according to guidelines with respect to patient 
characteristics, complication rate, and recurrence free, progression free and cancer 
specific survival.  
The results presented in chapter 2.3 justified the fact that comorbidity hardly affected 
colorectal cancer resection rates. There was no relation between comorbidity in general 
and surgical complications. It showed although that extra attention is needed for 
certain patients before, during, and after surgery: patients with COPD or deep vein 
thrombosis at time of cancer diagnosis were at higher risk of developing surgical 
complications. 
  
The studies in this thesis also showed that comorbidity negatively affected survival of 
patients with colorectal cancer (chapters 2.1, 2.2, and 3.2). Colon cancer patients 
without comorbidity aged 65-79 years old had a 5-year overall survival rate of 55%, 
decreasing to 44% in presence of 1 comorbid condition, and to 38% in presence of 2 
comorbid conditions. After adjustment for relevant patient and tumour characteristics, 
previous malignancies and COPD had the largest influence on survival. Among rectal 
cancer patients aged 65-79 years, the 5-year survival rate decreased from 33% for 
patients without comorbidity to 19% for patients with 2 or more concomitant 
conditions. COPD and hypertension had the largest impact on survival after adjustment 
for patient and tumour characteristics. It was shown that the adverse effects of 
increasing age and comorbidity on survival appeared to be independent of cancer 
treatment, so less aggressive treatment could not (fully) account for the observed 
differences in survival. 
Comorbidity is a multidimensional variable, which means that diseases that affect life 
expectancy may not be the same as those influencing function or tolerance to 
treatment. Although there is general agreement on the prognostic importance of 
comorbidity, there is no consensus about the types of diseases that should be included, 
or about the weighing of the conditions. Several scales for measuring comorbidity have 
been developed and validated. The most commonly used comorbidity indices are the 
Charlson Comorbidity index, the cumulative index rating scale, and the Kaplan-
Feinstein index. 72, 78, 226-228 When measuring comorbidity, the scale should be carefully 
chosen, because the prevalence of comorbidity varies qualitatively and quantitatively 
between different scales. For example, in a lung cancer study comorbidity influenced 
survival when measured with the cumulative index rating scale but not with the 
Charlson scale.226 The Charlson scale is a relatively restrictive way to assess 
comorbidity, and may result in underestimation of prevalence of (less severe?) 
comorbidity. Recently, the Adult Comorbidity Evaluation-27 (ACE-27) was developed, 
based on previous classification systems, especially the Kaplan-Feinstein Index. 78, 227 
This index has been validated and has been shown to discriminate expected 
complications and survival in elderly cancer patients. 73 In some recent studies this 
comorbidity index has shown to discriminate expected complications and prognosis in 
elderly patients. 78, 229-233 Until now, elderly are often not included in clinical trials, and 
evidence-based guidelines are often based on results of treatment in middle-aged 
patients without serious comorbidity. 140, 234, 235 Forthcoming studies will have to 
describe treatment difficulties and outcome in unselected elderly patients, to indicate 
whether it is reasonable to extend the present treatment guidelines to the elderly, and 
to indicate relevant subgroups for which prospective clinical trials can be initiated. 
 
 
 
                                
 
Chapter 5.5  
 
Guideline adherence and variation 
 
 
 
Promoted by concerns regarding practice variations, the standard of care for colorectal 
cancer in the Netherlands is formulated in clinical practice guidelines since the mid 
1990s. Clinical practice guidelines are defined as systematically developed statements 
to assist both practitioner and patient decisions about appropriate health care for 
specific clinical circumstances 125. Recommendations in guidelines are not always 
followed; this was well documented by several studies presented in this thesis 
(chapters 3.1, 3.2 and 3.3).  
There might be well established good clinical reasons to refrain from adjuvant 
chemotherapy in case of severe comorbidity (chapters 3.1, 3.2, and 3.3). This thesis 
however also showed that females and patients with a low socio-economic status 
received less often adjuvant chemotherapy than their counterparts, even after 
adjustment for age and comorbidity. Possible reasons for this were described in 
chapter 3.2. At first sight, there seems to be no clinical reason for this undertreatment. 
However, maybe the lack of a supportive partner among elderly women makes the 
choice for not treating her with adjuvant chemotherapy the right one; patients with a 
low socio-economic status might cope less well with the effects of chemotherapy 63, 69, 
161, 162. Furthermore, patient preferences were not taken into account, while these may 
be of significant importance. Among rectal cancer patients, there were large differences 
between hospitals in the rate of referral for radiotherapy (Cox S et al, submitted for 
publication). Here, a remarkable difference could be observed between the east part 
and the west part of the CCCS region, although this has decreased over time. 
Nevertheless, this suggests that clinical tradition can still play a large role within 
medical practice.   
The central question remains: when is deviance from standard treatment guidelines 
inferior clinical practice, and when does this reflect good quality of care? 
Individualisation of treatment, especially among older cancer patients, is often 
considered to be beneficial. In many instances this might lead to an alternative 
treatment or even withholding treatment. If this prevents treatment related 
complications without exposing the patient to a disproportionate risk of tumour 
recurrence or death, this might be considered good quality of care.  
For rectal cancer, it is argued that preoperative radiotherapy may be omitted in 
patients with perfect mesorectal excision 236. However, results from the CRO7 trial 
show that even with perfect surgery there is added value of preoperative radiotherapy 
237. An ongoing Scandinavian study investigates the effect of delaying surgery after a 
short course of radiotherapy 238. The study goal is to see whether delay leads to 
downsizing and staging for the tumour. It could be that after a waiting period of 6-12 
weeks the patient recovers from the radiotherapy and avoids the double jeopardy of 
  
radiotherapy and a major surgical trauma. Nutritional, metabolic, cardiac, or pulmonary 
disorders may be optimised in the waiting period. In the study described in chapter 2.2, 
we also found significantly less complications among patients who, for any reason, had 
a longer interval between end of radiotherapy and surgery (subgroup analysis of small 
sample of patients, therefore these results were not shown in chapter 2.2).  
The dogma for diagnosis of colorectal cancer is the same as it is for treatment: when 
does deviating from standard guidelines reflect diminished quality of care, or when 
does it reflect the opposite? For example, this thesis showed that the proportion of 
colon cancer patients who underwent a complete colonoscopy amounted to only 60% 
(chapter 3.1). However, often there were good reasons not to perform 
pancolonoscopy; for example serious discomfort as indicated by the patient, and the 
inability to pass a malignant structure. The latter was confirmed by our finding that 
especially patients with larger, more penetrating tumours underwent less often a full 
colonoscopy. A recent study suggested a large variation in practice between 
gastroenterologists, reason why in 2007 in the CCCS region a study will be performed 
to investigate variation in colonoscopy practice 239. 
This thesis revealed low adherence to treatment guidelines concerning lymph node 
examination (chapter 3.3). In the present guidelines, a minimum of 12 examined nodes 
is required for adequate staging. A median number of 6 nodes was examined among 
patients with stage I-III colon carcinoma in the period 1999-2002 in the CCCS region. 
This median number ranged from 3 to 8 between the six departments of pathology in 
the region. After correction for relevant patients and tumour characteristics, this 
variation remained, and led to significant differences in stage distribution between the 
departments. A higher yield of lymph nodes was correlated with improved survival, and 
indeed survival was worse for patients who had their lymph nodes examined in the 
departments of pathology with the lowest median number of nodes examined. There 
may be substantial inter-individual variation concerning the number of lymph nodes 
that can be found, depending on i.e. tumour site, neoadjuvant treatment, and the 
immune response 147, 167, 183. For the latter, we could not control in our analyses, but it 
is highly unlikely that there are geographically differential patterns in this respect within 
the CCCS region. Therefore, the variation had to be due to the either the thoroughness 
of the surgical lymphadenectomy, and/or the diligence of the pathologists examination. 
Our study indicated that the diligence of the pathologists examination probably 
contributed more strongly to both the low number of examined nodes and the variation 
between the departments. This was supported by the interesting finding that there  
was no difference in the number of lymph nodes examined between the hospitals 
covered by one and the same department of pathology, while there was a significant 
difference in the number of nodes between two departments of pathology serving one 
and the same hospital within the study period. Although lymph node examination partly 
explained survival differences between the various departments, differences not 
related to nodal evaluation- remained. This indicates that other relevant clinical 
features differ between institutions, in addition to the determinants we assessed in our 
analyses.
                                
 
In one of the Dutch National Cancer Society projects starting in 2007, surgical 
procedures for colon cancer will be recorded in detail, together with the 
implementation of a method for improving the lymph node yield. This method, 
developed by dr. Rutten (surgeon, Catharina Hospital Eindhoven) and dr. van 
Lijnschoten (pathologist, PAMM), consists of 3 key points: firstly, injection of 0.5cc of 
blue dye by the surgeon into the mesocolon (ex vivo!), without opening the specimen; 
secondly, fixation in formalin for 48 hours instead of the commonly used 24 hours; and 
thirdly, opening the specimen by transverse slicing, according to the method described 
by Quirke 240. The results of a pilot study in 4 hospitals during spring and summer 2007 
already showed a dramatically increased yield of lymph nodes, without increasing 
procedure time for the pathologist. Implementation of this method on a wide scale 
would ensure adequate nodal staging of colon cancer patients. There might however 
also be other approaches to enhance lymph node examination 174, 241, 242. In the new, 
evidence-based colon cancer treatment guidelines, high-risk stage II colon cancer 
patients are considered eligible for adjuvant chemotherapy. High-risk comprises 
patients with non-adequate lymph node sampling (less than 10), T4 tumours, and/or 
poorly differentiated tumours. In the present situation, this would mean that the 
majority of stage II patients would indeed have to receive adjuvant chemotherapy. By 
increasing the proportion of patients who were adequately staged, for example by 
using the new method described above, many patients (about 20%) do not 
unnecessarily have to go through treatment with chemotherapy. This even gains 
importance in view of the new, and, although effective, expensive chemotherapeutics. 
 
 
 
  
 
Chapter 5.6  
 
Future perspectives 
 
 
 
Prevention and screening 
As shown in chapter 1, a large range of risk factors is described in literature. Besides 
modifications in life-style, which requires large changes in the individuals behaviour 
and the Western societal environment in general, several nutrients and 
chemopreventive agents have been subject of study. Promising are vitamin D and 
calcium, and Cox-2 inhibitors, such as certain non-steroidal anti-inflammatory drugs 28, 
243-245. For the first two, fortification of foods might be a safe and effective option to 
increase daily amounts ingested, but regarding COX-2 inhibitors it will be first necessary 
to identify inhibitors with lower risks of cardiovascular adverse effects 246. Prognostic 
molecular signatures of individuals at high risk of developing colorectal cancer and 
predictive markers of response to preventive agents have to be addressed in further 
studies 247.  
It has been estimated that widespread application of screening technologies that 
address the whole colon could decrease colorectal cancer incidence by as much as 60% 
to 70% and reduce colorectal cancer deaths by up to 80% 247. Varying levels of clinical 
evidence exist for the effectiveness of available colorectal cancer screening options, and 
most guidelines offer a panel of acceptable screening options including fecal occult 
blood testing, sigmoidoscopy, and colonoscopy. The question is when, and using which 
(combination of) screening instrument(s), mass screening for colorectal cancer will be 
implemented in the Netherlands. This will also depend on the outcome of three large 
trials which are now underway in the Netherlands. However, raising awareness among 
both health care professionals and members of the general public about the fact that 
colorectal cancer can be prevented or detected early remains a crucial goal. Moreover, 
endoscopy capacity will have to be increased. 
To circumvent the invasiveness, time, and cost of colonoscopy, several techniques have 
been developed including computed tomography (CT) and colography (virtual 
colonoscopy). Virtual colonoscopy has been shown to be safe and well tolerated by 
patients 247. Indications for virtual colonoscopy include screening for polyps, incomplete 
or failed colonoscopy, and preoperative assessment of the colon proximal to an 
obstructive cancer that cannot be endoscopically traversed. Virtual colonoscopy may 
increase patient participation in screening programs, leading to early diagnosis of 
colorectal cancer. Although virtual colonoscopy seems a potentially attractive screening 
method for colorectal cancer, its cost-effectiveness is yet to be determined 248. Other 
emerging technologies for colorectal cancer screening include fecal immunochemical 
testing, stool DNA mutational analysis, and proteomic analysis of serum 247. 
Encouraging the rapid evaluation of new approaches to colorectal cancer screening at 
different levels are important research goals for the near future.  

  
Diagnostics and staging 
In colorectal cancer, methylation likely represents a third disease pathway in addition to 
the established genetic pathways of chromosomal and microsatellite instability 247, 249-
251. One form of epigenetic methylation that has been shown to have a potential role in 
risk evaluation and stratification is loss of imprinting, an epigenetic form of gene 
silencing that occurs in the gamete and results in hemizygosity and decreased gene 
expression. It was reported that loss of imprinting of IGF2 occurred in greater 
percentages of colorectal adenoma and cancer patients compared with controls 252. 
Epigenetic markers also show considerable promise and should be considered in 
addition to genetic and proteomic markers in studies of colorectal cancer risk and 
progression 247.  
As long as conventional detection is the norm, it will be of utmost importance to 
increase adequacy of lymph node examination for adequate staging of colon cancer, for 
example by the method described in chapter 5.5. This peri-operative staging may also 
be of relevance in rectal cancer, but staging in rectal cancer is of at least equal 
importance in the preoperative setting. Magnetic resonance imaging (MRI) has the best 
overall results, with better imaging of the circumferential resection margin compared to 
sonography and CT 253. There are no clear differences between MRI, CT, and 
sonography concerning preoperative lymph node staging 254. Further advances in 
staging may be achieved with novel magnetic resonance contrast agents (such as 
superparamagnetic iron oxide particles) and positron emission tomography scanning 
247.  
 
Treatment 
In a recent review including stage II colon cancer patients, adjuvant FU therapy was 
associated with a disease-free survival benefit, but the benefit was small and not 
necessarily associated with improved overall survival 255. In another study, adding 
oxaliplatin to infusional FU plus leucovorin (FOLFOX4) resulted in an advantage in 
disease-free survival for stage II patients that was comparable to that in stage III 
patients compared with the use of FU plus leucovorin alone 256. Despite these results, 
surgery alone remains the primary option of treatment until better techniques of 
identifying high-risk stage II patients are developed.  
Promising strategies for further improvement of treatment of stage III colon cancer, 
besides the addition of oxaliplatin which is already considered standard in the 
Netherlands, are targeted therapies with monoclonal antibodies bevacizumab or 
cetuximab. It will be of high importance to develop genetic markers that will be able to 
predict response to chemotherapy, such as thymidylate synthase 257.  
As said, surgical resection will undoubtedly remain the cornerstone of colorectal cancer 
treatment. One of the main changes in colon cancer surgery will be the more 
widespread use of laparoscopic surgery, which has been proven to be safe in a recent 
meta-analysis 258. Total mesorectal excision is likely to remain the basis of rectal cancer 
management. Accurate radiological staging, optimal surgery and detailed 
histopathological assessment together with consideration of a preoperative adjuvant 
strategy will remain the basis for current treatment and future research in rectal cancer 
259. 
  
 
 
 
Elderly 
We are still unable to discern fully from current evidence why doctors chose not to treat 
their patients or why patients chose not to be treated or to discontinue treatment. 
Treatment decisions will have to be individualized to fit the needs of each older patient 
as much as possible. In the adjuvant setting, even the reduction in the risk of cancer 
recurrence offered by chemotherapy may not be as important to older patients as their 
quality of life. Despite a growing body of data, a lot of work is still needed to establish 
optimal strategies to care for patients diagnosed with cancer later in life 206. It is also 
important to our understanding of how to communicate risk and benefit to older 
patients and their families (de Vries M. et al, Eur J Cancer, in press).  
 
 
 
  
Chapter 5.7  
 
Concluding remarks 
 
 
 
In this thesis we gave an overview of clinical epidemiology of colorectal cancer in the in 
the South of the Netherlands, covering a period of more than 40 years. We could 
demonstrate large increases in incidence and improvements in management and 
survival of colorectal cancer patients. Progress can however still be made, especially 
regarding management of older patients, early detection and staging of colorectal 
cancer.  
Many aspects of the clinical epidemiology of colorectal cancer were only marginally or 
not at all discussed in this thesis. Stage IV colorectal cancer, intra-operative radiation, 
laparoscopic surgery, transanal microscopic microsurgery, management of familial 
cancer, quality-of-life-related issues, stoma care, and many more items were not 
addressed or shed insufficient light on. Among others, a broad coalition of forces and a 
higher awareness of colorectal cancer in the population are necessary. This means 
that, although this thesis is finished now, the work continues. Besides further work on 
the issues described in this thesis, priorities include studies on early detection, 
diagnosis (involve family doctors), treatment of recurrences and metastases, and 
palliative care.  
 
 
 
 
  
Summary 
 
 
 
This thesis presented studies on different aspects of the clinical epidemiology of 
colorectal cancer in the south of the Netherlands, with an emphasis on elderly cancer 
patients. The Eindhoven Cancer Registry (ECR) was used as the main data source. 
 
The influence of age and comorbidity on clinical care of colorectal cancer was described 
in chapter 2.1. The prevalence of comorbid conditions increased with age. Of patients 
aged 50 to 64 years, 29% had 1 comorbid disease, compared to 35% of patients aged 
65 to 79 years, and 34% of patients over the age of 80. Fourteen percent of patients 
aged 50 to 64 years old suffered of 2 or more comorbid conditions, compared to 29% 
of patients aged 65 to 79, and 37% of patients older than 80 years. For all age groups 
the most frequent single concomitant diseases were hypertension (9% of patients, 
however decreasing with age), previous malignancy (7%, increasing with age) and 
cardiovascular disease (6%, increasing with age). The most frequent combination of 
comorbid conditions was cardiovascular disease plus hypertension (3%).  
Age and comorbidity did not influence resection rates, but clearly decreased the 
proportion of patients receiving adjuvant therapy, even after controlling for relevant 
factors. Five-year survival was largely influenced by comorbidity. Crude 5-year survival 
rates for patients with colon carcinoma aged 65 to 79 years old decreased from 55% 
among patients without comorbidity, to 44% among patients with one comorbid 
condition, and to 38% among patients with 2 or more concomitant diseases. For 
patients with rectal carcinoma, 5-year survival decreased from 54%, to 44%, and to 
33%, respectively. Also after controlling for other prognostic factors such as age, stage, 
and treatment, the influence of comorbidity on survival remained. Previous malignancy, 
cardiovascular disease and COPD had the largest impact on survival. 
 
In a previous ECR study it was shown that survival of rectal cancer patients had been 
improving between 1980 and 2000, but that this improvement was restricted to 
patients younger than 75 years. The goal of the study presented in chapter 2.2 was to 
investigate whether the absence of improvement in the elderly was related to a higher 
complication rate.  
Of stage I-III patients aged 70 or older, 36% underwent adjuvant radiotherapy, 
compared to 49% of patients aged 60 to 69. Fifty-one percent of patients aged 60-69 
years old had any complication within one year of diagnosis compared to 65% of 
patients aged 70 or older. Elderly suffered more from cardiac complications and 
pneumonia. The presence of comorbidity also increased the risk of complications, 
especially among patients older than 70. Compared to patients who received surgery 
alone, the risk of developing complications was larger among those treated with 
adjuvant radiotherapy. Local recurrence rate did however not differ between those who 
were operated on with or without adjuvant radiotherapy. In a multivariable analysis, 
age, comorbidity, and the presence of 2 or more complications had a negative impact 
on survival.  
Elderly had a relatively higher risk of complications, which may partly explain the status 
quo in survival among elderly rectal cancer patients. 
 
  
An accurate preoperative assessment is important, especially in view of the growing 
proportion of elderly patients. In chapter 2.3 the influence of specific comorbid 
conditions on the development of postoperative surgical complications was investigated 
among stage I-III colorectal carcinoma patients.  
Older patients, patients with a tumour located in the rectum, and patients operated on 
in an emergency setting more often developed postoperative complications. The 
presence of COPD at time of cancer diagnosis among patients with colon carcinoma 
increased the risk of developing a pneumonia (18% vs. 2%) or haemorrhage (9% vs. 
1%) postoperatively compared to patients who did not have any comorbidity. Patients 
with a tumour located in the rectum who suffered from COPD more frequently had any 
surgical complication (73% vs. 46%). Although the number of patients with deep vein 
thrombosis (DVT) at time of cancer diagnosis was relatively small (N=15), it seemed to 
lead to an increased frequency of postoperative complications.  
This study showed that especially among patients with preoperative COPD or probably 
also DVT extra attention has to be paid to preventing and anticipating surgical 
complications. 
 
In chapter 3.1 the level of adherence to clinical guidelines for colorectal cancer in the 
ECR region in 2002 was investigated. Adherence to guidelines was determined for 
diagnostic assessment, pathology, and treatment. 
Surgical procedures and referral for preoperative radiotherapy were carried out largely 
conform the recommendations. Although all patients should undergo a complete 
colonoscopy according to the guidelines, the number of performed colonoscopies 
among colon cancer patients amounted up to only 60%; contrast enemas after 
incomplete colonoscopy were performed in only 27% of patients. The median number 
of examined lymph nodes was only six for patients with colon cancer and five for rectal 
cancer, while a minimum number of 12 was mentioned in the guidelines. The 
administration of adjuvant chemotherapy for patients with stage III colon cancer 
decreased from 95% of patients younger than 70 years to 48% of patients over 70. 
Adherence to clinical guidelines was not optimal, although in some cases there were 
apparent reasons to deviate from guidelines, such as not performing a complete 
colonoscopy in case of patient discomfort or in presence of a malignant structure in the 
bowel. Especially nodal assessment and adjuvant treatment among older patients have 
to be studied in more detail to reveal reasons for non-compliance. 
 
In relation with the results presented in the previous chapter, the determinants of 
receiving adjuvant chemotherapy among stage III colon carcinoma patients aged 65 to 
79 years old were examined in chapter 3.2, including their influence on survival. 
The proportion of elderly patients receiving adjuvant chemotherapy increased from 
19% in 1995 to 50% in 2001, but large inter-hospital variation remained. In a 
multivariable analysis, females, patients with comorbidity, and patients with a low 
socio-economic status (SES) had a lower chance of receiving adjuvant chemotherapy. 
The fact that older patients or patients with comorbidity were treated less often with 
adjuvant chemotherapy might be due to uncertainty on the side of the treating 
physician about the risk-benefit ratio of adjuvant treatment in those patients. There 
seems to be however no obvious rationale for the undertreatment of women and 
patients with a low SES. Previous studies reported that older women are more prone to 
decline adjuvant chemotherapy when offered, but unfortunately we did not have data 
on patient preferences. Patients with a low SES might communicate in a less assertive 
  
way with their physician, and have a lower self-rated health, which may all affect 
clinical decision making.  
Even after adjustment for adjuvant chemotherapy, there was a clear improvement in 
survival for stage III colon carcinoma patients between 1995 and 2001, which may 
point at other improvements besides the increased treatment with adjuvant 
chemotherapy. Patients treated with adjuvant chemotherapy had a better survival than 
patients who did not receive this treatment; however, even after adjusting for 
comorbidity and age, there still might be a bias due to selection of the fitter patient by 
the treating physician. Unfortunately, we did not have information on the performance 
status of the patient. 
 
Also chapter 3.3 was based on the study described in chapter 3.1. An adequate lymph 
node examination is important for correct staging. The factors influencing lymph node 
examination and survival were studied among stage I-III colon carcinoma patients 
diagnosed between 1999 and 2002. 
A median number of 6 lymph nodes was examined, while the guidelines in that period 
mentioned a minimum number of 12. There was a large variation between the 
pathology departments in the number of examined nodes, ranging from a median 
number of 3 to 8. The number of examined nodes also depended on age, comorbidity, 
tumour localisation, tumour size, and nodal status. After adjustment for these 
variables, the variation between the departments of pathology remained. This variation 
led to differences in stage distribution, which was correlated with the number of 
examined nodes. Patients who had more lymph nodes evaluated had a better 5-year 
survival. 
Future research has to demonstrate whether the low number of examined nodes, 
including the variation between the departments, persists. Probably, new methods for 
nodal detection should be implemented which enables the pathologist to increase the 
yield of nodal examination. 
 
In chapter 4.1 the clinical and epidemiological trends in colorectal cancer in the ECR 
region from 1975 to 2004 were described. Large changes have taken place in this 
period. First of all, there has been a gradual increase in incidence, which was most 
marked for males and proximal tumours. Furthermore, survival increased dramatically, 
especially among patients younger than 70 years. This was at least partly due changes 
in treatment; particularly, since the mid-1990s, a growing proportion of patients 
underwent adjuvant chemo- or radiotherapy. Also large changes in rectal cancer 
surgery took place. The advances in survival led in turn to decreased mortality rates, 
and consequently to increased prevalence rates. An increase in stage III patients 
suggested improved nodal staging procedures over time, but there was no evidence 
that patients diagnosed more recently were diagnosed at an earlier stage of the 
disease (I or II). 
The results of this study showed that the workload of all clinicians involved will keep 
increasing considerably in the near future. The steady increase in age-adjusted 
incidence, the demographic changes in the Dutch population and the likely future 
implementation of colorectal cancer mass screening will necessitate investments related 
to education, recruitment, materials and infrastructure. In many other European 
countries, the situation is presumably the same. Nevertheless, this study demonstrated 
large improvements in management and survival of patients with colorectal cancer 
between 1975 and 2004.  
 
  
In chapter 5, the results presented in this thesis were commented, and some questions 
which were not answered within this thesis were discussed. The future perspectives of 
a number of aspects of the clinical epidemiology of colorectal cancer were reviewed.  
 
The overall conclusion of this thesis is that age and comorbidity are important 
predictors of treatment and outcome of colorectal cancer. Patients with comorbidity are 
treated less aggressively and have a dismal prognosis, which is only partly explained by 
the less aggressive treatment. Although large improvements could be noted in survival, 
there remains room for improvement in view of the inter-institutional variation 
regarding staging and treatment.  
 
 
 
  
Samenvatting 
 
 
 
Dit proefschrift beschrijft de klinische epidemiologie van dikkedarmkanker in Nederland, 
met een nadruk op de oudere patiënt. Voor alle studies werd gebruikgemaakt van de 
Kankerregistratie van het Integraal Kankercentrum Zuid (IKZ) te Eindhoven. De 
hoofdvragen waren: a) welke factoren zijn van invloed op behandeling, complicaties 
van behandeling, en overleving van dikkedarmkanker, met de nadruk op de oudere 
patiënt? b) in hoeverre heeft de behandeling van dikkedarmkanker plaatsgevonden 
volgens de richtlijnen, en bestond er variatie tussen de ziekenhuizen? en c) wat waren 
de trends in vóórkomen, behandeling, stadiumverdeling, en overleving van 
dikkedarmkanker in de IKZ-regio? 
 
Voor een goed begrip: met coloncarcinoom wordt een tumor in het eerste 2/3de deel 
van de dikke darm bedoeld, met rectumcarcinoom of endeldarmkanker een tumor in 
het laatste 1/3de deel van de dikke darm. Indien gesproken wordt over 
dikkedarmkanker, wordt de gehele darm (colon plus rectum) bedoeld. 
 
In hoofdstuk 2.1 werd het vóórkomen van potentieel ernstige co-morbiditeit 
(bijkomende ziekten naast de kanker) bij patiënten met dikkedarmkanker beschreven. 
Er is een duidelijke toename van co-morbiditeit met een stijgende leeftijd; bij patiënten 
van 50 tot en met 64 jaar heeft 45% co-morbiditeit, bij patiënten van 80 jaar en ouder 
is dit al ruim 70%. De meest voorkomende co-morbiditeit is hoge bloeddruk, gevolgd 
door een eerdere kwaadaardige tumor, en hart- en vaatziekten. Co-morbiditeit was, 
evenals leeftijd, van invloed op de adjuvante behandeling van dikkedarmkanker-
patiënten. Bij patiënten met stadium III (patiënten met uitzaaiingen in de lymfeklieren) 
coloncarcinoom ontvingen vooral zij met eerdere tumoren of chronisch obstructieve 
longziekte (COPD) minder vaak chemotherapie na de operatie (adjuvante 
chemotherapie). Patiënten met een rectumcarcinoom ondergingen minder vaak 
adjuvante radiotherapie in aanwezigheid van co-morbiditeit. Naast de aanwezigheid 
van co-morbiditeit verkleinde ook hogere leeftijd de kans op adjuvante behandeling.  
De overleving van patiënten met co-morbiditeit was slechter dan die van patiënten 
zonder co-morbiditeit. De ruwe 5-jaarsoverleving voor patiënten met coloncarcinoom in 
de leeftijd van 65 tot en met 79 jaar nam af van 55% voor patiënten zonder 
bijkomende ziekten tot 38% voor patiënten met 2 of meer bijkomende ziekten; voor 
patiënten met een rectumcarcinoom nam dit af tot 33%.  
 
In een eerdere studie van het IKZ is beschreven dat de overleving voor patiënten met 
een rectumcarcinoom aanzienlijk is toegenomen tussen 1980 en 2000, met 
uitzondering van patiënten ouder dan 75 jaar. In hoofdstuk 2.2 werd nagegaan of 
leeftijd en co-morbiditeit van invloed waren op de effectiviteit van behandeling. Hoewel 
patiënten ouder dan 70 jaar weliswaar minder vaak verwezen werden voor adjuvante 
radiotherapie, bleek deze behandeling gepaard te gaan met een grotere kans op 
complicaties bij deze ouderen ten opzichte van chirurgie zonder radiotherapie. Ook de 
aanwezigheid van co-morbiditeit en een hogere leeftijd vergrootten de kans op het 
ontwikkelen van complicaties. Het percentage lokale recidieven bleek niet groter in de 
groep bestraalde patiënten dan in de groep patiënten welke alleen geopereerd werden. 
  
Een hogere leeftijd, co-morbiditeit, en het optreden van 2 of meer complicaties ging 
gepaard met een hogere sterftekans.  
Ouderen bleken dus vaker behandelingsgerelateerde complicaties te ontwikkelen dan 
jongere patiënten, hetgeen voor een deel het uitblijven van verbeteringen in prognose 
zou kunnen verklaren. 
 
De preoperatieve beoordeling van het risico op postoperatieve chirurgische complicaties 
is van groot belang, juist in de groeiende groep oudere patiënten. In hoofdstuk 2.3 
werd middels statusonderzoek bij dikkedarmkankerpatiënten (exclusief patiënten met 
uitzaaiingen op afstand) bepaald welke specifieke bijkomende ziekten van invloed 
waren op het optreden van postoperatieve complicaties. De aanwezigheid van COPD op 
het moment van diagnose bleek de kans op postoperatieve pneumonie en bloedingen 
bij patiënten met een coloncarcinoom te verhogen. Bij patiënten met een 
rectumcarcinoom en COPD kwamen complicaties in het algemeen vaker voor. Verder 
nam het risico op postoperatieve complicaties toe bij aanwezigheid van diep veneuze 
trombose (DVT) op het moment van diagnose, hoewel het hier slechts om een klein 
aantal patiënten ging (N=15).  
De resultaten van dit onderzoek laten zien dat men vooral bij patiënten met 
preoperatieve COPD en mogelijk bij DVT in verhoogde mate alert moet zijn op 
chirurgische complicaties, en waar mogelijk deze complicaties trachten te voorkomen. 
 
In hoofdstuk 3.1 werd nagegaan in hoeverre de behandelingsrichtlijnen voor 
dikkedarmkanker in 2002 werden opgevolgd in de IKZ-regio. Er werd onderscheid 
gemaakt tussen diagnostiek, behandeling, en pathologie.  
Chirurgische procedures (voor zover na te gaan in het medisch dossier), en verwijzing 
voor radiotherapie gebeurden grotendeels in overeenstemming met de richtlijnen. 
Hoewel de richtlijn complete colonoscopie voorschrijft, werd dit bij 40% niet gedaan, 
echter vaak met goede redenen zoals discomfort bij de patiënt of een obstruerende 
tumor. Adjuvante chemotherapie werd, zoals ook al gezien in hoofdstuk 2.1, minder 
vaak voorgeschreven bij oudere patiënten met een stadium III coloncarcinoom. Een 
belangrijke bevinding was dat het mediaan aantal onderzochte lymfeklieren bedroeg 6 
voor patiënten met een coloncarcinoom, en 5 voor patiënten met een 
rectumcarcinoom, terwijl de richtlijn een minimum van 12 voorschrijft. 
Het merendeel van de procedures werd conform de richtlijn uitgevoerd; indien hiervan 
af werd geweken waren daar vaak goede redenen voor. Echter, het minder vaak 
toepassen van adjuvante behandeling bij ouderen dient nader onder de loep genomen 
te worden (zie hoofdstuk 3.2). Ook een hernieuwde evaluatie van het 
lymfeklieronderzoek is gewenst (zie hoofdstuk 3.3).  
 
Op basis van de in hoofdstuk 3.1 beschreven bevindingen, werd in hoofdstuk 3.2 
onderzocht welke factoren van invloed zijn op het al dan niet ontvangen van adjuvante 
chemotherapie bij stadium III coloncarcinoom, en in hoeverre deze factoren 
samenhangen met overleving. Data van patiënten in de leeftijd van 65 tot en met 79 
jaar, gediagnosticeerd tussen 1995 en 2001 in de IKZ-regio werden hiervoor gebruikt.  
Tussen 1995 en 2001 was er een toename in behandeling van 19% tot 50%. Er was 
echter een behoorlijke variatie tussen de ziekenhuizen, zelfs nog in 2001. De resultaten 
van een multivariabele analyse lieten zien dat behalve patiënten met een hogere 
leeftijd en co-morbiditeit, ook vrouwelijke patiënten (ten opzichte van mannen) en 
patiënten met een lage sociaal-economische status (SES) (ten opzichte van patiënten 
met een hoge SES) minder vaak adjuvante chemotherapie kregen. Voor deze laatste 
  
bevindingen lijkt er geen voor de hand liggende verklaring te zijn. Echter, uit de 
literatuur blijkt dat oudere  vaker alleenstaande- vrouwen vaker adjuvante 
chemotherapie weigeren, maar helaas hadden we in deze studie geen informatie over 
patiëntvoorkeuren. Patiënten met een lagere SES communiceren wellicht minder 
assertief met de behandelende arts, en beoordelen de eigen gezondheid vaak slechter, 
wat vervolgens weer op de klinische beslissing van invloed kan zijn. Het minder vaak 
behandelen van patiënten met hoge leeftijd of co-morbiditeit lijkt te wijzen op 
onzekerheid bij de behandelende arts met betrekking tot de gunsten-baten verhouding 
van adjuvante behandeling in deze groep. 
De overleving voor patiënten met een stadium III coloncarcinoom steeg tussen 1995 
en 2001, zelfs na correctie voor de toename in gebruik van adjuvante chemotherapie. 
Dit duidt erop dat behalve de toegenomen adjuvante behandeling ook op andere 
vlakken verbeteringen optraden. Patiënten die chemotherapie ondergingen hadden ten 
opzichte van patiënten die alleen geopereerd werden een gunstigere overleving, ook 
wanneer rekening werd gehouden met leeftijd en co-morbiditeit; dit is waarschijnlijk 
voor een deel te verklaren door het feit dat de behandelende arts bij een fittere 
patiënt eerder geneigd zal zijn om deze chemotherapie toe te dienen. Helaas ontbrak 
de mogelijkheid om de functionele status van de patiënt in dit onderzoek mee te 
nemen. 
 
Ook hoofdstuk 3.3 heeft de bevindingen van hoofdstuk 3.1 als uitgangspunt, namelijk 
het lage aantal onderzochte lymfeklieren bij coloncarcinoom. Een adequaat 
lymfklieronderzoek, met een voldoende aantal klieren, is van belang om het juiste 
stadium van de tumor vast te stellen. Dat laatste is dan weer van invloed op de 
behandelingskeuze. In de literatuur is ook een relatie met overleving aangetoond. De 
tijdens de studieperiode (1999-2002) geldende richtlijn ging uit van een minimum 
aantal van 12 klieren. Of dit aantal wordt gehaald is van vele factoren afhankelijk, maar 
is in ieder geval afhankelijk van zowel de chirurg, die voldoende lymfeklieren moet 
wegsnijden en aanleveren bij de patholoog, en laatstgenoemde die de lymfeklieren in 
het resectiepreparaat moet vinden en onderzoeken op aanwezigheid van eventuele 
uitzaaiingen van de tumor. In de hier beschreven studie werd bij stadium I-III 
coloncarcinoom-patiënten bestudeerd welke factoren van invloed waren op het aantal 
onderzochte lymfeklieren, en of er een relatie tussen deze factoren en de 5-
jaarsoverleving kon worden aangetoond. 
Er bleek variatie te bestaan tussen de 6 pathologielaboratoria (PA-labs) in de IKZ-regio; 
het mediaan aantal onderzochte klieren varieerde tussen 3 en 8. Het aantal 
onderzochte klieren was ook afhankelijk van leeftijd, geslacht, co-morbiditeit, 
tumorlokalisatie, tumorgrootte, en klierstatus. De variatie tussen de PA-labs bleek niet 
te verklaren door verschillen in een van deze factoren . Deze variatie vertaalde zich ook 
in een verschil in stadiumverdeling tussen de PA-labs, hetgeen gecorreleerd was met 
het aantal onderzochte lymfeklieren. Patiënten met een groter aantal onderzochte 
klieren hadden een betere overleving.  
Vervolgstudies zullen kunnen aantonen of deze variatie in en de lage opbrengst van 
lymfeklieronderzoek bleef bestaan. Het ligt voor de hand om nieuwe methoden toe te 
passen welke de patholoog in staat stelt meer klieren te detecteren en te onderzoeken, 
zonder evenredige verhoging van de werklast. 
 
In hoofdstuk 4.1 werden de klinische en epidemiologische trends in het zuiden van 
Nederland (de IKZ-regio) van de afgelopen 30 jaar beschreven (1975-2004). Er deden 
zich in deze periode grote veranderingen voor; zo was er een forse toename in het 
  
vóórkomen van dikkedarmkanker, met name bij mannen. Dikkedarmkanker bevond 
zich steeds vaker in het begin (het opstijgend deel) van de dikke darm. Verder was er 
een verbetering in overleving; deze was het grootst bij rectumcarcinoom en stadium III 
coloncarcinoom. Hieraan gingen veranderingen in de behandeling vooraf, zoals de 
reeds uitgebreid beschreven adjuvante chemotherapie bij stadium III coloncarcinoom, 
de verschuiving van post- naar preoperatieve radiotherapie bij rectumcarcinoom, de 
introductie van nieuwe chirurgische technieken als de Total Mesorectal Excision (TME). 
In feite was de verbetering in overleving van rectumcarcinoom de meest aanzienlijke 
van alle tumoren. De stijging in zowel incidentie als overleving leidde ertoe dat de 
prevalentie (het aantal patiënten in leven dat ooit is gediagnosticeerd met de ziekte) 
gestaag toenam. 
Een degelijke beschrijving van veranderingen in risico en prognose, waarvoor de data 
van de Kankerregistratie van het IKZ zeer geschikt zijn, kan aanwijzingen geven over 
de invloed van veranderingen in leefstijl, stagering en behandeling. Ook kan het, door 
middel van bijvoorbeeld het aantonen van variatie in diagnostiek en behandeling, 
demonstreren waar nog verbetering te behalen valt. Het kan al met al ook zeer 
behulpzaam zijn bij het anticiperen op de ontwikkelingen in de nabije toekomst. 
 
In hoofdstuk 5 werden de resultaten zoals beschreven in dit proefschrift 
bediscussieerd, en werd ingegaan op enkele nog niet beantwoorde vragen, evenals een 
bespreking van een aantal toekomstige klinische aspecten. 
 
Concluderend: leeftijd en co-morbiditeit bleken belangrijke voorspellers van 
behandeling en behandelingsuitkomst. Patiënten met co-morbiditeit werden minder 
agressief behandeld, en hebben een slechtere overleving, hetgeen niet volledig wordt 
verklaard door de minder agressieve behandeling. Hoewel de 5-jaarsoverleving 
duidelijk is verbeterd blijft er ruimte voor verbetering, gezien de variatie in stagering en 
behandeling. 
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